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MANAGEMENT OF HEAD AND NECK CANCER

Abdallah Sherif Radwan Mohamed, M.D., M.Sc.
Advisory Professor: Clifton D. Fuller, M.D., Ph.D.

Abstract

The aim of the clinical component of this work was to determine whether the currently
available clinical imaging tools can be integrated with radiotherapy (RT) platforms for
monitoring and adaptation of radiation dose, prediction of tumor response and disease
outcomes, and characterization of patterns of failure and normal tissue toxicity in head and
neck cancer (HNC) patients with potentially curable tumors. In Aim 1, we showed that the
currently available clinical imaging modalities can be successfully used to adapt RT dose
based-on dynamic tumor response, predict oncologic disease outcomes, characterize RTinduced toxicity, and identify the patterns of disease failure. We used anatomical MRIs for the
RT dose adaptation purpose. Our findings showed that after proper standardization of the
immobilization and image acquisition techniques, we can achieve high geometric accuracy.
These images can then be used to monitor the shrinkage of tumors during RT and optimize the
clinical target volumes accordingly. Our results also showed that this MR-guided dose
adaptation technique has a dosimetric advantage over the standard of care and was
associated with a reduction in normal tissue doses that translated into a reduction of the odds
of long-term RT-induced toxicity.
In the second aim, we used quantitative MRIs to determine its benefit for prediction of
oncologic outcomes and characterization of RT-induced normal tissue toxicity. Our findings
showed that delta changes of apparent diffusion coefficient parameters derived from diffusionv

weighted images at mid-RT can be used to predict local recurrence and recurrence freesurvival. We also showed that Ktrans and Ve vascular parameters derived from dynamic contrastenhanced MRIs can characterize the mandibular areas of osteoradionecrosis.
In the final clinical aim, we used CT images of recurrence and baseline CT planning
images to develop a methodology and workflow that involves the application of deformable
image registration software as a tool to standardize image co-registration in addition to granular
combined geometric- and dosimetric-based failure characterization to correctly attribute sites
and causes of locoregional failure. We then successfully applied this methodology to identify
the patterns of failure following postoperative and definitive IMRT in HNC patients. Using this
methodology, we showed that most recurrences occurred in the central high dose regions for
patients treated with definitive IMRT compared with mainly non-central high dose recurrences
after postoperative IMRT. We also correlated recurrences with pretreatment FDG-PET and
identified that most of the central high dose recurrences originated in an area that would be
covered by a 10-mm margin on the volume of 50% of the maximum FDG uptake.
In the translational component of this work, we integrated radiomic features derived
from pre-RT CT images with whole-genome measurements using TCGA and TCIA data. Our
results demonstrated a statistically significant associations between radiomic features
characterizing different tumor phenotypes and different genomic features. These findings
represent a promising potential towards non-invasively tract genomic changes in the tumor
during treatment and use this information to adapt treatment accordingly. In the final project of
this dissertation, we developed a high-throughput approach to identify effective systemic
agents against aggressive head and neck tumors with poor prognosis like anaplastic thyroid
cancer. We successfully identified three candidate drugs and performed extensive in vitro and
in vivo validation using orthotopic and PDX models. Among these drugs, HDAC inhibitor and
LBH-589 showed the most effective tumor growth inhibition that can be used in future clinical
trials.
vi
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Chapter 1: Introduction
1.1 Background and significance
Head and neck cancers (HNCs) encompass a diverse group of tumors that arise at
different locations in the upper aerodigestive track and affect around 65,000 individuals per
year in the United States, with approximately 14,000 deaths from the disease.(1) The prognosis
of HNCs is considerably variable in different tumor types ranging from excellent prognosis, as
in early stage Human papillomavirus (HPV) positive squamous cell carcinoma (2, 3), to very
deadly disease as in advanced HPV-negative tumors and anaplastic thyroid carcinoma.(4-7)
Radiation treatment (RT) is a cornerstone of HNCs treatment both in the definitive (i.e. organ
preserving) and the adjuvant post-operative setting. The goal of RT is to maximize the
tumoricidal dose to abnormal cancer cells while minimizing the toxic dose to adjacent normal
tissues.(8, 9)
Tumors with good prognosis such as early-stage HPV positive oropharyngeal
carcinomas (OPC) in non-smokers are relatively sensitive to RT and have good survival
outcomes compared to advanced-stage disease in heavy smoker and HPV negative
tumors.(10-16) In this subset of patients local control and survival probabilities exceed 80-85%
in most of the reported studies. However, many patients continue to exhibit dose-dependent
normal tissue injury. This can leave these comparatively young patients with potentially qualityof-life altering permanent radiation sequelae that can persist for decades of survivorship.(1720) This is because, fundamentally, RT dose to normal tissue organs-at-risk (OARs) such as
the swallowing muscles, mandible, parotid glands, and submandibular glands are the cause of
1

subsequent long-term RT side effects. Ideally, we would prefer to restrict dose to OARs, while
maintaining tumoricidal doses to active tumor volumes. However, it remains to be seen whether
RT dose reduction to the entire tumor volume will compromise disease control in a tumor site
where prolonged survival is achievable with current standard multimodality treatment despite its
long-term toxicity implications.(21-27) Consequently, as oncologic control becomes a realizable
goal for most of these patients, reduction of treatment-induced toxicity for the increasing
fraction of long-term survivors becomes an unmet priority.(28)
On the contrary, other head and neck cancer types such as HPV negative or advanced
stage tumors in heavy smokers remain to have grim outcome rates despite maximal
multimodality therapy. The local-regional control (LRC) for these patients can go as low as 3040%. In addition, these tumors have variable sensitivity to RT leading to different disease
response rates.(29, 30) Current RT dose and fractionation are largely driven by empirical data
rather than tumor specific information regarding potential radiosensitivity or radioresistance.(47, 30) Therefore, the ability to predict RT response in these higher-risk patients before and/or
during the treatment course can allow for the timely adaptation of RT doses and potentially
achieve better treatment outcomes.
Recent RT delivery techniques like intensity-modulated radiation therapy (IMRT),
volumetric modulated arc therapy (VMAT), and intensity-modulated radiation therapy (IMPT)
are important innovations in modern RT and represent a paradigm shift in the treatment of
HNCs. However, there are certain hazards that may increase the risk of loco-regional failure
including inadequate definition of the tumor extension and clinically important target volumes
2

(TVs), uncertainties related to daily positioning, weight loss or deformation of tumor and normal
tissues during the course of treatment, and uncertainties in plan optimization, dose calculation
and treatment delivery.(25, 31-34) The accurate and specific definition of the exact site of
failure, in addition to the radiation dose given to this site is, therefore, mandatory to identify the
possible cause(s) of failure. The classic definition of failures as “local”, or “regional”, was
appropriate in previous eras of conventional RT using large homogeneous dose-volumes, but
is no longer helpful nor descriptive of distinct types of failure in patients treated with advanced
conformal RT techniques.(35-37) The ability to accurately describe the relation of the origin of
disease failure to original TVs or RT dose mandates a fairly precise analysis methodology and
represent another important priority in these patients.
Non-invasive imaging such as magnetic resonance imaging (MRI) can provide
important information related to tumor characteristics and response to RT. The development of
MRI correlates of RT response and normal tissue toxicity could be critical for implementing
adaptive RT strategies that maximize therapeutic ratio where patients with aggressive nonresponsive tumors may require RT dose escalation (5, 7) while patients with radiosensitive
tumors may benefit from dose de-escalation to spare normal tissues with equivalent tumor
control.(6) This represents a significant unmet clinical need since patients with radiosensitive
tumors are being over-treated and patients with radio-resistant tumors are being under-treated.
The leading-edge solution to the anatomic adaptive therapy problem has been to integrate MRI
into radiation delivery devices (e.g. MR-Linear accelerator).(38, 39) The richer data of MRI
enables computer-driven identification of tumors and normal tissues and allows radiation plans
3

to be adapted on a daily basis with limited human intervention.(39, 40) Yet, gross anatomic
changes represent only one dimension of patient response to RT. Having incorporated highfield MRI into the delivery device, there is now the potential to monitor, on a daily basis, the
biologic changes within the patient using functional MRI sequences without excess radiation,
contrast exposure, or excess burden on patients’ time or institutional resources.
Moreover, the integration of granular quantitative imaging data acquired during the 6-7
weeks course of RT can increase our ability to individualize and optimize the RT dose
according to the response of target volumes and therefore, the development of effective
treatment adaptation at an actionable time point. Pilot data from our group and other
investigators has recently demonstrated that diffusion-weighted imaging (DWI) has a promising
predictive utility in HNC applications. Specifically, DWI has been shown to predict response to
induction chemotherapy(41, 42) RT(42-50), and tumor recurrence.(51) Preliminary data from a
prospective trial at our institution(52), supported by other group’s data(42, 44-46, 49, 53, 54),
has demonstrated that DWI was able to discriminate patients who will have a complete
response at mid-RT. That is, patients with lower pre-treatment diffusion measurement (ADC)
values were associated with early radiologic complete response, whereby there was no
residual disease by mid-therapy. In addition, lesions that showed a mid-treatment complete
response had significantly higher change in diffusion measurements (ΔADC) values than
lesions that did not show an early complete response.(52) Additionally, recent data from our
group demonstrated that early tumor regression rate ≥25% at fraction 15 (i.e. mid-RT) in HNC
patients is associated with better local control and overall survival.(55) This favorable risk group
4

represent suitable candidates for RT dose de-escalation if dose could be coupled to a
quantitative marker of tumor response probability (i.e. ADC). As adaptive dose painting
techniques could serially track and identify early responders to therapy, modify their radiation
plans by shrinking the target volume coverage, and thus allow increased treatment efficacy with
minimal normal tissue toxicity.
Another promising quantitative MR technique is dynamic contrast-enhanced MRI (DCEMRI). DCE-MRI can be used to monitor changes in tissue vascularity and can play a role in the
assessment of both treatment response and normal tissue toxicity. Our group has recently
demonstrated the DCE-MRI can be used to measure the changes in mandibular bone
vascularity induced by RT. Vascular parameters derived from DC-MRI such as Ktrans and Ve
have been also suggested to be associated with tumor response and normal tissue injury in
other cancer sites.
Another avenue for integration of advanced biomedical imaging for tumor response and
normal tissue injury assessment is radiomic feature analysis. Radiomics is a method of medical
image analysis that extracts a large number of quantitative tissue characteristics from a 2- or 3dimensional images. Radiomic features describe the texture, shape, and size of an ROI defined
on an image, and can be mined to predict RT outcomes. These features may allow to detect
characteristics of tissues that cannot be appreciated by the naked eye.(56-58) Early results
from radiomic studies also showed that these features can used to discriminate distinct tumor
phenotypes (e.g. HPV status, lymphovascular invasion, and extracapsular extension).
However, the relationship between tumor imaging phenotypes and underlying tumor genomic
5

mechanisms remains to be interrogated. Imaging-genomics translational research combines
radiographic image analysis with genomic research to improve disease diagnosis and
prognosis, discover novel biomarkers, and identify genomic mechanisms associated with
phenotype formation.(59-63) Such imaging-genomics studies have been performed for multiple
cancer sites(59-65) and remains to be investigated in HNC.
All the approaches described above including functional MRI, radiomic, and patterns of
failure analysis can allow for better stratification of patients to accurate risk group, tailoring of
RT dose with potential dose escalation/de-escalation, and prediction of side effects. However,
certain tumor types still fail treatment despite maximal RT dose delivery combined with
multimodality treatment that may include surgery, chemotherapy, and/or targeted therapy.
Anaplastic thyroid carcinoma (ATC) is a clear example of such tumor with a median survival of
less than 12 months despite maximal therapy. At the present time, there are not widely
accepted and effective systemic drugs against aggressive thyroid cancers. Although
combination therapy of targeted agents such as BRAF and MEK inhibition has been recently
FDA approved for treatment of ATC, it remains effective mainly in patients with BRAF V600E
mutations that ultimately develop drug resistance.(66, 67) This creates the necessity to identify
effective novel systemic agents against this aggressive disease. Therefore, it is necessary to
reorient translational efforts for such tumor types. One approach is to evaluate the broad array
of currently available agents with anti-solid tumor activity, which may demonstrate substantial
efficacy in ATC with already established safety profiles.
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Most previous drug identification and preclinical testing efforts in the context of ATC
have been restricted by several deficiencies including: 1) limited availability of validated human
cell lines with a known genomic and epigenetic background, 2) limited utilization of orthotopic
models, and 3) limited availability of relevant patient derived xenograft (PDX) models.(68) All
three of these factors can severely impact the ability to identify promising systemic agents, both
due to false positive and false negative results. The increasing availability of well-characterized
ATC human cell lines as well as increasing stocks of PDX models will allow for better
identification of more effective drugs against such deadly tumors. A high-throughput drug
screening (HTS) as an initial filter can represent a proper initial step for subsequent preclinical
testing and drug validation in these tumors.(69) This is an attractive approach since our group
has already generated and authenticated a large panel of thyroid cancer cell lines as well as
PDX models for further validation.(70-72)
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1.2 Hypothesis and specific aims
The current dissertation has two main research components: clinical and translational.
The central hypothesis of the clinical component is that the currently available clinical imaging
tools can be integrated with radiotherapy platforms for prediction of tumor response and
outcomes, monitoring and adaptation of radiation dose, as well as characterization of patterns
of failure and normal tissue toxicity in head and neck cancer patients with potentially curable
tumors. The central hypothesis of the translational component is that a high-throughput drug
screening with subsequent preclinical testing and drug validation in authenticated in vitro and in
vivo tumor models will identify effective agents against aggressive head and neck tumors with
poor prognosis.
To test these hypotheses, we propose the following specific aims:
Specific Aim 1: Determine the feasibility and dosimetric benefits of MR-guided dose-adaption
strategy for HPV positive oropharyngeal cancer patients using serial in-treatment MRIs
acquired in radiation treatment positioning and immobilization setup.
The working hypothesis is that T2 weighted MRI can be used for MR-guided RT dose
adaptation to achieve same tumor control as standard therapy but with additional sparing of
surrounding normal tissue. To achieve this aim two projects were done.
Project 1.1: Standardization of MRI integration in radiotherapy application for head and neck
cancer.
Project 1.2: MR-guided dose adaptation.
8

Specific Aim 2: Determine quantitative MRI parameters associated with tumor response,
oncologic outcomes, and normal tissue toxicity in head and neck cancer patients treated with
definitive radiation therapy.
The working hypothesis is that quantitative MRI parameters can be used for prediction
of tumor response to radiation therapy as well as for the prediction of long-term oncologic
outcomes. The quantitative MRI parameters can be also used for the characterization of
radiation-induced normal tissue toxicity.
To achieve this aim two projects were done.
Project 2.1: Diffusion-weighted MRI as a biomarker for tumor response and disease control.
Project 2.2: Dynamic Contrast-Enhanced MRI for assessment of normal tissue toxicity.
Specific Aim 3: Develop and apply a methodology to standardize the analysis and reporting of
the patterns of failure after radiation for head and neck cancer patients.
The working hypothesis is that using novel deformable image registration analyses of
combined spatial and dosimetric patterns of failure parameters will allow for the accurate
identification of the radiation-technique related causes that led to radiation treatment failure and
the possible interventions to reduce these failures in radiation therapy practice. Using a
standardized typology for reporting patterns of failure can be adopted by multiple institutions in
a manner that allows improved detection of possible modes of preventable causes of disease
recurrence. This could allow for pooling of data to infer differences in treatment approaches
and subsequent outcomes amongst different institutions.
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To achieve this aim three projects were done.
Project 3.1: Methodology for analysis and reporting patterns of failure after radiation therapy.
Project 3.2: Patterns of locoregional failure following post-operative intensity-modulated
radiotherapy.
Project 3.3: Patterns-of-failure guided biological target volume definition: FDG-PET and
dosimetric analysis of dose escalation candidate subregions.
Specific Aim 4: Determine the associations between imaging phenotypes and genomic
mechanisms in head and neck tumors and identify effective systemic agents against
aggressive tumors with a reasonable toxicity profile to allow for rapid translational development.
The working hypothesis is that imaging-genomics translational research can improve
disease diagnosis and prognosis, discover novel biomarkers, and identify genomic
mechanisms associated with phenotype formation. In addition, the utilization of high-throughput
drug screening with subsequent preclinical testing and drug validation in authenticated in vitro
and in vivo tumor models will identify effective agents against aggressive head and neck
tumors with poor prognosis.
To achieve this aim two projects were done.
Project 4.1: Associations between imaging phenotypes and genomic mechanisms.
Project 4.2: A high-throughput approach to identify effective systemic agents for the treatment
of anaplastic thyroid cancer.
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Chapters 2: Standardization of MRI integration in radiotherapy application for head and neck
cancer.
This chapter is based upon:
Joint Head and Neck Radiotherapy-MRI Development Cooperative. Mohamed AS, Hansen C,
Weygand J, Ding Y, Frank SJ, Hwang K, Hazle J, Fuller CD, Wang J. Prospective analysis of in
vivo landmark point-based MRI geometric distortion in head and neck cancer patients scanned
in immobilized radiation treatment position: Results of a prospective quality assurance protocol.
Clin Transl Radiat Oncol. 2017 Oct 10;7:13-19. doi: 10.1016/j.ctro.2017.09.003. PMID:
29594224; PMCID: PMC5862642.
This article is under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/)
which permits reproduction in any format.
2.1 Introduction
There has been a steady increase in the utilization of magnetic resonance imaging
(MRI) in radiation therapy (RT) for treatment planning because of its superior soft tissue
contrast, including tumor conspicuity. Recent advancements in integrated MRI guided radiation
therapy systems further enable the tracking of patient’s gross tumor volume (GTV) and other
critical organs in real-time during treatment (73-75). This significant technical improvement
promises increasing accuracy and fidelity of the actual dose delivered. However, MRI can have
larger geometric distortions than x-ray computed tomography (CT), resulting from the scanner’s
magnetic field imperfections (B0 inhomogeneity and gradient non-linearity) (76-80), and patientrelated effects such as susceptibility variations between different tissues (81, 82). To be used
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as a primary RT planning modality, MRI’s geometric distortion must be compensated by
increasing margins after target delineation, resulting in limited capacity for dose reduction to the
surrounding normal tissues.
At present, CT remains the imaging modality of choice for treatment planning and the
gold standard for GTV delineation and adaptive RT applications. Compared with MRI, CT has
minimal geometric distortion and its intrinsic information on electron density for dose calculation
of various tissues, making it a natural imaging choice for treatment planning (83). In head and
neck cancer (HNC), CT provides better visualization of cortical bone invasion and tumor-fat
boundaries than MRIs. However, poor soft tissue contrast, which is extremely critical in
determining tumor edges, organs at risk, and bone marrow, remains a major limitation for CT
utilization as a single image modality in RT applications(79). Additionally, CT is susceptible to
metal artifacts caused by dental fillings and other prosthesis. These limitations require the
additional use of other imaging modalities, like MRI or positron emission tomography (PET),
which complement each other to allow for precise target definition and organ at risk sparing.
As a part of an on-going research effort aiming to develop MR-guided RT platforms, we
have been acquiring MR images of HNC patients in their customized radiation immobilization
devices, to match their radiation therapy treatment position, as well as their CT treatment
scanning position(84). In this study, we aim to quantify the geometric distortion in patient
images by comparing their in-treatment position MRIs with the corresponding planning CTs,
using CT as the non-distorted gold standard.
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Our specific aims are to 1) determine the intra- and inter-observer variation that exists
when measuring specific distances between landmarks on both CT and MR images after rigid
co-registration, and 2) verify that MRI geometric distortion is within practical limits to support
increased clinical utility of MRI guided radiotherapy, particularly for future MRI-only treatment
planning and the combined MR-CT systems.
2.2 Materials and Methods
2.2.1 Patient selection
As part of a programmatic effort to develop quality assurance and performance
tolerance for MRI-guided radiotherapy, twenty-one HNC patients were selected in this
prospective study, after obtaining institutional review board approval and written informed
consents from all participants. Criteria of patient’s inclusion were; age≥ 18 years, histologically
documented stage III or IV human papillomavirus positive (HPV+) squamous cell carcinoma of
the oropharynx, definitive chemoradiotherapy, Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 2, and no contraindications to MRI. All patients had their treatment
planning CT done within one week of the MRI to avoid any significant anatomical changes
between both images (e.g. tumor progression or weight loss). Both images were collected prior
to the initiation of treatment.
2.2.2 Imaging acquisition
2.2.2.1 MRI
MR images were acquired with a 3.0-T Discovery 750 MRI scanner (GE Healthcare,
Waukesha, WI, USA) with laterally placed 6-channel phased array flex coils (GE Healthcare)
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centered on tumor covering from palatine process down to the lower edge of cricoid cartilage.
T2-weighted fast spin echo (FSE) sequence were acquired in the same immobilization position
as in the treatment planning CT scans as described in details in a previous report(84). By doing
so, we minimized patient positioning differences in the acquisition of CT and MR images
resulting in a minimized registration error between the two sets of images. Specific imaging
acquisition parameters of the T2-weighted FSE sequence are as follows: FOV=256 mm, Slice
thickness=2.5 mm and Matrix=512 x 512, giving pixel size of 0.5x0.5x2.5mm; Repetition Time
(TR) =3.7s; Echo Time (TE) = 97ms; Echo Train Length (ETL) =16. The distance from the skin
surface to the center of FOV was less than 10 cm for all patients included in this study.
2.2.2.2 CT
CT was acquired using the standard institutional protocol for simulation non-contrast
enhanced CT; slice thickness= 2.5 mm, tube current=350 mA at 120 kVp, display field of
view=500 mm, matrix of 512 x 512 pixels, pixel size of 0.98 x 0.98 mm, isocenter at arytenoid
cartilage, and coverage from vertex to carina.
2.2.3 Image selection and evaluation of geometric distortion
CT and T2-weighted MRI were transferred to commercial image registration and
segmentation software VelocityAI (Velocity Medical Solutions, Atlanta, GA). The navigator
module was selected, and the T2 MRI was rigidly registered to the CT. The module consists of
selection of primary (CT) and secondary (T2 MRI) images, manual alignment, selection of
region of interest, and rigid registration. Deformable registration was not used in order to
assess the inherent distortion in MRI.
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Utilizing the measurement tool within the VelocityAI software, several skin to skin (STS,
total of 9 landmarks), bone to bone (BTB, 9 landmarks), and soft tissue to soft tissue (TTT, 3
landmarks) measurements were done at specific levels in horizontal and vertical direction of
both CT and MRI images. Landmarks were anatomical features that can be reliably identified
and reproduced by observers on both CT and MRI. Table 2.1 illustrates the details of the
anatomical boundaries of the selected landmarks. The difference between measurements of
corresponding anatomical landmark on both MR and CT images was considered to be overall
geometric distortion. Figure 2.1 summarizes the workflow process utilized to obtain these
measurements.
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Figure 2. 1: Study workflow
This figure depicts the workflow of anatomical landmark measurements and comparison.
The landmarks were mainly selected in three levels (i.e. upper, middle, and lower).
Criteria for selecting each of the three specific imaging levels were as follows: the top slice was
the cranial-most co-registered image depicting clear maxillary sinuses and homogenous
intensity. Clear lower edge of the mandible, anterior vertebral body, and complete vertebral
encasing of the vertebral canal distinguished the middle slice. Similarly, the caudal-most image
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was selected based on clear superior border of the body of hyoid bone, anterior vertebral body,
and complete vertebral encasing of the vertebral canal. Nearly 43% of the anatomical
landmarks are peripheral (skin to skin) while the rest are more central landmarks such as two
points on a bony structure or muscle structures as illustrated in Table 2.1. For each patient, ten
(48%) of the measurements were distances in the horizontal direction while the rest were in the
anteroposterior direction. Also, the landmarks were chosen to be distributed in the upper,
middle and lower sections of the head and neck (Figure 2.2). Geometric error was
subsequently compared for all different axes, levels, and nature.
Table 2. 1: List of the selected landmarks
Skin to skin landmarks
1- Horizontal line at the level of
pterygomaxillary fissure
2- Horizontal line at level of tip of lateral
pterygoid plate
3- Horizontal line at level of the pterygoid
notch
4- Oblique line passing through the left
zygomatic process and pharyngeal tubercle
at midline
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5- Vertical line passing through the left
zygomatic process and the lateral edge of
left cerebellar tonsil.
6- Vertical midline at the level of superior
border of body of hyoid bone
7- Horizontal line at the level of anterior
vertebral body of the inferior border of C2
8- Horizontal line at the level of anterior
vertebral body of the inferior border of C4
9- Vertical midline at the level of inferior border
of C4
Bone to bone landmarks
1- Horizontal line between the medial edge of
bilateral mandibular condyles
2- Horizontal line between the tip of bilateral
mastoid processes
3- Vertical line between the mentum and the
midpoint of the anterior surface of the
vertebral body
4- Vertical midline of the spinal canal of C2
5- Horizontal line of the spinal canal of C2
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6- Horizontal line between the angles of the
mandible
7- Vertical midline of the spinal canal of C4
8- Horizontal line of the spinal canal of C4
9- Vertical line between the midpoint of the
posterior border of the superior surface of
body of hyoid bone to the midpoint of
anterior vertebral body
Soft tissue to soft tissue landmarks
1- Right lateral pterygoid muscle vertical length
2- Vertical midline cerebellar length
3- Left sternocleidomastoid muscle vertical
width
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Figure 2. 2: Examples of anatomical landmarks included in the study.
This figure shows the landmarks that were strategically selected to encompass a broad
coverage of the anatomical areas and varieties of anatomical structures (bone, soft tissue) and
direction (vertical vs. horizontal).

2.2.4 Inter- and intra-observer variation
For assessment of intra-observer variation, a single observer repeated a total of 100
landmark measurements (i.e. 10 landmark measurements per patient for 10 patients) to
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determine the intra-observer variation. For assessment of inter-observer variation in landmark
measurement, four observers collectively repeated the assigned 100 measurements
independently to assess the inter-observer variation.
2.2.5 Statistical analysis
Numeric variables are expressed in mean and SD. Comparison of mean errors by
different stratification was done using non parametric statistics, p < 0.05 was considered
statistically significant. Intraclass correlation (ICC) was calculated for intra- and inter-observer
variation. All analyses were done with JMP v 11Pro (SAS institute, Cary, NC), and Microsoft
Excel (Redman, Washington).
2.3 Results
2.3.1 Geometric distortion
Eleven landmark points were not attainable due to variation in the range of MR
coverage in four patients’ scans, leaving a total of 430 landmark measurements for final
analysis. The mean distortion for all landmark measurements in all scans was 1.6±1.7 mm.
There was no statistically significant difference of distortion magnitude for measurements at the
horizontal vs. vertical direction (1.5±1.6 vs. 1.6±1.7 mm, respectively, p=0.4) as shown in figure
2.3. Likewise, there were no significant differences in error measurements in the upper, middle,
and lower section of the head and neck (1.5±1.6 vs 1.4±1.2 vs 1.7±1.9 mm, respectively,
p=0.3) as shown in figure 2.4. However, we observed a statistically significant difference in
peripheral (STS) vs. more central landmarks (2.0±1.9 vs. 1.2±1.3 mm, respectively, p<0.0001)
as shown in figure 2.5.
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Figure 2. 3: Box plots for the landmark measurements in horizontal vs. vertical axis.
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Figure 2. 4: Box plots for the landmark measurements in the upper, middle, and lower
section of the head and neck.
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Figure 2. 5: Box plots for the landmark measurements in the peripheral vs. central
landmarks.
2.3.2 Inter- and intra-observer variations
The average error measurements between the MRI and respective CT for the selected
100 landmarks were 1.05±0.87, 1.23±0.82, 1.06±0.99 and 1.05±0.79 mm for observer 1, 2, 3,
and 4, respectively as shown in figure 2.6. The ICC for inter-observer variation was 0.84 (95%
CI, 0.78-0.88). Likewise, the average error for repeated measurements of observer 1 were 0.97
mm for the initial measurement and 0.99 mm for the repeats (p=0.9) and the ICC for intraobserver variation was 0.76 (95% CI, 0.64-0.84).
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Figure 2. 6 Box plots of the inter-observer variability for the landmark measurements
between observers.
2.4 Discussion
Our results showed that the overall average discrepancies of geometric fidelity of MRI
were within 2 mm from that of the CT. We also demonstrated that there were no significant
differences in the degree of geometric distortion in different axes and levels of the studied MR
images. However, distortions were significantly higher peripherally for skin to skin landmarks
than for more central bone to bone of soft tissue to soft tissue landmarks. These results were
consistent among different observer and with repeated measurements for the same single
observer with excellent ICC for both inter- and intra-observer observations.
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One of the main goals of radiotherapy is to accurately define the tumor target with high
certainty. MRI has superior soft tissue contrast enabling better delineation of tumor from those
of surrounding healthy tissues, where the relatively poor contrast of CT resulted in uncertainties
in target delineation. Therefore, in spite of the fact that MRI has a certain degree of distortion,
MRI may still provide higher confidence in target delineation and consistency compared with
CT. Our data support that additional margins around target volumes to account for geometric
uncertainty may not be needed for radiotherapy planning using anatomical MR sequences
particularly if tumors are close to the image isocenter. This is partly because the relatively small
error introduced by geometric distortion compared with higher inter-observer delineation error
observed in radiotherapy planning using CT, as widely published in the literature (34, 85, 86).
We are also running a separate investigation of the inter-observer delineation error using
anatomical MR sequences acquired using the radiotherapy immobilization platform used in the
current study. However, for functional MR sequences (e.g. diffusion weighted imaging) the
magnitude of distortion is much higher and requires dedicated study to investigate its optimal
use in radiotherapy planning context.(87, 88)
Geometric distortion due to MRI scanner system imperfection is also spatially
dependent. The magnitude of distortion is typically small at isocenter (the center of the magnet
and gradient system) and larger in areas away from isocenter (i.e. near the skin) due to the
falloff in gradient linearity at the periphery. Therefore, the actual geometric distortion in practice
can be smaller than the average distortion reported in this study, depending on the tumor and
other structure location. For head and neck cancer patients, the region of MR imaging volume
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is relatively small and can be completely contained by the “sweet zone” (i.e. area of relatively
linear gradients and homogeneous B0 field). For other anatomical areas such as the GI and
GU, and when the tumor is off to the peripheral of the body, the geometric distortion may be
larger than that of the central location. Thus, the geometric distortion for those specific
anatomical areas may still need to be assessed for radiation therapy applications. Additionally,
each MRI scanner system’s geometric distortion is different and, thus, must be assessed
individually.
Susceptibility-induced geometric inaccuracies occur at boundaries between tissues with
large differences in susceptibility (e.g. bone-tissue, air cavity-tissues). Those geometric
inaccuracies are difficult to assess but usually occur in the frequency encoding direction and
can be somewhat minimized by increasing the bandwidth in the MRI acquisition. From the
results of our measurements, the overall discrepancies (which include the susceptibility
induced inaccuracies, system-specific inaccuracies, and the registration error between CT and
MR) are within 2 mm, which is an encouraging finding.
Additionally, MRI is more complicated than CT in which many acquisition parameters
may affect the geometric distortion. Therefore, for each clinical practice, the commonly used
MRI acquisition sequences and parameters need to be optimized based on the
recommendations of physicists or vendors. The actual distortion must be assessed by
phantoms, and quality control program needs to be in place to ensure such consistency and
quality.
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At the present, there is no specific, commonly agreed upon guidelines for the quality
control and quality assessment for MRI geometric distortion. Professional organization such as
the AAPM has established several task groups (e.g. AAPM TG117) looking into these very
issues. There is lack of commonly agreeable phantom to use in the assessment of geometric
fidelity. For radiotherapy applications, minimizing geometric distortion is a fundamental element
before clinical implementation. Several prior attempts were implemented to optimize the MR
sequences, including using 3D spin echo sequences with vendor-supplied distortion correction
and widening the bandwidth to reduce susceptibility related distortion(89, 90). Placement of the
region of interest at or near the isocenter of the magnet, where gradient field nonlinearities are
minimum is another solution. Additionally, increasing the sampling bandwidth at the cost of
SNR, because the bandwidth is inversely proportional to susceptibility-induced errors is another
alternative for radiotherapy applications where very high SNR may not be as critical as in
diagnostic applications.
Our study is limited by the relatively small number of patients in the study. However, this
is our attempt to measure the actual discrepancies in geometric fidelity as compared with CT,
which is considered to have little or no distortion. This study is still valid because the large
number of landmark measurements included. Furthermore, the MRI sequence (T2w) we used
in this study was a multiple 2D acquisition with a slice thickness of 2.5 mm (superior-inferior
direction) which, thereby, has lower resolution compared with the in-plane (anterior-posterior
and right-left) that was 0.5 mm. Therefore, reliable and reproducible landmarks in the superiorinferior direction were not attainable. While for slice locations away from the isocenter, the axial
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planes tend to “warp”, introducing out-of-plane distortion. This introduces additional
uncertainties in geometric fidelity in MRI. Therefore, it is critical to apply 3D geometric distortion
correction in the acquisition to minimize the out-of-plane distortion. Also, our study did not
explore the possibilities of further optimizing the pulse sequences in the image acquisition such
that distortion due to MRI can be further minimized, and the scanner used in our study is a
regular MRI scanner used for diagnostic purpose, rather than optimized for radiation therapy
treatment planning purposes. It is expected that with MRI scanners that are designed for such
purpose, the geometric distortion and optimization of MRI sequences, the distortion due to MRI
can be reduced further.
Our future works include the assessment of geometric discrepancies between CT
simulation scans and that of MRI in other anatomical areas such as GI and GU. These other
studies present other challenges including patient and internal organ motion and the needs of
developing patient immobilization devices and procedures for MRI scans. Despite the
challenges, these kinds of validation studies are important and much needed for using MRI in
radiotherapy applications. This current study has given us the confidence that the geometric
distortion in MRI is manageable and is within a reasonable range. With proper immobilization
devices, optimization of MRI sequences, and QA/QC procedure in the future, implementing
MRI for radiation therapy treatment planning in most if not all anatomical areas are possible.
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Chapter 3: MRI-guided dose adaptation
This chapter is based upon:
Mohamed ASR, Bahig H, Aristophanous M, Blanchard P, Kamal M, Ding Y, Cardenas CE,
Brock KK, Lai SY, Hutcheson KA, Phan J, Wang J, Ibbott G, Gabr RE, Narayana PA, Garden
AS, Rosenthal DI, Gunn GB, Fuller CD; MD Anderson MRLinac Development Working Group.
Prospective in silico study of the feasibility and dosimetric advantages of MRI-guided dose
adaptation for human papillomavirus positive oropharyngeal cancer patients compared with
standard IMRT. Clin Transl Radiat Oncol. 2018 May 5;11:11-18. doi:
10.1016/j.ctro.2018.04.005. PMID: 30014042; PMCID: PMC6019867.
This article is under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/)
which permits reproduction in any format.
3.1 Introduction
Human-papilloma virus positive (HPV+) oropharyngeal cancer (OPC) is epidemic in the
United States, with an estimated 20,000 new cases annually, and rising incidence projected in
the coming decades.(91) HPV+ cancers are sensitive to radiotherapy but despite excellent
survival outcomes and the introduction of intensity modulated radiotherapy, current regimens
continue to be associated with toxicity to adjacent normal tissue.(10-16) This leaves
comparatively young survivors with potentially quality-of-life altering, permanent radiation
sequelae that can persist for decades of survivorship, and limit future compensatory
functionality in the face of new challenges.(17-20) To address this issue, it is necessary to find
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the optimal therapeutic window of HPV+ OPC, where dose to organs at risk (OARs) can be
reduced while tumoricidal doses to active tumor volumes can be achieved. However, safely
achieving this target by anatomically adapting the dose to follow serially shrinking tumor
volumes during the 6-7-week radiation therapy course is currently impossible using CT without
repeated use of exogenous contrast. In addition, existing functional imaging biomarkers, such
as radiolabeled positron emission tomography (PET) tracers cannot be safely repeated
iteratively during treatment. Therefore, the ability to image tumors during therapy to adapt
radiation fields for responding tumors, reducing OAR dose and subsequent toxicity, is currently
an unmet need.
Adaptive radiotherapy strategies have been previously implemented at our facility.(92,
93) Schwartz et al. performed adaptive replanning mid-therapy for head and neck cancer
patients, using daily computed tomography (CT)-on-rails image-guidance. The lack of contrast
delivery for the CT-on-rails impeded the accurate visualization of tumor changes during
treatment, and thus did not allow for reduction of clinical target volumes as tumor shrank, but
instead accounted for weight-loss and normal tissue deformation.(92, 93) Magnetic resonance
imaging (MRI) provides superior tumor/soft tissue contrast(94). In a recent study by our
group(52), 31 patients with locally advanced HPV+ OPC were examined for mid-treatment
response as assessed by MRI. The study showed that approximately 50% of patients had
complete resolution of clinical and radiographically primary disease at mid-therapy. Using serial
MRI-guided dose adaptation in this cohort of patients would allow selective, patient-specific
precise dose-reduction, such that patients with brisk radiation response would have
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commensurate dose reduction, while comparatively radiation resistant tumor subvolumes
would be ensured a tumoricidal dose. Using serial in-treatment MRI without exogenous/IV
contrast, we can potentially track tumor shrinkage during treatment, conceivably de-escalating
OARs doses to reduce side effects without sacrificing locoregional control and survival.
In this dosimetric study, we propose a novel MRI-guided IMRT dose-adaption strategy
for HPV+ OPC, whereby dose to gross disease is reduced on an “as needed” basis, such that
responders could achieve substantive dose reduction to adjacent normal tissue at levels not
observed with standard radiotherapy, while non-responsive disease would not be a priori deescalated. This represents a truly “personalized” therapy, as, rather than assigning dose a
priori, the cumulative dose received by each patient would be predicated on imaging response.
To this end, we aim to determine the feasibility and dosimetric benefits of this MRI-based doseadaption strategy for HPV+ OPC patients using serial in-treatment MRIs acquired in radiation
treatment positioning and immobilization setup.
3.2 Materials and Methods
3.2.1 Patients
Patients in the current study were prospectively enrolled under an Institutional Review
Board (IRB)-approved imaging protocol (PA14-0582) after signing a study-specific informed
consent form. Patients were scanned between July 2015 and June 2016. Inclusion criteria were
age older than 18 years; histologically proven P16+ oropharyngeal squamous cell carcinoma;
eligibility for definitive IMRT; intact primary tumor; Stage III, IVa, or IVb disease as defined by
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American Joint Committee on Cancer (AJCC) 7th edition cancer staging criteria; ECOG
performance status of 0-2; no administration of induction chemotherapy before radiotherapy;
and no contraindications to MR imaging.
3.2.2 MRI Protocol
Serial MRI simulation images were acquired at baseline (within one week prior to first
radiation fraction), and every two weeks during the IMRT course (i.e. at weeks 2, 4, and 6).
Patients were dispositioned to receive a custom-fitted oral stent and an immobilization mask
same to that used for radiotherapy treatment planning prior to receiving their study MRIs. The
stent was made by the dental oncology team to hold the tongue and the remainder of the oral
cavity in place. The thermoplastic mesh mask, for the head and neck region, was made during
the simulation phase to immobilize the head, neck, and shoulders of the patient in a
reproducible way. We previously detailed the positioning and immobilization setup for our MRIsimulation process in a separate publication.(84)
Patients’ images were acquired using a 3.0T MR scanner (Ingenia, Philips Healthcare,
Best, The Netherlands) with two SENSE Flex-M coils laterally and SENSE spine coil
posteriorly. MRI sequences included axial T2 weighted image (repetition time/echo time =
8755/100 ms, echo train length = 15, field of view = 25.6 cm, spatial resolution = 0.5x0.5x2.5
mm3, number of signal averages = 2, pixel bandwidth = 184 Hz, number of slices = 90).
Geometrical scan parameters were prescribed for a standardized spatial region encompassing
the vertex cranially to the cricoid cartilage caudally for all scans.
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3.2.3 CT Simulation
Standard simulation CTs were acquired for each patient at baseline prior to treatment,
followed by serial simulation CT imaging for adaptive replanning at the same time points of MRsimulation (i.e. at weeks 2, 4, and 6) using identical positioning and immobilization setup (see
schema of protocol, Figure 3.1).

Figure 3. 1: Schema of in silico adaptive planning protocol.

3.2.4 Target Volumes and dose specification
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Target volumes were delineated, and peer reviewed by MD Anderson’s Radiation
Oncology Head-and-Neck Planning and Development Clinic. The process of peer-review of
segmented contours was explained in details in a prior report by our group.(95) In brief, the
process entails comprehensive review of a patient’s history, pathology, diagnostic imaging,
and discussion of the planned treatment. All patients undergo physical examination (PE)
including video-camera nasopharyngolaryngoscopy and bimanual palpation performed by a
team of head-and-neck radiation oncology sub-specialists. The proposed segmentations
were reviewed slice-by-slice for gross tumor volume (GTV), clinical target volume (CTV) and
OAR segmentation, as well as dose-volume specifications. By this manner, intra- and interobserver variability in segmentation are minimized because of the utilization of multiobserver’s agreement contours rather than single-observer contours.
The initial gross tumor volume (e.g. GTV_pinitial for primary disease and GTV_ninitial
for nodal disease) was manually segmented using T2-weighted MR images at baseline then
propagated to the co-registered simulation CT acquired at the same day. The initial clinical
target volume (CTVinitial) was defined as the GTVinitial plus 5mm expansion, trimmed from
uninvolved bone, muscle, skin or mucosal surfaces; to incorporate high-risk subclinical
disease.
For each patient, two IMRT plans were created: a standard and an adaptive
treatment plan. The prescription dose for the standard plans was 2.12 Gy/fx for 33 fractions
to the PTVinitial (CTVinitial +3mm). For adaptive plans, a new GTVadaptive was segmented on
serial MRIs using T2-weighted MR images at time points showing a detectable shrinkage of
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the GTVinitial. Subsequently, a new CTVadaptive was generated to cover the GTVadaptive
propagated from MRI to the corresponding same day CT with additional 5mm margin.
Detectable shrinkage was defined as any GTVinitial reduction of more than 2mm in the
reference plane (largest cross-sectional distance axially on the pretherapy imaging).
The prescription dose to PTVadaptive (CTVadaptive+3mm) was 2.12 Gy/fx to allow
delivery of maximum dose to the residual disease, resulting in a cumulative dose, should
disease persist through therapy, of up to 70 Gy. Prescription dose for any previously involved
volumes was 1.52 Gy/fx to ensure a minimum “floor” dose of 50.16 Gy to any region ever
deemed to have been directly involved with tumor. All uninvolved upper-neck elective nodal
volumes outside the CTVinitial/CTVadaptive were encompassed in the CTVelective, and prescribed
1.52 Gy/fx for a total prescription of 50.16 Gy/33 fractions. Figure 3.2 illustrates the workflow
for adaptive vs. standard plans.
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Figure 3. 2: Adaptive dose reduction workflow.
Adaptive dose reduction workflow shown on the left; as GTV (green) shrinks, so does the high
dose (CTV 2.12 Gy/day region) which become included in the low dose target (CTV 1.52
Gy/day region). Standard radiotherapy doses are shown on the right.
3.2.5 OAR Segmentation
Organs at risk (OARs) were auto-segmented on simulation CTs at baseline and at
weeks 2, 4, and 6 using a previously validated atlas-based auto-segmentation software
program ADMIRE v1.13 (Elekta AB, Stockholm, Sweden). This was followed by review and
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correction of the contours when needed by an experienced radiation oncologist (ASRM). The
following OARs were included: spinal cord; brain stem; bilateral parotid and submandibular
glands; thyroid gland; larynx; oral cavity; brachial plexus; superior, middle, and inferior
pharyngeal constrictors; medial and lateral pterygoid muscles; masseter; sternocleidomastoid;
intrinsic and extrinsic tongue muscles; hard palate; and soft palate.
3.2.6 Radiation planning
All plans were optimized to full dose (70Gy or 50.16 Gy if no residual disease was
present) to keep the total dose to each OAR below the tolerance limit for every adaptive plan
while maintaining at least 99% coverage to the PTV with a hot spot less than 110% to ensure
that no normal tissue limit would be reached for a specific organ before the end of treatment.
Once the plan was finalized, the number of fractions was adjusted to the number that would be
delivered for the next adaptive phase. Dose accumulation was performed at the end of each
adaptive phase to ensure target volumes met prescription dose and OARs met dose
constraints.
Planning was performed with Pinnacle3 v.9.10 (Philips Medical Systems, Fitchburg,
WI). All patients were planned with volumetric modulated arc therapy. For bilateral neck
irradiation, two 360-degree arcs were utilized, while for cases of unilateral neck irradiation, two
half arcs were used. The duration of the MRI-simulation was one hour and the duration of
segmentation and replanning was four hours per patient.
3.2.7 Statistical analysis
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Three dimensional volumetric changes of GTV_p and GTV_n were recorded at all time
points. Dosimetric parameters of target volumes and OARs were recorded for standard vs.
adaptive plans for each patient. Subsequently, normal tissue complication probability (NTCP)
for toxicity endpoints was calculated using literature-derived multivariate logistic regression
models (96-99). The toxicity endpoints examined were: 1) persistence of feeding tube 6 months
after treatment (96), 2) grade ≥2 dysphagia 6 months after treatment (97), 3) hypothyroidism 12
months after treatment (98), and 4) xerostomia 6 months after treatment (99). The rationale for
NTCP model selection was detailed in a previous publication by our group(100). All statistical
analyses were performed using statistical software (JMP Pro version 11, SAS Institute, Cary,
NC).
3.3 Results
Five patients were included in this pilot study; 3 men and 2 women. Median age was 58
years (range 45-69). Three tumors originated at the tonsillar fossa and two at the base of
tongue. Patient demographic, disease, and treatment characteristics are summarized in Table
3.1.
Table 3. 1: Patient demographic, disease, and treatment characteristics.
Patien
t

Origin

Gende
r

Age
(years
)

Smokin
T
g history stag
e

N
stag
e

AJC
C
stage

Concurrent
chemotherap
y

1

Tonsil

Female

45

Never

N2c

IVA

weekly
Cisplatin

T2

39

2

Base of
Tongu
e

Male

60

Never

T2

N1

III

No
chemotherapy

3

Tonsil

Female

69

Former

T2

N2b

IVA

weekly
Cetuximab

4

Tonsil

Male

51

Never

T2

N2c

IVA

weekly
Cisplatin

5

Base of
Tongu
e

Male

58

Never

T2

N2b

IVA

weekly
Cetuximab

The average decrease in GTV_p volume at weeks 2, 4, and 6 was 44%, 90%, and
100%, respectively. The GTV_n volume shrinkage, however, had a relatively slower pace with
average decrease in GTV_n volume at weeks 2, 4, and 6 of 25%, 60%, and 80%, respectively.
These significant shrinkages qualified all patients for adaptive plans at weeks 2, 4, and 6. The
course of target volume response is presented graphically in figure 3.3 for all patients included
in the analysis.
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Figure 3. 3: Volumetric response of target volumes.
Details of volumetric response of target volumes for all patients at each time point, over the
course of therapy. Patient 2 had an excisional biopsy prior to definitive IMRT and, therefore,
had no GTVn at radiation start.
Results demonstrated that the vast majority of OARs showed a decrease in dosimetric
parameters when adaptive plans were used compared with standard plans, particularly for
swallowing related structures, as illustrated in Table 3.2. Regarding target volumes, the
average dose to 95% of PTVinitial volume was 70.7 Gy (SD, 0.3) for standard plans versus 58.5
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Gy (SD, 2.0) for adaptive plans. Details of dose parameters for target volumes are presented in
Table 3.3.

Table 3. 2: Dosimetric criteria of organs at risk using standard vs adaptive plans.
Organ at risk
(OAR)
Supraglottic
larynx
Glottic larynx
Superior
pharyngeal
constrictor
Middle
pharyngeal
constrictor
Inferior
pharyngeal
constrictor
Cricopharygeou
s muscle
Mylo/geiohyoid
muscle
Intrinsic tongue
muscles
Genioglossus
muscle
Oral cavity
Soft palate
Ipsilateral ant.
Diagastric
muscle
Contralateral
ant. Diagastric
muscle

Mean dose
Standard IMRT
in Gy

Standard
Deviation
Standard IMRT
Gy

Mean dose
Adaptive IMRT
in Gy

Standard
Deviation
Adaptive IMRT
Gy

52.7

10.7

45.8

10.4

33.8

21.7

31.0

18.9

62.8

6.7

58.1

5.0

51.6

16.4

48.4

12.5

34.7

23.3

32.0

18.6

30.0

19.0

27.5

17.5

37.8

10.5

33.4

11.2

44.7

14.5

40.1

12.9

51.8

13.5

47.4

11.0

42.1
55.0

11.3
10.7

38.0
49.2

10.8
10.6

44.4

6.9

40.6

7.1

29.9

10.2

26.0

12.7
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Ipsilateral
parotid gland
Contralateral
parotid gland
Ipsilateral
submandibular
gland
Contralateral
submandibular
gland
Esophagus
Brain Stem
Spinal cord
Thyroid gland

30.2

11.3

26.9

8.3

17.4

8.6

16.5

8.4

69.7

3.6

65.0

6.0

40.9

20.3

39.9

19.6

19.2
10.8
21.8
36.1

12.3
1.9
6.5
23.2

16.8
8.3
21.2
32.8

9.9
2.7
8.0
20.7

Table 3. 3: Dosimetric parameters of target volumes using standard vs. adaptive plans.
Patient

Patient
1
Patient
2
Patient
3
Patient
4
Patient
5

PTV mean
dose
(Standard)
71.61

PTV mean
dose
(Adaptive)
62.2

PTV max
dose
(Standard)
74.88

PTV max
dose
(Adaptive)
72.6

PTV
D95%
(Standard)
70.56

PTV
D95%
(Adaptive)
56.02

71.47

61.68

73.61

65.31

70.46

59.08

71.86

66.25

76.02

72.16

70.61

57.42

72.7

69.38

76.4

73.4

71.12

61.8

72.1

65.2

75.7

72.6

70.98

58.1

Using NTCP models, the average reduction of the probability of developing dysphagia ≥
grade 2 and feeding tube persistence at 6-month post-treatment using adaptive strategy was
11% (37% vs 26%, odds ratio (OR) = 0.6, 95% CI 0.2-1.5) and 4% (10% vs 6%, OR = 0.5, 95%
CI 0.1-3), respectively as depicted in Figure 3.4.
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Figure 3. 4: NTCP of standard versus adaptive methods.
Boxplots depicting the comparison of normal tissue complication probability (NTCP) between
standard and adaptive methods.
The probability of developing hypothyroidism at 1-year post-treatment was also reduced
by average 5% (41% vs 36%, OR= 0.8, 95% CI 0.3-2) while the probability of xerostomia at 6month was only reduced by average 1% for adaptive plans compared with standard IMRT
(35% vs 34%, OR= 0.95, 95% CI 0.4-2.5).
3.4 Discussion
In this study, we report the feasibility of an MRI-guided IMRT dose-adaption workflow
for HPV+ OPC. To our knowledge, this is the first study reporting on the dosimetric advantage
of MRI-based adaptive radiation de-intensification in head and neck cancers. The proposed
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approach was associated with an average reduction in the dose to the PTV of 12 Gy. Adaptive
replanning was associated with reduction of dose to the OARs, in particular to the swallowing
musculature, which translated into a reduction of the odds of dysphagia ≥ grade 2, feeding tube
persistence at 6-months, and hypothyroidism at 1-year post-treatment.
HPV+ OPC has been shown to be a favorable subtype of head and neck cancer with
improved prognosis compared to non-HPV+ OPC (4, 101). The distinctive epidemiologic,
clinical and molecular characteristics (102) of HPV+ OPC are now reflected in the new cancer
staging proposed in the American Joint Committee on Cancer 8th edition (103). Given the
excellent outcomes of HPV+ OPC, it is increasingly considered that many patients with HPV+
OPC may be over-treated with current standard chemoradiation. It is, in fact, recognized that
current standard treatment is associated with high rates of toxicities that were shown to
adversely impact patients’ health-related quality of life (104). Given the high probability of longterm survival and typical young age of patients with HPV+ OPC, treatment de-intensification
aiming at reducing long-term toxicities and improving survivorship has become a central
concern in the management of these patients (105). To this end, multiple clinical trials are
currently on-going to assess various treatment de-escalation strategies in this group (106, 107).
The overall goal of all treatment de-intensification strategies is to maintain excellent
cancer outcomes while reducing morbidity. Current evaluated strategies include the use of
targeted therapies versus systemic chemotherapy (106), reduced radiation dose based on
response to induction chemotherapy response (108-110), or modulation of radiation dose in the
context of chemoradiation (111, 112). Proton therapy may be also an alternative way to reduce
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normal tissue toxicity and is currently investigated in randomized trial (NCT01893307)
comparing IMPT versus standard IMRT. A recent study by Blanchard et al. demonstrated the
validity of a set of NTCP models for head and neck cancer patients treated with proton therapy.
However, improvement in model performance remains to be required for better selection of
patients for proton therapy(113). Furthermore, minimally invasive surgery such as trans-oral
robotic surgery (TORS) has been also introduced as alternative approach to avoid radiation
toxicity with equivalent oncologic outcomes(114). An ongoing randomized clinical trial
(NCT02984410) is currently assessing the patient-reported swallowing function over the first
year after randomization to either IMRT or TORS in OPC patients.
It is fairly well established that radiation dose is closely related to radiation-induced
long-term toxicities, notably to rates and severity of dysphagia as well as rates of stricture
formation, feeding tube dependence and aspiration (115-117). In a recent systematic review by
Duprez et al., mean dose to pharyngeal constrictors was the strongest predictor of late
swallowing dysfunction, with clinical reduction of swallowing dysfunction observed with dose of
52-55 Gy vs. 61-64 Gy, suggesting that even mean OAR dose reduction of less than 10 Gy
could translate into clinically impactful toxicity reduction (118). In this context, de-escalation
strategies aiming at reducing radiation dose are particularly appealing. Chera et al. (111)
recently investigated rates of complete response of a de-intensified chemoradiation strategy in
favorable risk HPV+ OPC. Treatment de-escalation consisted of delivery of 60 Gy to the gross
disease and reduced cisplatin dose (30 mg/m2 weekly). The reported clinical complete
response rates reached 98% and 60% at the primary and regional sites respectively,
suggesting that dose de-escalation may be suitable in selected patients. However, optimal
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strategy for patients’ selection, notably the potential role of adaptive de-escalation based on
individual response, remains to be investigated.
The principle of adaptive radiotherapy planning relies on monitoring temporal and
spatial anatomical changes over the course of radiotherapy, and modulating radiation dose
based on observed changes. These changes can include changes in target volumes, OAR
volume or shape, weight loss, alteration in muscle mass, or edema (92, 119, 120). Several
previous studies have assessed the role of per-treatment imaging response during the course
of radiotherapy for head and neck cancer, including CT (92, 93, 121, 122), PET-CT (123),
anatomic MRI and functional MRI (diffusion weighted or dynamic contrast enhanced) (124),
with tumor changes observed in the majority of patients, as early as by fraction 11 (125). Using
CT-on-rails image guidance in patients undergoing head and neck radiotherapy, Schwartz et al.
at reported that all patients benefited from at least one re-plan and 36% required a second replan to account for weight loss, CTV and normal tissue changes (92, 93). More recently, Lee et
al. (112) reported outcomes of an adaptive approach consisting of 10 Gy dose de-escalation to
involved lymph nodes based on early treatment hypoxia assessment using 18Ffluoromisonidazole-PET. Among 33 patients, 30% received reduced radiation dose; 2-year
locoregional control rate was as high as 100%. This study suggests that functional imaging
may play an important role in guiding adaptive radiation strategies. The increasing use of MRI
for head and neck radiotherapy planning has the advantage of improved soft-tissue
visualization (94), which allows to more confidently assess anatomical tumor changes during
treatment. In addition, MRI also offers the possibility of frequent per-treatment functional
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assessment, without addition of ionizing radiation. The recent introduction of the MR-Linac
technology holds the promise to facilitate such adaptive IMRT workflows by mean of daily online MRI during radiation treatment (38).
This in silico study is limited by its small sample size. However, the aim of this study
was to establish the feasibility and the dosimetric advantage of this proposed MRI-guided IMRT
dose-adaption workflow for HPV+ OPC, in preparation for future clinical application. In addition,
this study used only anatomical MR-sequences for treatment adaption. However, although the
role of functional MRI certainly seems promising for assessment and prediction of tumor
response (124), observed functional changes require further investigation to establish clear
thresholds to be used clinically for treatment adaptation. Finally, the safety, in terms of cancer
control outcomes, as well as the toxicity advantages of this workflow will be validated in an
upcoming clinical trial by our institution. The results of this study guided the sample size
calculation of this upcoming phase II clinical trial designed to validate the superiority of MRIguided radiotherapy dose adaptation for improving the toxicity profile of HPV+ oropharyngeal
cancers without compromising the outcomes.
3.5 Conclusions
This in silico results showed the suggested MRI-guided adaptive approach is technically
feasible, safe (with no normal tissue exceeding modeled dose constraints), and advantageous
in reducing dose to OARs, especially swallowing musculature, thus reducing the NTCP of
dysphagia ≥ grade 2, feeding tube persistence at 6-month post-treatment, and hypothyroidism
at 1-year post-treatment.
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Chapter 4: Diffusion-weighted MRI as a biomarker for tumor response and disease control
4.1 Introduction
Radiation therapy (RT) is a cornerstone of head and neck cancer (HNC) treatment both
in the definitive (i.e., organ preserving) and the adjuvant post-operative setting. The goal of RT
is to maximize the dose to cancer cells while minimizing the dose to adjacent normal tissues.
However, tumors have variable sensitivity to RT leading to different disease response
rates.(29) Current RT dose and fractionation are largely driven by empirical data rather than
tumor-specific information regarding potential radiosensitivity or radioresistance.(5-7, 126) The
ability to predict tumor response before and/or during the RT course can allow for the
adaptation of RT doses and potentially achieve better treatment outcomes for patients.

Non-invasive imaging such as magnetic resonance imaging (MRI) can provide
important information related to tumor characteristics and response to RT. The development of
MRI correlates of RT response would be critical for implementing adaptive RT strategies that
maximize therapeutic ratios. Specifically, patients with aggressive non-responsive tumors may
require RT dose escalation (5, 7), while patients with radiosensitive tumors may benefit from
dose de-escalation to spare normal tissues with equivalent tumor control.(6) This represents a
significant unmet clinical need since patients with radiosensitive tumors are over-treated and
patients with radio-resistant tumors are under-treated. A leading-edge solution to the anatomic
adaptive therapy problem has been to integrate MRI into radiation delivery devices (e.g., MRLinear accelerators).(38) The richer data of MRI compared with standard of care CT images,
enables computer-driven identification of tumors and normal tissues and allows radiation plans
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to be adapted on a daily basis with limited human intervention. (39, 40) Yet, gross anatomic
changes represent only one dimension of patient response to RT. Having incorporated highfield MRI into delivery devices, there is now the potential to monitor the biologic changes within
the patient using functional MRI sequences without excess radiation, contrast exposure, or
excess burden on patients’ time.
The central hypothesis of this study is that quantitative MR diffusion-weighted imaging
(DWI) can be used as a predictive biomarker of treatment response and oncologic outcomes in
HNC. Functional changes in a tissue (e.g., a reduction in cellular density through RT-induced
apoptosis) is reflected in an alteration in the detected diffusion measures, using a metric known
as the apparent diffusion coefficient (ADC). The ADC component of DWI has been previously
used to detect treatment response in HNC.(50, 127, 128) Specifically, DWI has been shown to
predict response to induction chemotherapy(41, 42), RT(42-50), and tumor recurrence(51).
Preliminary data from a prospective trial at our institution(52), supported by other group’s
data(42, 44-46, 49, 53, 54), has demonstrated that DWI was able to discriminate patients who
will have a complete response at mid-RT. Additionally, recent data from our group
demonstrated that early tumor regression rate ≥25% at fraction 15 (i.e., mid-RT) in HNC
patients is associated with better local control and overall survival.(55) These low-risk patients
represent suitable candidates for RT dose de-escalation if dose could be coupled to a
quantitative marker of tumor response probability (i.e., ADC). However, these findings remain
to be validated in larger prospective studies with more mature follow-up data to correlate with
oncologic outcomes and overall survival. To this end, we aim to determine DWI parameters
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associated with tumor response and oncologic outcomes in a prospective cohort of HNC
patients treated with definitive RT.
4.2 Methods
4.2.1 Patient selection
HNC patients enrolled in an active prospective imaging study (NCT03145077) from
January 2017 to March 2021 were included after institutional-review board approval and studyspecific informed consent. Patients in this cohort had MRIs at pre-RT, mid-RT, and post-RT.
Inclusion criteria were adult patients with histologic evidence of malignant head and neck
neoplasm obtained from the primary tumor or metastatic lymph node; indicated for curativeintent treatment with radiotherapy with or without chemotherapy (induction or concurrent); good
performance status (ECOG score 0-2); and with no contraindications to MRI.
Patients evaluated in this study received RT using standard daily fractionation for a period of 67 weeks. Tumor staging was based on clinical imaging consisting of contrast (CE) CT prior to
treatment initiation using current AJCC 8th edition staging criteria.
4.2.2 MR Imaging

All patients enrolled in the study had imaging acquired using individualized
immobilization devices. Head immobilization was performed to decrease motion artifacts during
the imaging study, according to the methodology presented previously by our group.(84)
Patients were scanned using a MAGNETOM Aera 1.5T MR scanner (Siemens Healthcare,
Erlangen, Germany) with two large four-channel flex phased-array coils. After the scout scan,
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an anatomic T2-weighted (T2w) fast spin‐echo sequence (TR/TE = 4.8 s/80 ms; echo train
length = 15, pixel bandwidth = 300 Hz, slice thickness= 2 mm, matrix= 512 x 512) was
performed. One hundred and twenty axial slices with a field of view (FOV) of 25.6 cm were
selected to cover the primary tumor and neck nodes. Acquisition parameters for DWI MRI were
multi shot radial turbo spin-echo (i.e., BLADE), axial acquisition; TR = 6.5 s; TE = 50 ms; pixel
bandwidth = 1220 Hz; FOV = 25.6 x 25.6 cm2; echo train length = 15; EPI factor = 7, acquisition
matrix = 128 x 128; voxel size = 1 x 1 x 2 mm3; 24 contiguous slices; two b-values = 0 and 800
(sec/mm2) for each orthogonal diffusion direction. DWI acquisition of patients scanned after
2018 was performed with multi shot spin-echo echo-planar imaging (i.e. readout segmentation
of long variable echo-trains, RESOLVE), axial acquisition; TR = 3.5 s; TE = 65 ms; pixel
bandwidth = 780 Hz; FOV = 25.6 x 25.6 cm2; acquisition matrix = 128 x 128; slice thickness =
4 mm; reconstruction voxel size = 1 x 1 x 2 mm3, 48 contiguous slices; number of average = 8;
two b-values = 0 and 800 (sec/mm2) for each orthogonal diffusion direction. ADC maps were
subsequently autogenerated using a scanner specific on-line software during image
generation. RESOLVE was selected because of shorter scan time (3:30 vs. 7:03 minutes for
BLADE) and relatively higher signal-to-noise ratio. Our quality assurance study using phantom,
volunteer, and patient images showed that both methods display similar ADC values with no
differences in repeatability studies.
4.2.3 Image Segmentation/Registration
The regions of interest (ROIs) for the primary gross tumor volume (GTV-P) and the
nodal gross tumor volume (GTV-N) were manually segmented by an expert radiation oncologist
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(ASRM) using the pre-RT T2w images. Deformable image registration (DIR) was used to
register MR sequences at different time points (i.e., baseline and mid-RT) using the
benchmarked commercially available image registration software (Velocity AI, version 3.0.1,
Atlanta, GA). All baseline GTV-P ROIs were then propagated to the mid-RT T2w images (i.e.,
mid-RT GTV-P) which represent the same three-dimensional (3D) volume of the original GTVP on mid-RT images and include both responding and non-responding voxels. This was
followed by quality assurance (QA) review and manual editing whenever needed to exclude air
gaps or non-anatomically relevant parts in case of massive tumor shrinkage. Residual GTV-N
ROIs, on the other hand, were all manually segmented on mid-RT images. Subsequently, DWI
images were co-registered with the corresponding T2w of each time point and finally all ROIs
were propagated to extract corresponding ADC values. Additional ROIs were created on midRT images for patients with non-complete GTV-P response at mid-RT to assess DWI
differences between responding and non-responding sub-volumes within the mid-RT GTV-P.
The first sub-volume was labeled mid-RT GTV-P-RD which represents the residual disease
and the second sub-volume was labeled mid-RT GTV-P-RS which represents the area of
response. Figure 1 illustrates the workflow process for image registration and segmentation.

53

Figure 4. 1: Workflow process of the study.
Illustration of the workflow process for image registration and segmentation in the study using
an example of a patient with T4N1 tumor of the base of tongue. Panel (A) shows the GTV-P
segmentation on baseline T2w MRI followed by rigid co-registration (RIR) and contour
propagation to baseline DWI (B) and then ROI propagation to corresponding ADC map (C).
Panel (D) shows mid-RT T2w image with partial response. The image was co-registered to
baseline T2w using deformable image registration (DIR) and baseline GTV-P was propagated.
Subsequently, the residual and response sub-volumes were segmented (E), then contours
were propagated to mid-RT DWI after RIR (F), and finally to the corresponding mid-RT ADC
map (G).
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4.2.4 Outcome definition

Treatment response was assessed at mid-RT and at 8-12 weeks post-RT using
RECIST 1.1 criteria and was defined as: complete response (CR) vs. non-complete response
(non-CR). All patients had complete physical examination, fiberoptic endoscopy, MRI, and
CECT or FDG PET-CT performed 8-12 weeks after RT completion to assess the final treatment
response. Oncologic outcomes included two-year local control (LC), regional control (RC),
freedom from distant metastasis (FDM), recurrence-free survival, and overall survival.
4.2.5 Statistical analysis

Continuous data were presented as mean ± standard deviation (SD), and categorical
data were presented as proportions. The Kolmogorov–Smirnov test was used to assess the
difference in baseline ADC in BLADE vs. RESOLVE DWI sequences. The ADC values for all
voxels included in GTV-P and GTV-N ROIs were assessed by histogram analysis and the
following parameters were extracted using in-house MATLAB script (MATLAB, MathWorks,
MA, USA): ADC mean, 5th, 10th, 20th, 30th, 40th, 50th (i.e. median), 60th, 70th, 80th, 90th, 95th
percentile. Pre-RT ADC parameters were correlated with RT response (CR vs. non-CR) at midand post-RT time points using the non-parametric Mann-Whitney U test to compare ADC
values between the mid-RT CR and non-CR groups. The non-parametric Wilcoxon signed-rank
test was used to compare the mid-RT versus baseline ADC. Delta ADC (Δ ADC) were
calculated as the percent change of ADC relative to baseline value for each parameter
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𝑚𝑖𝑑𝑅𝑇 𝐴𝐷𝐶−𝑃𝑟𝑒𝑅𝑇 𝐴𝐷𝐶
𝑃𝑟𝑒𝑅𝑇 𝐴𝐷𝐶

(i.e.,

𝑥 100). Delta volumetric changes for both GTV-P and GTV-N at mid-

RT were also calculated and the non-parametric Spearman’s Rho test was used to determine
the relationship between Δ ADC and Δ volume changes. Recursive partitioning analysis (RPA)
was performed to identify Δ ADC threshold associated with relapse. Oncologic and survival
endpoints were calculated using the Kaplan-Meier method and the statistical significance was
determined using a p-value <0.05. Uni- and multi-variable analyses for oncologic and survival
endpoints were performed using Cox regression. For multivariable analysis, we tested the
impact of including the ADC parameter of choice compared with baseline models of standard
clinical variables. We subsequently compared the new model using Bayesian information
criteria (BIC).(129) A lower BIC indicates improved model performance and parsimony, using
the BIC evidence grades presented by Raftery (130) with the posterior probability of superiority
of a lower BIC model, where a BIC decrease of < 2 is considered “Weak” (representing a 50–
75% posterior probability of being superior model), 2–6 denoted “Positive” (posterior probability
of 75–95%), 6–10 as “Strong” (posterior probability of > 95%), and > 10, “Very strong” (posterior
probability > 99%). In addition, Cox proportional hazards models were constructed using the
Lifelines Python package (DOI: 10.21105/joss.01317) using Python version 3.9.7. Clinical
models that includes T stage, HPV status, and Smoking pack-year for LC and AJCC stage 8th
edition, Age at Diagnosis, and Smoking pack-year for RFS were done. Additive models that
include the clinical parameters plus the addition of ADC changes were then constructed to
assess the potential additive value. Models were only constructed for patients with a GTV-P. C-
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index values were derived from fitted models. All other analyses were executed with JMP Pro
version 15 software (SAS Institute, Cary, NC).
4.3 Results
4.3.1 Patients

Eighty-six patients were enrolled. Five patients were excluded from this analysis
because of lack of visible GTVs after induction chemotherapy (n = 3) and loss to follow-up (n =
2) leaving a total of 81 patients in the final analysis. At pre-RT, 53 patients had both baseline
GTV-P and GTV-N, 6 patients had baseline GTV-P without GTV-N, and 22 patients had GTV-N
with no GTV-P (i.e., total GTV-P=59 and total GTV-N=74). Patients with no visible GTV-P at
baseline had either carcinoma of neck nodes of unknown primary (CUP; n=12), tonsillectomy
prior to RT (n=6), or CR to induction chemotherapy (n=4). The majority of patients were men
(n=74, 93%) and the median age was 61 years (range 33-78). Most patients had human
papillomavirus (HPV) positive disease (n= 73, 90%). A summary of patient demographic,
disease, and treatment criteria is presented in Table 4.1.
Table 4. 1: Patient demographic, disease, and treatment characteristics.
Characteristic

Patients
No. (%)

Age (years)
median (range)

61 (33-78)

Sex
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Male

75 (93)

Female

6 (7)

Smoking status
Never

37 (46)

Former

35 (43)

Current

9 (11)

Smoking pack-year
mean (SD)

15 (26)

Disease subsite
Base of tongue

29 (36)

Tonsil

38 (47)

CUP

12 (15)

Others

2 (2)

T stage
T0

12 (15)

Tx

6 (7)

T1

13 (16)

T2

24 (30)

T3

9 (11)

T4

17 (21)

N stage

58

N0

6 (7)

N1

42 (52)

N2

31(38)

N3

2 (3)

AJCC 8th ed. Stage
I

38 (47)

II

20 (25)

III

17 (21)

IVa

6 (7)

HPV status
Positive

73 (90)

Negative

8 (10)

Radiation Dose
Mean in Gy (SD)

69.6 (1.3)

Radiation Fractions
Mean (SD)

33 (0.9)

Radiation technique
IMRT/VMAT

55 (68)

IMPT

26 (32)

Chemotherapy
None

16 (20)
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Induction

1 (1)

Concurrent with RT

54 (67)

Induction + Concurrent 10 (12)
Abbreviations: CUP, carcinoma of unknown primary; SD, standard deviation; Gy, Gray; IMRT,
intensity-modulated radiotherapy; VMAT, Volumetric Modulated Arc Therapy; IMPT, intensity
modulated proton therapy.
4.3.2 Treatment outcomes

For patients with GTV-P at baseline (n=59), 18 (31%) had mid-RT CR at the primary
site which increased to 53 (90%) post-RT. Only 6 patients (10%) had persistent local disease
as assessed by imaging at post-RT. Amongst the 6 patients, all had subsequent pathological
confirmation of residual/recurrent disease. For patients with GTV-N at baseline (n=75), no
patient had CR at the neck at mid-RT while 65 patients (87%) had CR as assessed by imaging
at post-RT. Upon further pathological assessment, 6 out of 10 patients with non-CR at the neck
had residual/recurrent disease while the reminder had necrotic non-active tissue.
The median follow-up time was 31 months (IQR, 18-38). The 2-year LC, RC, and FDM
for the entire cohort were 91%, 92%, and 91%, respectively. While the 2-year RFS and OS
were 83% and 94%, respectively. The total number of recurrence events was 15 (18%). Two,
three, and five patients had an isolated local, regional, and distant recurrence events,
respectively. While one, two, and two patients had combined local & distant, locoregional, and
locoregional & distant recurrences, respectively.
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4.3.3 DWI correlates of outcomes
4.3.3.1 Baseline ADC parameters

Baseline mean, median, and different histogram percentile ADC values for BLADE vs.
RESOLVE were not significantly different for both GTV-P and GTV-N ROIs (p >0.05 for both,
Figure 2). There was no statistically significant correlation between pre-RT ADC parameters
and CR at mid-RT and post-RT time points for GTV-P. Similarly, there was no significant
correlation between pre-RT parameters and CR at post-RT for GTV-N (p >0.05 for all).
Univariable analysis also did not show a significant correlation between pre-RT ADC
parameters and all oncologic and survival endpoints.

Figure 4. 2: BLADE vs. RESOLVE histograms
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Histogram illustration of the distribution of tumor and nodal volumes’ ADC mean at baseline
using the BLADE vs. RESOLVE DWI acquisition methods in the study. The RESOLVE in pink
is overlaid on BLADE in light blue. There were no statistically significant differences using the
Kolmogorov–Smirnov test (p=0.4).
4.3.3.2 Mid-RT and delta ADC parameters

There was a statistically significant increase in all mid-RT GTV-P ADC parameters
compared to baseline values (p <0.0001 for all, Table 2). Additionally, there was a statistically
significant increase in all mid-RT GTV-N ADC parameters compared to baseline values (p
<0.0001 for all, Table 2). For patients with CR of the primary tumor at the end of RT, there was
a significant increase in GTV-P ADCmean at mid-RT compared to baseline ((1.8 ± 0.29) × 10–
3

mm2/s versus (1.37 ± 0.22) × 10–3 mm2/s, p < 0.0001). On the other hand, patients with non-

CR had no statistically significant increase in GTV-P ADCmean (p>0.05). All other studied ADC
parameters also had a significant increase at mid-RT for patients with CR of the primary tumor
at the end of RT compared to non-CR. However, there was a significant increase in GTV-N
ADC parameters at mid-RT for both patients with CR and non-CR at the end of RT.
RPA analysis identified GTV-P Δ ADCmean <7% at mid-RT as the most significant
parameter associated with worse LC and RFS (p =0.01). The 2-Year LC and RFS for patients
with Δ ADCmean <7% compared to patients with ≥7% at mid-RT were 48% and 42% versus 96%
and 87%, respectively (p <0.0001 and 0.001, Figure 3). Δ GTV-N ADC parameters at mid-RT,
however, were not significantly associated with any of the studied endpoints (P>0.05).
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Table 4. 2: ADC parameter changes at mid-RT versus baseline values.
ADC
parameter

End-RT

Baseline

Mid-RT

Baseline

Mid-RT

(x10-3

response

GTV-P

GTV-P

GTV-N

GTV-N

CR

1.37±0.2

1.8±0.3

<0.0001 1.27±0.3

1.6±0.4

<0.0001

Non-CR

1.3±0.2

1.6±0.4

0.07

1.28±0.3

1.54±0.3

0.01

ADC 5th

CR

0.87±0.3

1.2±0.3

<0.0001 0.76±0.2

1.04±0.3

<0.0001

percentile

Non-CR

1.1±0.6

1.3±0.5

0.4

1.02±0.4

1.19±0.3

0.2

ADC 10th

CR

0.97±0.3

1.32±0.3

<0.0001 0.86±0.2

1.16±0.3

<0.0001

percentile

Non-CR

1.2±0.5

1.42±0.4

0.3

1.26±0.2

0.02

ADC 20th

CR

1.1±0.3

1.47±0.3

<0.0001 0.97±0.3

1.3±0.4

<0.0001

percentile

Non-CR

1.2±0.4

1.47±0.3

0.4

1.34±0.2

0.01

ADC 30th

CR

1.17±0.3

1.58±0.3

<0.0001 1.06±0.3

1.4±0.4

<0.0001

percentile

Non-CR

1.2±0.3

1.5±0.3

0.3

1.16±0.2

1.4±0.1

0.009

ADC 40th

CR

1.25±0.3

1.68±0.3

<0.0001 1.14±0.3

1.5±0.4

<0.0001

percentile

Non-CR

1.22±0.3

1.56±0.3

0.

1.21±0.2

1.45±0.2

0.01

ADC

CR

1.35±0.2

1.8±0.3

<0.0001 1.22±0.3

1.58±0.4

<0.0001

Median

Non-CR

1.25±0.2

1.6±0.2

0.07

1.25±0.3

1.51±0.2

0.009

CR

1.42±0.3

1.9±0.4

<0.0001 1.32±0.4

1.67±0.4

<0.0001

P value

P value

mm2/s)

ADC Mean

1.06±0.3

1.11±0.3
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ADC 60th
Non-CR

1.3±0.2

1.68±0.5

0.1

ADC 70th

CR

1.52±0.3

1.95±0.4

percentile

Non-CR

1.36±0.3

ADC 80th

CR

percentile

1.3±0.3

1.57±0.3

0.009

<0.0001 1.43±0.4

1.78±0.5

<0.0001

1.7±0.6

0.1

1.36±0.4

1.64±0.4

0.009

1.6±0.3

2.1±0.4

<0.0001 1.57±0.4

1.91±0.5

<0.0001

Non-CR

1.4±0.3

1.8±0.7

0.07

1.45±0.4

1.72±0.5

0.01

ADC 90th

CR

1.79±0.4

2.22±0.4

<0.0001 1.76±0.4

2.07±0.5

<0.0001

percentile

Non-CR

1.52±0.4

1.99±0.8

0.03

1.84±0.6

0.1

ADC 95th

CR

1.9±0.4

2.36±0.5

<0.0001 1.93±0.4

2.2±0.5

<0.0001

percentile

Non-CR

1.61±0.6

2.09±0.9

0.03

1.97±0.8

0.1

percentile

1.57±0.5

1.65±0.7
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Figure 4. 3: LC and RFS by Δ ADCmean.
Kaplan–Meier curves calculated for patients with baseline GTV-P (n = 59) show better (A) local
control (LC) and (B) recurrence-free survival (RFS) for patients with ≥7% Δ ADCmean at mid-RT.
Shaded colors represent 95% confidence intervals, short vertical lines represent censored
data, and asterisks indicate significant log-rank p values.
Univariable analysis of local control showed that GTV-P Δ ADCmean at mid-RT ≥7% was
associated with improved LC (hazard ratio (HR), 0.06, 95% CI, 0.01-0.3, p =0.001). In a
multivariable model that also included T-stage, smoking pack-year, and HPV status, GTV-P Δ
ADCmean at mid-RT remained statistically significant (HR, 0.03, 95% CI, 0.01-0.6, p =0.02) and
achieved a better model performance as assessed using BIC criteria (BIC decrease =19.8).
Moreover, univariable analysis of recurrence-free survival showed that GTV-P Δ
ADCmean at mid-RT ≥7% was associated with improved RFS (HR, 0.2, 95% CI, 0.06-0.6, p
=0.003). In a multivariable model that also included age, AJCC 8th edition stage (i.e., which is
based on T-stage, N-stage, tumor site and HPV-status data), and smoking pack-year, GTV-P Δ
ADCmean at mid-RT remained statistically significant (HR, 0.3, 95% CI, 0.1-0.9, p =0.04) and
also improved the model performance using BIC criteria (BIC decrease =8). Similarly, a
univariable analysis of overall survival showed that GTV-P Δ ADCmean at mid-RT ≥7% was
associated with improved OS (HR, 0.2, 95% CI, 0.04-0.9, p =0.037). However, it was not
statistically significant when added to a multivariable model of age, smoking pack-year, and
AJCC 8th edition stage. The clinical LC model yielded a C-index of 0.86 while the additive LC
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model yielded a C-index of 0.94 while the clinical RFS model yielded a C-index of 0.73 while
the additive RFS model yielded a C-index of 0.78.
4.3.4 Volumetric analysis and ADC

There was a significant decrease in mid-RT residual tumor volumes for both GTV-P and
GTV-N compared to baseline pre-RT volumes (3.5 vs. 11.1 mm3 for GTV-P and 7.4 vs. 11.8
mm3 for GTV-N, p <0.0001 for both). However, the mean Δ volume decrease at mid-RT was
significantly higher in GTV-P compared with GTV-N (69% vs. 30%, p <0.0001). As shown in
Figure 4, there was no statistically significant correlation of the Δ volume and Δ ADCmean for
both GTV-P (Spearman’s Rho=-0.06, p =0.6) and GTV-N (Spearman’s Rho=-0.2, p =0.1). Δ
volume changes were not significantly correlated with any endpoints (P>0.05). Only baseline
GTV-P volume (i.e., a surrogate of T-stage) was significantly correlated with LC on univariable
analysis (p =0.03).
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Figure 4. 4: Relationship between delta volume and delta ADCmean.
Relationship between Δ volume and Δ ADCmean for both GTV-P (A) and GTV-N (B) at mid-RT.
Solid lines represent the linear fit and dotted lines represent the 95% confidence intervals.
4.3.5 ROI subvolume analysis

For patients with mid-RT non-CR at the primary site, there was no statistically
significant difference in all ADC parameters between GTV-P-RS and GTV-P-RD (p >0.05 for
all). RPA identified Δ ADCmean <5% and <10% as the strongest predictors of local recurrence
for GTV-P-RD and GTV-P-RS, respectively (p =0.02 for both). However, for RFS only Δ
ADCmean <5% for GTV-P-RD was significantly associated with worse RFS (p =0.01).
4.4 Discussion

Our results show that DWI imaging changes during RT are a significant predictor of
oncologic outcomes. The significant increase in mid-RT ADC parameters for both tumor and
nodal ROIs reflects a decrease in cellular density in tumor tissue caused by the radiation effect
that induces breakdown of cellular membranes which ultimately decrease the restriction of
diffusion shown in baseline tumor tissue.(131-133) The increased diffusion in mid-RT images
was successfully measured by the studied ADC parameters that showed a higher increase in
patients who ultimately developed CR at the end of treatment compared to patients with
residual disease.
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Our study also identified an ADC biomarker of local control and recurrence-free survival
using a Δ GTV-P ADCmean threshold of 7% increase relative to baseline ADCmean. These delta
ADC changes were volume independent as our analysis methodology, illustrated in Figure 1,
ensured that we use the same 3-D shape and volume of GTV-P propagated from baseline
DWIs after image co-registration. We also assessed the effect of subvolume analysis within the
subset of patients with non-CR at mid-RT images. In that subset, both Δ ADCmean changes in
the residual and responding subvolumes were significantly associated with local control with a
5% and 10% threshold of ADCmean increase. The threshold is lower in residual volumes as
expected because of the higher relative tissue density in these subvolumes. This also indicates
that quantitative DWI parameter maps can detect the mesoscale cellular changes that could
not be otherwise detected using gross visual assessment. Furthermore, this also shows that
even within the apparent residual tumors on anatomic imaging at mid-RT, there is a subset that
expresses higher ADC changes and those tend to have better LC and RFS. These changes
during treatment can serve as a biomarker to predict outcomes and can also be used as a
biological tool to adapt therapy dose according to the predicted response during therapy.
An additional significant finding in our study is that pretreatment DWI parameters had
no significant association with outcomes, indicating that dynamic information obtained from RTinduced imaging changes during treatment is likely more informative compared to baseline
status. Several previous studies matched our findings of no association between pretreatment
ADC and outcomes (49, 134, 135) while a prior pilot set from our group as well as other studies
showed a significant correlation.(43, 136-138) We believe that pretreatment ADC parameters of
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a relatively homogenous cohort with a majority of HPV positive oropharyngeal cancer would be
less predictive of outcomes when compared to a more heterogenous group of HNC subsites
and/or tumor types. A heterogenous group of tumors will likely have a mixture of well and
poorly differentiated tumors with different level of cellularity and stromal contents which thereby
lead to a more contrast in the degree of diffusion between different tumor types.(133)
Therefore, we think that the pretreatment DWI parameters may be a more prognostic than
predictive biomarker as it reflects the nature of the baseline tumor rather than predicts its
response to therapy.
In-treatment Δ ADC were investigated in prior studies with a relatively small sample
sizes consisting of mixtures of HNC subsites, and in concordance with our results, these
studies showed that Δ ADC during RT was a significant correlate of oncologic outcomes.(47,
50, 134) To our knowledge, we present the largest prospective imaging study to date
supporting that Δ primary tumor ADC changes during treatment are a strong biomarker of
important oncologic outcomes, particularly for local control and recurrence-free survival. The
threshold of Δ ADC used should be carefully interpreted according to the nature of the primary
tumor subsite, technique of segmentation/image registration, and DWI acquisition parameters
(i.e., b values). Notably, delta ADC is a relative rather than an absolute value which could
represent a more robust biomarker that is less susceptible to inter-patient and inter-scanner
variability and thereby more clinically generalizable. In patients with mainly HPV positive
oropharyngeal primary site using 3-D volumetric analysis of GTV-P at mid-RT relative to
baseline, Δ ADCmean <7% was shown to be a strong correlate of local failure.
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However, our study is not without limitations. Importantly, our study utilized a singleinstitution cohort without external validation of our findings with multi-institutional data. Another
limitation was the use of two DWI sequences during the study (i.e., BLADE and RESOLVE);
however, after analyzing the ADC values extracted from both DWI sequences using the
Kolmogorov–Smirnov test, no significant differences were found between the two sequences.
Lastly, we failed to show any significant correlation between Δ nodal DWI changes and regional
control, which could potentially be attributed to the cystic nature of the studied GTV-Ns in our
sample. As a future step, we plan to analyze these LNs using a morphologic distinction
between solid and cystic component in each node rather than the standard segmentation
approach.
4.5 Conclusions

In conclusion, our prospective imaging study of HNC patients demonstrated that Δ ADC
parameters at mid-RT represent a strong predictor of local recurrence and recurrence-free
survival. Patients with no significant increase of mid-RT ADC at the primary tumor site relative
to baseline values are at high-risk of disease relapse. Multi-institutional data are needed for
validation of our results.
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Chapter 5: Dynamic Contrast-Enhanced MRI for assessment of normal tissue toxicity
This chapter is based upon:
Joint Head and Neck Radiation Therapy-MRI Development Cooperative, Mohamed ASR, He
R, Ding Y, Wang J, Fahim J, Elgohari B, Elhalawani H, Kim AD, Ahmed H, Garcia JA, Johnson
JM, Stafford RJ, Bankson JA, Chambers MS, Sandulache VC, Fuller CD, Lai SY. Quantitative
Dynamic Contrast-Enhanced MRI Identifies Radiation-Induced Vascular Damage in Patients
With Advanced Osteoradionecrosis: Results of a Prospective Study. Int J Radiat Oncol Biol
Phys. 2020 Dec 1;108(5):1319-1328. doi: 10.1016/j.ijrobp.2020.07.029. Epub 2020 Jul 23.
PMID: 32712257; PMCID: PMC7680450.
This article is under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/)
which permits reproduction in any format.
5.1 Introduction
Osteoradionecrosis (ORN) of the mandible is a debilitating complication of external
beam radiation therapy (EBRT) for head and neck cancer patients.(139-141) Head and neck
squamous cell carcinoma (HNSCC) has an estimated annual incidence of approximately
62,000 cases in the United States.(142) The incidence of Human Papillomavirus (HPV)
associated HNSCC continues to rise unabated and is expected to continue to rise for the next
two decades until the effects of immunization will begin to impact incidence.(143, 144)
Recent data shows the rate of ORN development in HNSCC patients following EBRT is
approximately 7% despite aggressive dental care and close follow up.(145) Even with a
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relatively low incidence, the prevalence and burden of ORN is expected to rise because of the
excellent prognosis for HPV+ patients (i.e. 5-year overall survival of 80-90% for most patients).
Therefore, it is expected that the US will accumulate a large population of adults with a history
of mandibular radiation, a nearly 10-fold increase compared to historical trends when
prevalence was lower due to higher mortality of non HPV-associated cancers.
Despite the use of more conformal EBRT techniques such as intensity-modulated
radiotherapy (IMRT), the mandible remains exposed to significant radiation doses because of
its close proximity to target volumes that can eventually lead to the development of ORN
especially when coupled with infection and/or dental manipulation.(145, 146) Early-stage ORN
can be controlled with conservative measures such as antibiotics, surgical debridement,
hyperbaric oxygen (HBO) therapy, pentoxifylline or tocopherol.(147, 148) However, progression
to advanced ORN typically requires extensive surgical resection and complex reconstruction
and leads to a substantial reduction in the quality of life of HNSCC survivors.(149, 150)
Anatomic imaging using CT or conventional MRI does not identify ORN-related bony
changes until relatively late in the process, when the patient is generally already experiencing
symptoms. (151, 152) Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is
a clinically available imaging method that was shown to detect early-stage idiopathic
osteonecrosis of the femur otherwise not visible on conventional MRI.(153) DCE-MRI
parameters can be used to monitor bone-healing secondary to trauma or fracture, as well as
chronic changes in bone health associated with age-related osteoporotic changes.(154-156)
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The most commonly accepted biological mechanism of ORN development remains that
summarized by Marx’s three H’s of hypoxic, hypovascular, and hypocellular tissue. Therefore,
we expect that shifts in vascularity may portend development of ORN.(157) Hence, we focused
on DCE-MRI as opposed to other imaging modalities. Our group has recently demonstrated
that DCE-MRI can be used to detect alterations in bone vascularity following definitive
radiotherapy to head and neck cancer patients.(158) However, we do not yet know how early
changes in bone vascularity during radiation correlate with subsequent development of ORN. In
order to develop a predictive, imaging-based biomarker of ORN development, it is therefore
critical to identify DCE-MRI parameters in patients with existing ORN. This will facilitate the
discrimination of the quantitative DCE-MRI parameters associated with injured versus healthy
mandibular subregions. This characterization will ultimately serve as a guide to monitor
temporal DCE-MRI changes following EBRT in attempt to early detect mandibular pathology
before the development of symptoms.
Based on existing clinical and preclinical data, we hypothesized that ORN is associated
with critical changes in bone vascularity reflected in common DCE MRI parameters namely Ve
and Ktrans, as a reflection of overall poor vascular flow and integrity. To this end, we sought to
characterize the quantitative DCE-MRI parameters associated with the established diagnosis of
advanced mandibular ORN compared with normal mandible in the context of a prospective
clinical study with high intrinsic imaging acquisition consistency.
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5.2 Methods
5.2.1 Patient selection
Patients with a confirmed diagnosis of advanced ORN developed after curative-intent
radiation treatment of head and neck cancer were prospectively enrolled in an observational
imaging study (NCT03145077) after institutional-review board approval and study-specific
informed consent. Eligibility criteria included age>18 years, pathological evidence of head and
neck malignancy with history of curative-intent external beam radiotherapy, patients with
clinically confirmed high-grade ORN requiring surgical intervention, good performance status
(ECOG score 0-2), and no contraindications to MRI. Clinical staging of ORN was conducted
using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
5.2.2 DCE-MRI Imaging
DCE-MRI scans were obtained using GE 3.0T Discovery MR750 scanners with a 6channel Flex phased-array coil (GE Healthcare Technology, Milwaukee, WI). Prior to DCEMRI, T1 mapping was performed using six variable flip angles (FA) 3D spoiled gradient recalled
echo (SPGR) sequence (FA = 2°, 5°, 10°, 15°, 20°, and 25°; TR/TE = 5.5/2.1 ms, FOV = 25.6
cm, slice number = 30, voxel size = 2 × 2 × 4 mm3). The DCE-MRI was acquired using a multiphase 3D Fast SPGR sequence to gain sufficient signal-to-noise ratio (SNR), contrast, and
temporal resolution (FA = 15°, TR/TE = 3.6/1 ms, voxel size = 2×2×4 mm3, temporal
resolution = 5.5s, number of repetitions = 56, pixel bandwidth = 326 Hz, ASSET acceleration=
2). Gadobutrol (Gadovist, Bayer Healthcare, Germany) was administered at a dose of 0.1
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mmol/kg of body weight at 3 ml/s followed by the same amount of saline at 3 ml/s, via a power
injector (Spectris MR Injector, MedRad, Pittsburgh Pa).
5.2.3 Computation of the kinetic model
Post-processing of the DCE-MRI images was performed at a workstation running inhouse Matlab based pipeline (Matlab, MathWorks, MA, USA). Before quantitative analysis,
motion correction and noise suppression were applied using simultaneous spatial and temporal
higher-order total variations regularizations (HOTVs) as described by our group and by Chan et
al.(159, 160) As shown in Figure 5.1, filtering with HOTVs demonstrated noise suppression as
well as motion reduction.(160) To quantify the physiological parameters using DCE‐MRI, the
arterial input function (AIF) of the contrast agent (CA) entering the tissue was determined
individually. T1 map was calculated to convert the signal intensity into concentration time
course. Extended Tofts model assumes that the CA resides in and exchanges between two
compartments in the tissue: the vascular space and extracellular extravascular space (EES).

Figure 5. 1: Images before and after HOTVs.
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This figure shows consecutive DCE MRI frame time series (from left to right) before (row up)
and after (row down) filtering with HOTVs.
When this model is used, the differential equation describing the kinetic behavior of the
CA in the tissue of interest is given by:
dCTOI (t)
dt

= (𝐾 𝑡𝑟𝑎𝑛𝑠 + 𝑣𝑝 ∙ 𝑘𝑒𝑝 ) · Cp (t)– 𝑘𝑒𝑝 · CTOI (t) + 𝑣𝑝 ·

dCp (t)
𝑑𝑡

(1)

where CTOI(t) and Cp(t) are the concentrations of the CA at time t in the tissue of interest (TOI)
and blood plasma, respectively, Ktrans are the transfer (CA permeability rate) constants between
blood plasma and the EES of the TOI. kep = Ktrans/Ve is the transfer (CA permeability rate)
constant (min−1) from the TOI back to the blood plasma, where Ve is the distribution volume
fractions of CA in the EES per unit volume of tissue. When the kinetic model includes a
vascular term, Vp that is the capillary plasma volume fractions per unit volume of tissue.
Otherwise, by ignoring vascular term, the extended Tofts model is reduced to Tofts model as:
dCTOI (𝑡)
dt

= 𝐾 𝑡𝑟𝑎𝑛𝑠 · Cp (t)– 𝑘𝑒𝑝 · CTOI (𝑡) (2)
The AIF for the pharmacokinetic (PK) analysis was derived from selected arteries. The

relevance of several analytical AIF models in DCE-MRI have been previously extensively
investigated.(161) Recently computer simulations were performed to evaluate and compare a
population of AIF models with the Parker model.(162) The results demonstrated that a sixparameter linear function plus bi-exponential function AIF model was almost equivalent to the
Parker AIF. It should be noted the former is computationally faster and more reliable in
functional fitting when compared to the Parker AIF. However, predetermining the arrival time
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(AT) and time to peak (TTP) of upslope for each AIF time series is usually not accurate in using
the above six-parameter model. Therefore, we extended the six-parameter model to a biexponential and bi-linear function where the AT and TTP of the upslope are included as
parameters to be estimated in AIF fitting.
In order to acquire the corresponding AT and TTP time points of the upslope for each
AIF time series, we designed a special cost function, where fitting is performed with global
optimization on the AIF model function with seven parameters. The new AIF model function is
defined in equation 3 as AIFM where p1 to p7 are parameters to be determined by functional
fitting 23, min is minimal value operator, max is the maximal value operator, abs is absolute
value operator; p4 and p5 is AT and TTP to be determined, while min(p4, p5) give AT, max(p4,
p5) is TTP; t is time points, and “uplimit” is a constant that is estimated by the maximal possible
value of data to be fitted (e.g. twice of the maximum value in the time course).
The new AIF model function (AIFM) was defined as:
𝑝𝑎𝑟𝑡 1

⏞
𝑡 − min(𝑝4, 𝑝5)
𝑡 − min(𝑝4, 𝑝5)
AIFM = min (max (𝑝1, 𝑝1 + (𝑝2 − 𝑝1) ∙
+ (𝑝3 − 𝑝1) ∙
),
𝑎𝑏𝑠(𝑝5 − 𝑝4)
𝑎𝑏𝑠(𝑝5 − 𝑝4)
𝑝𝑎𝑟𝑡 2

⏞
min(𝑢𝑝𝑙𝑖𝑚𝑖𝑡, 𝑝2 ∙ exp(−𝑝6 ∙ (𝑡 − max(𝑝5, 𝑝4))) + 𝑝3 ∙ exp(−𝑝7 ∙ (𝑡 − max(𝑝5, 𝑝4))))) (3)
For each given AIF time point, the function can be described in two separate parts as
indicated in equation (3). Part one of the function determines the AT and TTP of the upslope as
well as the bi-linear functions through a maximization of operations containing parameters p1,
p2, p3, p4, and p5. Here p1 (first term in the bracket of part 1) will fit the static signal, and the
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second term in the bracket in part 1 will represent the upslope approximated by bi-linear
functions. p2 and p3 represent the end points at TTP of each linear approximation. Moreover,
the maximum value at each time point of part 1 represents the approximation of signal, and we
therefore apply a max operator on the entire set of terms.
Part two of the function determines the signal approximation after TTP of the upslope
with bi-exponential functions through a minimization of operations containing parameters p2,
p3, p4, p5, p6, and p7, and the uplimit, which can be seen as a constant larger than the ceiling
value the curve can take. Opposite to the implementation in part 1, the bi-exponential functions
should always below uplimit, so there is min operator applied to the set of terms in part 2. Since
the min operator in part 2, we can efficiently restrict the parameter estimation of the biexponential functions.
Since part 1 is strictly increasing while part 2 is strictly decreasing, we applied a min
operator on the combination of part 1 and part 2. Subsequently, the minimum of part one and
part two is noted to be AIFM as in equation (2). By enforcing these settings, the original
complicated constrained (multiple) optimization problems in data fitting is changed into an
unconstrained problem. Finally, the fitting cost function is implemented by optimization on
||DATA - AIFM||, where DATA could be DCE concentration or DCE signal. The fitting cost
function is implemented by optimization on ||DATA - AIFM||, where DATA could be DCE
concentration or DCE signal. By using this extended AIF model function, the AIF fitting can be
completed in a more precise and reliable manner. Figure 5.2 shows the fitting process as well
as the fitting results where a 56 time point AIF time series is presented. The PK modelling was
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done on a pixel-by-pixel basis using a linearization equation of the models used (i.e. Tofts and
extended Tofts) as described by Kenya Murase.25 Subsequently, we implemented the linear
least‐squares method to acquire the PK parameters.(163, 164) This method is preferred to the
conventional nonlinear least‐squares method(165), because it is faster and it does not require
initial estimation, and has no local optima problems.

Figure 5. 2: AIF fitting.
The fitting process and fitting results where a 56 time point AIF time series (in Cyan) is
presented.
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5.2.4 Image segmentation and registration

Manual segmentation of mandibular volumes harboring ORN was done by an expert
radiation oncologist (ASRM) and reviewed by expert neuroradiologist (JMJ). The segmentation
was done using the MRI anatomical sequences (T1, T2, and T1+contrast) as well as coregistered contrast enhanced CTs (i.e. aquired within two weeks of the MRI with no interval
therapy) to create ORN volumes of interest (ORN-VOIs) for all included patients. The
segmentation included abnormal signal intensity or irregular gadolinium enhancement of bone
marrow and soft tissues seen on MRIs(166, 167) as well as cortical erosions, sequestrations,
and/or fractures seen on CTs(168). Subsequently, normal mandibular VOIs were created on
the contralateral healthy mandible of similar volume and anatomical location (i.e. mirror image)
to create self-control VOIs. Finally, the MRI anatomical sequences were co-registered to the
DCE-MRI sequences and then the contours were propagated to the respective quantitative
parameter maps. This workflow is graphically summarized in Figure 5.3. For dosimetric
correlation, the original planning CTs and dose grids were retrieved when available to extract
mandibular dose parameters (mean and maximum dose). In addition, ORN depicting CTs were
co-registered to planning CTs using a validated commercial image registration software
(Velocity AI 3.0.1). Finally, ORN-VOIs were mapped to planning CTs and dose grid and
dosimetric parameters were extracted for each VOI. The RT dose parameters included
minimum, mean, dose to 95% volume (D95%) and maximum dose to ORN-VOIs in Gray (Gy).
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Figure 5. 3: Workflow of advanced ORN analysis.
5.2.5 Statistical analysis
Continuous data were presented as mean ± standard deviation, while categorical
data were presented as proportions. The comparison of quantitative DCE-MRI parameters
between ORN and Control VOIs was assessed using the non-parametric Wilcoxon signed-rank
test. The effect size was calculated and the magnitude of the effect size was determined using
Cohen’s criteria where r of 0.1=small effect, 0.3=medium effect and 0.5=large effect.(169) The
non-parametric Spearman's Rho test was used to measure the correlation between radiation
dose to ORV-VOIs and DCE-MRI parameters. P values <0.05 were deemed statistically
significant. All statistical analyses were performed using JMP 14 Pro (SAS Institute, Cary, NC).
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5.3 Results:
5.3.1 Patients

Thirty patients with grade 3 ORN requiring surgery were included. Median age at
diagnosis was 58 years (range 19-78), and 83% were men. The site of tumor origin was in the
oropharynx, oral cavity, salivary glands, and nasopharynx in 13, 9, 6, and 2 patients,
respectively. IMRT was the radiation technique for all patients. The median IMRT prescription
dose was 68 Gy in 32 fractions. The median time to ORN diagnosis after completion of IMRT
was 38 months (range 6-184) while the median time to ORN progression to advanced grade
after initial diagnosis of ORN was 5.6 months (range 0-128). Table 5.1 summarizes patient,
disease, and treatment criteria.

Table 5. 1: Patient, disease, and treatment characteristics.
Characteristic

patients (n=30)
No. (%)

Age*
median (range)

58 (19-78)

Sex*
Male

25 (83)

Female

5 (17)

Ethnicity*
Caucasian

29 (97)

82

African American

1 (3)

Smoking status*
Never

11 (37)

Former

13 (43)

Current

6 (20)

Smoking pack-year
Mean (SD)

14.7 (24)

Disease subsite
Nasopharynx

2 (7)

Oropharynx

13 (43)

Oral Cavity

9 (30)

Salivary glands

6 (20)

T stage
T1

7 (23.33)

T2

7 (23.33)

T3

9 (30)

T4

4 (13.33)

Recurrence

3 (10)

N stage
N0

9 (30)

N1

3 (10)
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N2

15 (50)

Recurrence

3 (10)

HPV status (p16 IHC)
Positive

8 (26.66)

Negative

2 (6.66)

Unknown

20 (66.66)

Pre-RT dental status
No dental procedures

32 (47)

Dental extractions

35 (51.5)

Edentulous

1 (1.5)

Radiation Dose
Mean in Gy (SD)

66.1 (4.7)

Radiation Fractions
Mean (SD)

32 (2.8)

Chemotherapy
None

11 (36.66)

Induction

1 (3.33)

Concurrent with RT

14 (46.66)

Induction + Concurrent 4 (13.33)
Surgery
Yes

14 (46.66)
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No

16 (53.33)

5.3.2 Radiation Dose

The RT dosimetric data were available for 21 patients (70%). The average of mean and
maximum doses to the entire mandibular volumes were 51.4 Gy (range 35-64) and 69.4 Gy
(range 52-76), respectively. The average of minimum doses to ORN VOIs (i.e. the isodose line
that covers 100% of the ORN volume) was 46.7 Gy (range 26-66). The average of mean and
maximum doses to ORN VOIs were 62.2 Gy (range 44-75) and 67.9 Gy (range 51-76),
respectively; the average D95% was 55.6 Gy (range 32-69).

5.3.3 DCE-MRI parameters

The median volume of segmented VOIs was 5.2 cm3 (range 1.8-10.9). Using the
extended Tofts model, the average Ktrans values in ORN-VOIs were significantly higher
compared with controls (0.23±0.25 vs 0.07±0.07 min−1, p<0.0001). The average relative
increase of Ktrans in ORN-VOIs was 3.2 fold those the healthy mandibular control VOIs (range
1.2-10.3). The effect size was large with r=0.52.

Likewise, the average Ve values in ORN-VOIs was significantly higher compared with
controls (0.34±0.27 vs 0.15±0.15, p<0.0001). The average relative increase of Ve in ORN-VOIs
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was 2.7 fold those the healthy mandibular control VOIs (range 1.1-6.9). The effect size was
also large with r=0.69.

Using combined Ktrans and Ve parameters, 27 patients (90%) displayed at least double
the increase of either of the studied parameters in the ORN-VOIs compared with their healthy
mandible control VOIs.

Vp was also significantly higher in ORN-VOIs compared with controls (0.17±0.2 vs
0.07±0.12, p<0.0001). However, Kep, as expected, did not show a significant difference
between ORN-VOIs versus controls (0.5±0.19 vs 0.46±0.13 min−1, p=0.2) because of the
increase of both Ktrans and Ve parameters. Figure 5.4 depicts the comparison of Ktrans, Ve, Kep,
and Vp values in ORN-VOIs compared with controls. Detailed histograms of patients’ ORN
versus Control VOI DCE-MRI parameters are presented for the entire cohort as Appendix A. 1.
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Figure 5. 4: ORN versus control Boxplots.
Boxplots showing the comparison of DCE-MRI parameters between ORN and Control
volumes-of-interest (VOI). * indicates statistically significant p values. Connected lines
represent each patient parameter value changes in ORN versus Control VOIs.

Using the Tofts model, the mean Ktrans values in ORN-VOIs were, likewise, significantly
higher compared with controls (0.27±0.29 vs 0.08±0.08 min−1, p<0.0001). The average relative
increase of Ktrans in ORN-VOIs was 3.4-fold of the control VOIs (range 1.5-12.3). In addition, the
mean Ve values in ORN-VOIs was significantly higher compared with controls (0.34±0.28 vs
0.13±0.13, p<0.0001). The average relative increase of Ve in ORN-VOIs was 4.04 fold of the
healthy mandibular control VOIs (range 1.2-15.3). Using combined Ktrans and Ve parameters,
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also showed that 90% of patients had more than two-fold increase of either of the studied
parameters in the ORN-VOIs compared with their healthy mandible control VOIs. Using the
Spearman's Rho test, there were no significant correlations between any of the dosimetric
parameters of ORN-VOIs (minimum, mean, D95% and maximum doses) and any of the DCEMRI parameters (P>0.05 for all) for patients with available dose data (70%). The bivariate
correlation between RT dose and DCE-MRI parameters is detailed in the Appendix material
(Appendix A.2).

5.4 Discussion

Nearly four decades ago, R.E. Marx postulated a theory for development of ORN
predicated in large part on altered bone vascularity, resulting in poor regenerative capacity and
a decreased ability to resist mechanical and microbial insults.(157) Although this remains the
most likely mechanism for ORN, to date scientists and clinicians have lacked the means to
study bone vascularity with sub-centimeter spatial resolution in a non-invasive manner and
have largely been forced to infer mechanisms of ORN development by combining limited preclinical studies, with static anatomic imaging and histologic evaluation of ORN specimens. For
the first time, we now have the opportunity to leverage a clinically available imaging approach
to provide real-time, non-invasive information about bone vascularity in the context of ORN
(Figure 5.5). This represents a breakthrough both in our ability to study this devastating disease
and to begin to develop clinical trials designed to ameliorate the disease using objective,
quantitative measures. In addition, implementation of this approach can generate utility in the
context of surgical extractions post-radiation, as well as in the context of real-time image88

guided surgical planning for resection of necrotic bone by distinguishing injured/poorly
vascularized bone from viable bone.

Figure 5. 5: Mechanistic vascular changes of ORN.
Schematic cartoon of the suggested mechanistic changes of ORN. Right mandibular body with
area of ORN and associated altered vascularity; contralateral body with normal body and
vascularity. Normal blood vessels have intact walls (continuous red lines) with well-regulated
fractional volume plasma (Vp) and appropriate contrast exchange (black dots) across the vessel
wall (Ktrans) to extracellular extravascular compartment in blue (Ve) and normal mandibular
cellularity in yellow. Vessels associated with ORN demonstrate higher Vp with increased
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leakiness (Ktrans) through fragile vessels (dotted red lines) that leads to increased Ve and
hypocellularity.

Our findings demonstrated a distinct profile of DCE-MRI parameter maps in mandibular
volumes harboring ORN as compared to the normal mandible. DCE-MRI parameters indicating
vascular compromise showed a significantly higher degree of leakiness in mandibular
vasculature as measured using Ktrans and Ve of areas affected with advanced grade of ORN
versus healthy mandible. The fractional volume of plasma (Vp) was also higher in ORN-ROIs.
We were able to measure significant increases in quantitative parameters with an average
increase of approximately three-fold of both Ktrans and Ve compared to values from the healthy
mandibular bone. The vast majority of patients (90%) had at least doubling of the values of
either Ktrans or Ve for ORN-VOIs as compared with control VOIs. We also demonstrated a clear
separation of parameter histogram distribution for the majority of patients with higher median
and interquartile range of Ktrans, Ve and Vp parameter values of ORN versus control VOIs as
detailed in Appendix A. 1.

The quantitative perfusion characteristics of mandibular injury after radiation treatment
of the head and neck cancer have never, to our knowledge, been assessed before. One study
has previously investigated the qualitative nature of contrast enhancement of DCE-MRI in
patients with mandibular ORN.(166) That study showed that all patients with ORN had marked
contrast enhancement of the osteoradionecrotic bone marrow, which was reduced after
treatment with HBO treatment.(166) DCE-MRI has also shown the ability to detect early-stage
idiopathic osteonecrosis of the femur not otherwise visible on conventional MRI as reported by
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Chan et al.(153) In addition, DCE-MRI parameters were also used to monitor bone healing
secondary to trauma or fracture, as well as chronic changes in bone health associated with
age-related osteoporotic changes.(154-156) DCE-MRI was also reported to identify changes
related to the development of bony metastasis and tumor response to treatment.(170, 171)

We have recently demonstrated that DCE-MRI can be used to detect radiation-induced
changes in mandibular bone vascularity and showed dose-dependent changes in both Ktrans
and Ve in a subset of patients.(158) Unlike the findings of our previous study that showed
variability in the dose-dependent changes of vascular parameters where a percentage of
patients had a decrease in the measured parameters after treatment, the current study
demonstrated only an increase of these parameters. The increased fractional plasma and
vascular leakiness in ORN areas reflects fragile vasculature that may be attributed to a process
of neovascularization following the post-radiation chronic hypoxia in high-dose areas. A serial
imaging study of the natural history of vascular changes of the mandible is currently ongoing to
determine at which time point this phenomenon of neovascularization begins to develop and to
what extent this development could be correlated with early ORN symptoms development.
However, our findings suggest that a two-fold increase in either Ktrans or Ve parameters is an
alarming sign of ORN development if detected in patients with otherwise clinically apparent
normal mandible after radiation treatment especially in areas exposed to higher doses of
radiation due to tumor proximity.

Our group and others have previously demonstrated the dependency of DCE-MRI
quantitative output on the nature of PK models used for analysis.(172, 173) Thereby, we used
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the most widely accepted models such as Tofts and extended Tofts models. We also used the
patients’ contralateral mandible as an internal control to alleviate this model dependency.
Additionally, we have recently shown, using multi-institutional comparison of patient-derived
DCE-MRI data that quantitative values may not be reliably compared across different patients
due to the difference in patient’s specific imaging parameters, pre-processing, and postprocessing factors.(172) Our results also confirmed that inter-patient DCE-MRI parameter
variations were independent of the variation of the RT doses received by the ORN-VOIs as
shown in Appendix A. 2. Because of this limitation, in the current study we did not use the
absolute values of the parameters associated with ORN but instead compared the relative
changes of these parameters to respective controls in the same image for each patient using
the contralateral healthy mandibular VOIs. Therefore, our results may be more reproducible
and generalizable as they represent the relative changes measured in the irradiated
mandibular areas compared with the normal non-irradiated bony area and hence we avoided
the inter-subject variability of the parameter absolute values.

The thirty patients included in this study may be perceived as a limited sample size.
However, to date this represents the largest prospective quantitative imaging study of ORN
ever reported. Furthermore, this study represents the initial characterization of quantitative
vascular parameters driven from DCE-MRI for head and neck cancer patients treated with
IMRT and affected by radiation-induced advanced ORN toxicity.
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5.5 Conclusion
Our results confirmed higher degree of vascular leakiness in the mandibular areas
of ORN as measured using DCE-MRI parameters as compared with healthy mandible.
Additional efforts will be required to develop DCE-MRI parameter into viable non-invasive
biomarkers useful for the early detection of subclinical cases of ORN.
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Chapter 6: Methodology for analysis and reporting patterns of failure after radiation therapy
This chapter is based upon:
Mohamed AS, Rosenthal DI, Awan MJ, Garden AS, Kocak-Uzel E, Belal AM, El-Gowily AG,
Phan J, Beadle BM, Gunn GB, Fuller CD. Methodology for analysis and reporting patterns of
failure in the Era of IMRT: head and neck cancer applications. Radiat Oncol. 2016 Jul
26;11(1):95. doi: 10.1186/s13014-016-0678-7. PMID: 27460585; PMCID: PMC4962405.
This article is under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/)
which permits reproduction in any format.
6.1 Introduction

Intensity-modulated radiation therapy (IMRT) is one of the most important innovations in
modern radiation therapy and represents a paradigm shift in the treatment of head and neck
cancers (HNCs). However, there are certain hazards that may increase the risk of loco-regional
failure (defined as tumor persistence or recurrence) including inadequate definition of the tumor
extension and clinically important target volumes (TVs), uncertainties related to daily
positioning, weight loss or deformation of tumor and normal tissues during the course of
treatment, and uncertainties in plan optimization, dose calculation and treatment delivery(25,
31-34).
The accurate and specific definition of the exact site of failure, in addition to the
radiation dose given to this site is, therefore, mandatory to identify the possible cause(s) of
failure. The classic definition of failures as “local”, or “regional”, was appropriate in the setting of
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conventional radiotherapy using large homogeneous dose-volumes, but is no longer helpful nor
descriptive of distinct types of failure in patients treated with IMRT(35-37).
Several previous efforts have addressed the importance of studying the patterns of
failure after IMRT treatment of HNCs,(25, 32, 174-178) with most reporting failures as “infield”,
“marginal” or “outfield” based on the percentage of overlap between the failure volume and the
respective TV on the treatment planning CT (pCT)(25, 174, 175, 177, 178).
The ability to accurately describe the relation of failure to original TVs and dose
mandates a fairly precise method to co-register the diagnostic CT documenting recurrence
(rCT) to the original pCT. However, the majority of the previous studies implemented mainly
rigid image registration techniques (RIR)(25, 32, 175, 177, 178). RIR is simple, quick and
widely used but it allows only for 6 degrees of freedom and doesn’t account for changes in the
shapes or relative positions of different regions-of-interests (ROIs)(179). Emerging data
demonstrate the superiority of deformable image registration (DIR) compared to RIR in
registering pCT to on-treatment CT or conebeam CT in the setting of image guided
radiotherapy (IGRT) for HNCs(180-182). However, very few studies addressed DIR software
implementation for the purpose of registering the diagnostic rCT to the original pCT(35, 36).
Our group has recently validated different registration techniques used for co-registering
diagnostic contrast enhanced head and neck CT to non-contrast planning CT and showed DIR
was superior for this application(183). As a continuation of these efforts and to validate DIR as
a tool to improve accurate definition of the patterns of loco-regional failure in the era of IMRT
for HNCs, we sought to undergo the following specific aims:
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1) Develop a workflow methodology to standardize the analysis of HNCs patterns of failure
using both geometric and dosimetric parameters.
2) Assess the impact of registration (rigid vs. deformable) techniques on patterns of failure
quantitative analytic parameters.
3) Develop a granular classification and nomenclature to optimize the accurate reporting of
distinct failure typology.
6.2 Material and Methods
6.2.1 Patients

Tumor registry data for patients diagnosed with head and neck squamous cell
carcinoma, whom were treated by IMRT at The University of Texas, MD Anderson Cancer
Center between 2006 and 2009, were retrospectively reviewed under an institutional review
board approval. 600 patients were identified, of those 103 had a documented recurrence. A
total of 21 cases were randomly selected from the recurrence dataset based on the following
eligibility criteria: IMRT given for curative intent; treatment of intact tumor (i.e. post-operative
cases were excluded); equal distribution of various head and neck subsites (i.e. nasopharynx,
oropharynx, hypopharynx, and lateral neck “i.e. neck nodes of unknown primary site”);
radiological evidence of local and/or regional failure; available CT scan of failure site prior to
any salvage therapy; and pathologic and/or radiologic evidence of recurrence (i.e. biopsy, or
high SUV on PET).
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6.2.2 IMRT Treatment Planning and Delivery

All patients had been positioned supine in an individualized thermoplastic head and
shoulder mask for CT simulation and treatment and a custom dental stent used as an intraoral
immobilization device(184, 185). A treatment pCT scan was used for defining TVs. Target
volume definition was done in Pinnacle treatment planning system (Pinnacle, Phillips Medical
Systems, Andover, MA), with rigorous multi-physician target delineation and quality
assurance(186, 187).
Treatment was uniformly delivered using Varian (Varian Medical Systems, Palo Alto,
CA) linear accelerators delivering 6-MV photons. Three clinical target volumes (CTVs) were
typically defined. CTV definitions and dose prescriptions are summarized in Table 6.1.
Treatment was delivered in a conventional fractionation scheme (average 33 fractions).
Patients were treated using a monoisocentric technique with an antero-posterior low-neck
supraclavicular field matched to the IMRT fields or using whole neck IMRT for cases where
gross nodes are located at the match line.
Table 6. 1: IMRT target volume definitions and dose prescription.
Target Volume
High risk clinical target
volume (CTV1)

Definition
gross tumor volume (GTV)
plus margin, GTV included all
known gross disease
(primary tumor plus grossly
enlarged lymph nodes)

Dose prescription

66-69.96 Gy
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Intermediate risk clinical
target volume (CTV2)

Low risk clinical target
volume (CTV3)
Planning Target Volume
(PTV)

mucosal, bony, and nodal
volumes at intermediate risk
of harboring microscopic
disease
mucosal, bony, and nodal
volumes at low risk of
harboring microscopic
disease
CTV plus 3-4 mm margin,
with daily image guidance

57-63 Gy

54-57 Gy

6.2.3 Post-treatment follow-up
Initial post-treatment evaluations were made at 8-12 weeks after therapy completion
and subsequently every 2-3 months for the first year, every 3-4 months for the second year,
and at least twice a year up to 5 years.
6.2.4 Loco-regional Failure
Cases where local and/or regional recurrence was recorded had their immediate postfailure diagnostic images exported as DICOM files from the clinical PACS system to the
treatment planning system, where radiological evident recurrent gross disease (rGTV) was
manually contoured by a radiation oncologist (ASRM) and reviewed by a head and neck
service-specific attending radiation oncologist (CDF).
6.2.5 Image registration
For each patient, the rCT or rPET-CT was co-registered with pCT using both rigid and
deformable image registration techniques. DIR was performed using a commercial software
(ADMIRE, Elekta AB, 2015) validated previously by our group for the registration of contrastenhanced diagnostic CT to non-contrast enhanced planning CT(183). Deformation vector fields
were obtained from DIR algorithm, mapping the deformation of the rCT onto the pCT.
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Subsequently, in a custom written Matlab routine (MATLAB R2013a, The MathWorks Inc.,
Natick, MA, 2013), pCT; dose grid; original plan TVs; rCT; and rGTVs were imported. The
deformation fields were then applied to rGTVs segmented on the rCT to convert them into
‘deformed rGTVs’ on the pCT.
Evaluation of deformed rGTVs relative to original planning TVs was done using both
centroid-based method that assumed the center of mass of rGTV was the origin of the
recurrence volume and its location was compared relative to planning TV after applying
deformation vector fields (DVF). Simultaneously, RIR was performed using the rigid coregistration tool available in the Pinnacle planning system to rigidly align rCT to pCT, following
that rGTVs where exported to patient’s plan where dose volume histograms (DVHs) and rGTV
centroids were generated and analysis metrics were calculated. Figure 6.1 illustrates the
workflow process of our registration methodology.
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Figure 6. 1: Workflow process of patterns of loco-regional failure registration process.
6.2.6 Analysis of failure metrics
For both RIR and DIR mapped rGTVs the following metrics were evaluated:
1) Recurrence volume, 2) Location of the centroid relative to planning TV: Centroid is the
central voxel of the recurrence volume plus added 2mm margin to account for registration error,
3) Spatial relationship of rGTV centroids to IMRT/supraclavicular match line and ipsilateral
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parotid in case of peri-parotid failure, and 4) Mean and maximum dose to rGTVs, dose to 95%
failure volume (fD95%), and mean dose to centroid volume.
6.2.7 Classification of failure
In order to refine our reporting and quality assurance practices using a standard
nomenclature, we developed a granular typology of failure categories relative to the planning
TV and dose. As illustrated in Figure 6.2, failures were classified into five types based on
combined spatial and dosimetric criteria:
•

Type A: Central high dose failure, where the mapped failure centroid originates in high
dose TV and the dose to 95% failure volume (fD95%) is ≥95% dose prescribed to
corresponding TV of origin.

•

Type B: Peripheral high dose failure, where the mapped failure centroid originates from
high dose TV but its fD95% receives <95% dose prescribed to this TV.

•

Type C: Central elective dose failure, where the failure centroid originates from elective
dose TV and its fD95% receives ≥95% dose prescribed to the respective TV.

•

Type D: Peripheral elective dose failure, where the failure centroid originates from
elective dose TV and its fD95% receives <95% dose prescribed to the respective TV.

•

Type E: Extraneous dose failure, where the failure centroid originates outside all TVs.

For patients treated with low-neck supraclavicular field matched to the IMRT fields, two
additional types were added:
•

Type F: Junctional failures at the site of IMRT/supraclavicular match line.

•

Type G: Low neck failures at the site of low-neck supraclavicular field.
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Figure 6. 2: Classification scheme of IMRT patterns of failure
This diagram illustrates the classification of the patterns of failure using combined centroid
based geometric method coupled with the dosimetric parameters.
6.2.8 Statistical analysis
Non parametric statistics were used to compare analysis metrics for centroid locations
and dosimetric parameters of failures mapped using RIR versus DIR registration techniques. A
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p-value ≤ 0.05 was deemed significant. Statistical assessment and data tabulation was
performed using JMP v 11Pro (SAS institute, Cary, NC).
6.3 Results
6.3.1 Patients
A total of 21 patients with HNSCC were included in this pilot methodology/workflow
development study. Median age was 58 years (range 30-75), and 86% were men. Patient,
disease, and treatment characteristics are presented in table 6.2. Recurrences were delineated
using diagnostic contrast-enhanced CT in 16 patients and using PET-CT in 5 patients.
Table 6. 2: Patient demographics, disease, and treatment characteristics
Characteristic

Total
n=21

Age (years)
Median
Range
Time to Failure (months)
Median
Range
Sex
Male
Female
Origin
Nasopharynx
Oropharynx
Hypopharynx
Unknown primary
T-category
T0
T1
T2
T3
T4
N-category
N0
N1

(%)

58
30-75
12
5-69
18
3

(86)
(14)

6
5
5
5

(28)
(24)
(24)
(24)

5
1
7
5
3

(24)
(5)
(33)
(24)
(14)

1
5

(5)
(24)
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N2
N3
Treatment
Radiation alone
Concurrent ChemoRadiation
Induction Chemotherapy + Radiation
Induction Chemotherapy + Concurrent ChemoRadiation
Radiation dose
Mean (SD)
Radiation fractions
Mean (SD)

12
3

(57)
(14)

4
9
1
7

(19)
(43)
(5)
(33)

69.2

(1.7)

33

(2)

6.3.2 Spatial/dosimetric failure mapping
6.3.2.1 Spatial mapping
A total number of 26 rGTVs were delineated. Mean rGTVs volume was 12.5 cm3 (range
1-105). The registration method independently affected the spatial location of mapped failures.
Failures mapped using DIR were significantly assigned to more central TVs compared to
failures mapped using RIR. 38% of centroids (n= 10) mapped using RIR were located
peripheral to the same centroids mapped using DIR (p= 0.0002). Table 6.3 illustrates the sites
and geometric details of all failures mapped to the pCT.
Table 6. 3: Geometric details of failed rGTVs.
N. of recurrences
Recurrence Volume
Mean (SD)
Location of centroid using
RIR
GTV
CTV1
CTV2
CTV3
PTV1
Supraclavicular field

n.
26

(%)

12.5

(23)

12
7
1
1
4
1

(46)
(27)
(4)
(4)
(15)
(4)
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Location of centroid using
DIR
GTV
22
(84)
CTV1
1
(4)
CTV2
1
(4)
CTV3
1
(4)
Supraclavicular field
1
(4)
Abbreviations: NPX = DIR = Deformable image registration, RR = Rigid Registration, GTV=
gross tumor volume, CTV= clinical target volume, PTV= planning target volume.
6.3.2.2 Dosimetric mapping
rGTVs mapped using DIR had statistically significant higher mean doses when
compared to rGTVs mapped rigidly (mean dose 70 vs. 69 Gy, p = 0.03) while comparison of
mean fD95% was not statistically significant (mean fD95% 68 vs. 66 Gy, p = 0.07), and
comparison of maximum, and centroid doses showed no-significant differences between both
registration methods (p = 0.7 and 0.4, respectively). Table 6.4 shows the dosimetric details of
all failures.
Table 6. 4: Dosimetric patterns of failure.
rGTVs dose metrics using RIR
Mean Dose in Gy. (SD)
Mean
69 (6)
fD95%
66 (7)
Max.
71 (6)
Centroid
69 (6)
rGTVs dose metrics using DIR
Mean
70 (5)
fD95%
68 (6)
Max.
72 (5)
Centroid
70 (5)
Abbreviations: DIR = Deformable image registration, RIR = Rigid Image Registration, fD95%=
Dose to the 95% failure volume, Max.=Maximum, SD= standard deviation.
6.3.3 Classification of failure
Based on the proposed classification of failure using both the spatial location of the
centroids of the mapped failure volumes coupled with the dosimetric parameters (as illustrated
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in Figure 6.2), 22 (84.6%) out of the 26 failures mapped using DIR were of type A, one of type
B, 2 of type C, and one of type G. Whereas, 18 (69%) out of the 26 failure mapped using RIR
were of type A, 5 of type B, 2 of type C and one of type G. Figure 6.3 illustrates the difference
in classification using both registration methods. There was no type F (junctional) failures in
patient subset treated using anteroposterior low-neck supraclavicular field matched to the IMRT
fields. Additionally, no peri-parotid failures were detected.

Figure 6. 3: Bar chart of the differences in failure classification.
Bar chart illustrating the difference in failure classification using rigid (RIR) vs. deformable (DIR)
image registration methods.
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This combined spatial/dosimetric analysis shows that while 10 centroids (38%) of RIR
mapped rGTVs were located peripheral to the same centroids mapped using DIR as shown in
Table 6.3. However, after adding the dosimetric component of analysis, only 4 of those 10 RIR
mapped rGTVs were peripheral high dose failures (type B) and the other 6 were central high
dose failure (type A) because despite the centroids were spatially peripheral in location to the
respective DIR ones but dosimetrically, the rGTVs 95% volumes still had ≥95% dose. Figure
6.4 shows an example of the differences in spatial and dosimetric parameters for a DIR versus
RIR mapped failure. Those 4 rGTVs were seen in the following patients: two nasopharyngeal
(one primary “Figure 6.4” and one nodal site); one oropharyngeal (primary site); and one
unkown primary (nodal site). The secondary qualitative review by expert radiation oncologists
(CDF, DIR) of those 4 patients agreed with DIR classification that those recurrences are
actually central rather than peripheral in origin.
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Figure 6. 4: A case illustration.
A case of T2N0 Nasopharyngeal carcinoma recurred 63 months after IMRT. The upper panel
shows the axial, coronal and sagittal images of a RIR mapped rGTV on the original pCT where
its centroid is located at CTV1and the 95% rGTV volume contained on more peripheral PTV2
(contour not shown). The middle panel shows DIR mapped rGTV on the original pCT where its
centroid located at GTV and the 95% rGTV volume contained on more peripheral CTV2. The
lower panel shows RIR and DIR mapped rGTVs overlaid to plan isodose line. Note that RIR
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rGTV fD95% extends beyond the 95% isodose line “66.5 Gy” (red arrow in sagittal image)
which would erroneously characterize it as type B failure, while in fact DIR shows it as a type A
failure (i.e. the fD95% of DIR mapped rGTV is completely encapsulated with 95% isodose line,
shown by white arrow in sagittal image).
6.4 Discussion
Traditionally, failure reporting for HNCs has simply classified disease as “local”,
“regional”, or “locoregional”, thus relating location of failure to a crude anatomic reference.
However, such a reporting language gives no information regarding radiation fields/volumes or
delivered dose. In the pre-IMRT era, when large fields of homogenous dose were used, the
definition of “in-field” failure (i.e. within the field borders) or “marginal” failure (i.e. adjacent to
the block edges) were intuitive descriptors relating treatment parameters to sites of failure.
However, in the current era of conformal therapy(188, 189), dose gradients, and multiple TVs
make relating spatially accurate information about dose and recurrence far more complicated
for IMRT plans. In the same way that a standardized method for analysis and reporting for TVs
has been undertaken successfully (188-190), a similar effort is desirable for pattern of failure
reporting. In our opinion, reporting failure using only anatomic/field referents is insufficient for
complex multi-volume/multi-dose plans, and obscures clinically useful information which might
lead to improvements in future studies.
Likewise, the requirement of rigorous assurance for correctly localizing disease aftertherapy is increased in terms of required spatial accuracy. The steep dose gradients of modern
IMRT plans and proximate transition from high-risk CTVs to intermediate- or lower-risk CTVs
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implies inaccurate registration will erroneously assign the location of failure to incorrect
dose/prescription volume. We, in fact, show RIR for IMRT plans resulted in incorrect
localization relative to prior TVs and dose in 16% of failures in the current pilot dataset.
Consequently, this study presents a methodology and workflow that involves the application of
quality assured DIR software as a tool to standardize co-registration and to correctly attribute
sites of loco-regional failure.
Almost all previous studies have used RIR to describe the patterns of loco-regional
failure after IMRT(32, 175, 177, 178). Chao et al (175) reported 17/126 loco-regional failures
treated by definitive or postoperative IMRT; 53% of failures were inside CTV1, 12% marginal to
CTV1, 6% marginal to CTV2, and 28% were out of field. Eisbruch et al (32) reported on 21
recurrences in 133 patients with non-nasopharyngeal HNCs treated with parotid-sparing IMRT;
17/21 were in-field. Daly et al (177) reported on 69 HNCs treated with parotid-sparing IMRT; 8
patients developed a loco-regional failure, 7 relapsed within the high-dose CTV, with one
junctional failure observed. Sanguineti et al (178) described the patterns of failure for 50
patients with IMRT for oropharyngeal SCC; 5 recurrences were related to high dose regions
while 4 were at the low dose regions. All these reports relied on RIR, known to be less spatially
accurate than DIR(183); it is conceivable these results might be altered if DIR methods were
used. Due et al(36) reported that DIR showed slightly better reproducibility in identification of
the site of recurrence origin compared to RIR. Our previous work(183), as well as the current
study, confirm the qualitative superiority, in HNC applications, of DIR for CT-CT registration.
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In our classification scheme, we designed a combined geometric/dosimetric typology
definition to avoid the drawbacks of using each method separately. Centroid only method
suppose a single point of origin and ignore the dose given to the whole area of recurrence
while the dosimetric only analysis is agnostic to the geometric recurrence origin. Due et al(36)
previously reported that focal methods, such as the centroid method we used, are more
accurate to localize the origins of loco-regional recurrences than volume overlap methods,
which may incorrectly assign recurrences to more peripheral TVs. Raktoe et al(37) further
confirmed the superiority of focal methods like centroid expansion to the volumetric method in
identifying the origin of loco-regional recurrences. The combined method we used identify the
estimated site of recurrence origin relative to the respective TV in the planning CT and then
compare the dose to the mapped recurrence volume with the dose prescribed to the TV of
origin. Using this method, our results showed that DIR significantly assigned failures to more
central TVs and doses compared to RIR concordant with the results of Due et al.(36).
Our proposed nomenclature allows granular reporting of different types of failure. In our
classification, type A “central high dose” failures, are considered to be biological failures, as
they likely represent resistance to maximal therapy, and thus could not conceivably be
prevented by technical/operator dependant processes including IMRT QA or delineation
alteration. Type A failures motivate future investigation of alternative treatment stratgies (e.g.
integration of novel targeted drug therapies or dose escalation to identifiable biologically
aggressive subvolumes). Likewise, type E “extraneous dose” failures cannot be modified by
IMRT QA processes. They represent a possible diagnostic or decision error rather than a target
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delineation error (i.e. “One will never hit what one does not aim at.”). However, type B, C, and
D failures are of a special concern since they entail potential technical or radiotherapy process
failures. Type C “central elective (intermediate or low) dose” failures may be prevented by
prescribing higher doses (i.e. shifting to higher CTV levels). Importantly, type B “peripheral high
dose” or D “peripheral elective dose” failures necessitate a rigorous QA process including triple
DIR registration of pre-therapy diagnostic imaging (diagnostic CT, MRI, and/or PET-CT) to pCT
and the earliest rCT, to assess the potential causes: potential target delineation or dose
delivery error (modifiable) versus overgrown recurrence that represents actual type A or C
failure which is converted to type B or D, respectively, due to rapidly progressive disease or
neglected late diagnosed recurrence (not modifiable). This involves multi-physician review of
planning and recurrence contours, and review of IGRT data (i.e. set-up error, adaptive
replanning datasets), as well as examination of the follow-up interval between surveillance
images. By cataloging type B/D errors, we can then address the relevant issues dynamically for
future patients. For instance, the only type B patient (i.e. using DIR methodology), was noted
on secondary review of diagnostic imaging to have subsequent intracranial extension, route of
failure, despite optimum delineation and dose coverage.
The secondary qualitative review by expert radiation oncologists (CDF, DIR) of all the
clinical and imaging data of the four additional recurrences that were classified as peripheral
high dose (type B) using RIR while were type A using DIR, concurred with DIR classification
that those recurrences are actually central rather than peripheral in origin.
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In this dataset, our results showed the majority (84.6%) of DIR mapped failures were of
type A indicating, that biological, non-technically/non-operator dependant explanations for
failure predominated. However, using RIR type A failures would have been erroneously
reported as comprising only 69%. These results assert the need for a robust, quality assured
image registration technique, as error in the registration process would invalidate subsequent
results and thus might deceptively indicate a greater rate of technical/operator-attributable
therapy failures than DIR demonstrates. The current study, while underpowered to make
clinical extrapolations due to limited number of patients, nonetheless serves as a benchmark to
describe our standardized analytic and reporting method. Already, RTOG 1216, for example,
contains provisions regarding collection of imaging data post-failure(191), which will allow
careful analysis, and process quality improvement for future trials and large scale datasets.
6.5 Conclusions
Rigid image registration method tends to assign failures more peripherally compared
with deformable method. Using DIR, the vast majority of failures in the presented pilot study
originated in the high dose target volumes and received full prescribed doses suggesting
biological rather than technology-related causes of failure. We heavily recommend a validated
DIR-based registration technique in addition to granular combined geometric- and dosimetricbased failure characterization using novel typology-indicative taxonomy as a standard part of
large-scale patterns of failure reporting in the IMRT era.
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Chapter 7: Patterns of locoregional failure following post-operative intensity-modulated
radiotherapy

This chapter is based upon:
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deformable image registration workflow. Radiat Oncol. 2017 Aug 15;12(1):129. doi:
10.1186/s13014-017-0868-y. PMID: 28806994; PMCID: PMC5557312.
This article is under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/)
which permits reproduction in any format.
7.1 Introduction
Surgery is often the treatment of choice for oral cavity squamous cell carcinoma
(OCSCC). Post-operative radiotherapy is indicated for OCSCC of advanced stages or with
adverse prognostic factors(192-194). Intensity-modulated radiotherapy (IMRT) enables
conformal therapy and reduction of complications to surrounding normal tissue, and for many
centers has become the standard radiation approach for head and neck cancer(195).
Generally, OCSCC patients demonstrate relatively worse loco-regional control
compared to other head and neck subsites (e.g. oropharynx and larynx).(196-198) Studies that
have specifically examined cohorts of OCSCC patients receiving postoperative IMRT (PO114

IMRT) have consistently reported only fair locoregional control rates, as low as 53% at 3 years
in some series(199-204).
Moreover, most report failures as “infield”, “marginal”, or “outfield” based on percentage
overlap between failure volume and respective target volumes. However, these studies applied
non-uniform spatial methods for failure analysis, mainly utilizing non-validated rigid or manual
image registration tools and without including the dosimetric component in the analysis(199204). We have recently shown the potential impact of patterns of failure analysis methodology
using a validated image registration software paired with combined spatial and dosimetric
analysis of failure, in improving the accuracy of reporting the patterns of failure in the era of
IMRT(205-207). As a continuation of these efforts we sought to apply this unique analytic
methodology to our institutional large scale oral cavity cancer dataset of patients receiving POIMRT with documented treatment failure to achieve the following specific aims: 1) characterize
distinct spatial and dosimetric patterns of failure after PO-IMRT, 2) identify clinical risk features
associated with each failure type, 3) identify patterns of failure based target volume contouring
recommendations, and 4) generate hypotheses for future clinical trials.
7.2 Material and Methods
7.2.1 Patient Selection
Two hundred eighty-nine patients with pathological diagnosis of OCC who received POIMRT at the University of Texas MD Anderson Cancer Center from 2000-2012 were
retrospectively reviewed under an approved institutional review board protocol. Patients with
distant metastases or concurrent malignancies at the time of diagnosis, or treatment with
chemotherapy prior to staging at MDACC were excluded. Patients with prove of recurrence
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after PO-IMRT with available imaging documenting recurrence were included in the current
analysis.
7.2.2 Treatment Planning and Delivery
Treatment planning and delivery is described in details in previously published work,
which examines the outcomes for this same patient cohort.(208)
7.2.3 Clinical Data Collection
Diagnostic contrast-enhanced CT and/or PET/CT documenting the initial evidence of
local and/or regional recurrence (rCT) was identified. Recurrences were confirmed via
radiologic imaging (i.e. progression in subsequent CT imaging or high SUV on PET imaging) or
pathology specimens (i.e. from surgical biopsy). Radiologically evident recurrent gross disease
(rGTV) was manually segmented and reviewed by two experienced radiation oncologists
(ASRM, CDF). Corresponding original planning CTs (pCT) were also identified and original
plans were restored. Patient, disease, and treatment characteristics were gathered during chart
review.
7.2.4 Image Registration and Dosimetric Analysis
rCT was co-registered with pCT using a previously validated deformable image
registration (DIR) methodology (VelocityAI 3.0.1, Velocity Medical Solutions, Atlanta, GA, 20042013). (205, 206) rGTVs on the rCT were subsequently deformed to co-registered pCT (Figure
7.1). The centroid, assumed as the origin of tumor recurrence, is represented as the calculated
center of mass of the deformed rGTV. Dosimetric and volumetric parameters were obtained
from the dose-volume histogram.
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Figure 7. 1: Study workflow.
7.2.5 Patterns of Failure Classification
Failures are classified according to both spatial and dosimetric criteria as previously
described. (207) Briefly, for spatial mapping of recurrence origin, the centroid of each rGTV
was mapped to the corresponding TV in the planning CT. Subsequently, the dosimetric
characteristics were assessed by calculating the dose to 95% of the failure volume (fD95%)
then comparing it relative to the dose prescribed to the corresponding TV of origin as
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determined by the spatial mapping. Finally, failures were classified into five major types: Type
A (central high dose where the mapped failure centroid originates in high dose TV and fD95%
is ≥95% dose prescribed to corresponding high dose TV of origin), Type B (peripheral high
dose where the failure centroid originates from high dose TV but its fD95% is <95 % dose
prescribed to corresponding high dose TV of origin), Type C (central elective dose where the
failure centroid originates in lower dose TV and fD95% is ≥95% dose prescribed to
corresponding lower dose TV of origin), Type D (peripheral elective dose where the failure
centroid originates in lower dose TV but the fD95% is <95% dose prescribed to corresponding
lower dose TV of origin), and Type E (extraneous dose where rGTV centroid originates outside
all TVs). Type F describes junctional failures at the IMRT/supraclavicular match line, and Type
G describes low neck failures at the low-neck supraclavicular field. Type G is analogous to type
C if the fD95% is ≥95% dose prescribed to the low-neck and analogous to type D if the fD95%
is <95%. Examples demonstrating failure type definitions are illustrated in Figure 7.2.
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Figure 7. 2: Examples of Failure Types.
1) Type A (central high dose) failures. Centroid is mapped inside high dose TV and dose to
95% rGTV volume ≥ 95% dose prescribed to high dose TV. 2) Type B (peripheral high dose)
failure. Centroid is mapped inside high dose TV, but dose to 95% rGTV volume < 95% dose
prescribed to high dose TV. 3) Type C-int (central intermediate dose) failure. Centroid is
mapped inside intermediate dose TV and dose to 95% rGTV volume ≥ 95% dose prescribed to
intermediate dose TV. 4) Type D-int (peripheral intermediate dose) failure. Centroid is mapped
inside intermediate dose TV but dose to 95% rGTV volume < 95% dose prescribed to
intermediate dose TV. 5) Type E (Extraneous dose failure) where rGTV centroid originates
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outside all TVs. 6) Type G (low neck failure) where rGTV centroid is located at the low-neck
supraclavicular field.
Patients were then classified according to the predominant mode of failure. Patients
with more than single recurrence lesion were classified as the following: 1) for patients with
type A recurrence and concurrent non-type A lesions, the overall pattern of failure was defined
as type A because we believe type A for such patients is the true recurrence rather than
reseeding from the non-type A recurrence, 2) for patients whom exhibited more than one failure
type of non-type A simultaneously, pattern of failure of each patient was classified according to
the predominant type as determined by the most commonly encountered failure type (i.e.
higher number or higher volume).
7.3 Results
7.3.1 Patient and Treatment Characteristics
Sixty-three patients (22%) developed locoregional recurrences. Median time to
recurrence was 4 months (range 0 – 71). For spatial and dosimetric analysis of the patterns of
failure, 9 patients were excluded: 4 with post-surgical recurrence prior to initiation of IMRT, 3
with no retrievable IMRT plan, and 2 with no available imaging documenting recurrence. This
left 54 patients for the current analysis.
Patient, disease, and treatment characteristics for the analyzed 54 patients are
summarized in Table 7.1. The most common primary site was the oral tongue (39%). The most
common pathologic T and N staging were T2 (37%) and N2 (36%). Forty-seven (87%) patients
had Stage III-IV disease.
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Table 7. 1: Patient, Disease, and Treatment Characteristics.
Characteristic
Age
Median (range)
Gender
Female
Male
Tumor Site
Oral Tongue
Buccal Mucosa
Floor of Mouth
Hard Palate
Gingiva
Retromolar Trigone
Histologic Differentiation
Poor
Moderate
Well
Clinical T stage
T1
T2
T3
T4
Clinical N stage
Nx
N0
N1
N2a
N2b
N2c
Pathological T stage
ypT0
T1
T2

N (%)
59.5 years
(22-87)
20 (37)
34 (63)
21 (39)
10 (18.5)
2 (4)
3 (5)
10 (18.5)
8 (15)
13 (24)
36 (67)
5 (9)
8 (15)
19 (35)
9 (17)
18 (33)
2 (4)
23 (43)
11 (20)
0 (0)
14 (26)
4 (7)
2 (4)
8 (15)
20 (37)
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T3
T4
Pathological N stage
No dissection
N0
N1
N2a
N2b
N2c
Overall stage
Stage I
Stage II
Stage III
Stage IV
Primary Surgery Margin Status
Negative (>5 mm)
Close (≤ 5 mm)
Positive
Depth of invasion
≤1.5 cm
>1.5 cm
Unspecified
Perineural invasion
Yes
No
Lymphovascular invasion
Yes
No
Unspecified
Extracapsular extension
Yes
No
IMRT dose and fractionation
Median Dose (Range), in Gy
Median Fractionation (Range)
Laterality of Neck radiation

7 (13)
17 (31)
7 (13)
12 (22)
12 (22)
0 (0)
19 (36)
4 (7)
1 (2)
6 (11)
7 (13)
40 (74)
41 (76)
9 (17)
4 (7)
33 (61)
18 (33)
3 (6)
22 (41)
32 (59)
14 (26)
30 (56)
10 (18)
17 (31)
37 (69)
60 (56-70)
30 (28-33)
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Unilateral
Bilateral
Chemotherapy
Induction
Concurrent
Induction and concurrent
No chemotherapy

13 (24)
41 (76)
5 (9)
13 (24)
2 (4)
32 (59)

Surgical margins were positive and close (defined as ≤5 mm) in 4 (7%) and 9 (17%)
patients, respectively. Perineural invasion or lymphovascular invasion was present in 22 (41%)
and 14 (26%) patients, respectively. Depth of invasion was ≥1.5 cm in 18 patients (33%). Fortyseven patients (87%) had neck dissections, and of those 17 patients had nodal extracapsular
extension.
Mean RT dose was 60±7 Gy and mean number of fractions was 30±3. One patient did
not complete the full course of IMRT, discontinuing therapy after 6 fractions. Thirteen (24%)
and 41 (76%) patients received unilateral and bilateral neck irradiation, respectively. Mean
overall treatment package time, defined as time interval from date of surgery to last day of
irradiation, was 12.3±1.7 weeks.
7.3.2 Recurrence Characteristics
For patients included in the current analysis; 26 (48%) had local recurrence, 19 (35%)
had regional recurrence, and 9 (17%) had both local and regional recurrence. A total of 82
rGTVs were delineated. Median rGTVs volume was 3.7 cm3 (IQR 1.4-10.6). Figure 7.3 shows
the distribution of the predominant type of failure for the entire dataset using the proposed
classification schema. Thirty patients (55.5%) were classified as type A. Non-type A failures
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were distributed as follows: 2 (3.7%) type B, 10 (18.5%) type C, 1 (1.8%) type D, 9 (16.7%)
type E, and 2 (3.7%) type G. Because type A “central high dose” failures, are considered to
resistance to maximal therapy, and thus could not conceivably be prevented by
technical/operator dependent processes, however, non-type A failures represent a major goal
for IMRT quality assurance and improvement. Table 7.2 illustrates the details of the
characteristics for all non-type A failures.

Figure 7. 3: Ring chart of the predominant typology of failure.
Table 7. 2: Failure Sites for non-type A Failures.
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*Indicates type A failure with multifocal recurrence that includes non-type A lesions as well.
†This patient had received only 6 fractions and failed to appear for the remainder of her
treatments. Abbreviations. L: local; R: regional; LR: locoregional; FOM: floor of mouth; RMT:
retromolar trigone; -ve: negative; +ve: positive; Ipsilat: ipsilateral; Contralat: contralateral; Bilat:
bilateral; U/S: unspecified; I: induction chemotherapy; C: concurrent chemotherapy; I+C:
induction followed by concurrent chemotherapy; No; No chemotherapy.
7.3.3 Local Failure typology
Of the 26 patients with local disease failure without synchronous regional recurrence,
16 (62%) were type A central high dose failures. Ten patients (38%) had non-type A local
failure; two (8%) were type B, three (11%) were type C (intermediate dose), one (4%) was type
D (intermediate dose), and four (15%) were extraneous type E failure. Three of patients with
type A failure had multifocal recurrence; two patients with two foci of recurrences (both within
the central high dose region), and one had four foci of recurrences (three in the intermediate
dose and one in the high dose).
For the two patients with type B failure, one had a primary tumor in the left mandibular
gingiva and developed recurrence involving the left maxillary sinus, with erosion of its lateral
wall and extension along the buccal mucosa to the retromolar trigone. The second patient had
a primary tumor in the floor of mouth with rapid disease progression subsequent to
discontinuing radiation treatment after six fractions.
Regarding patients with type C failure, one patient had his primary tumor in the
retromolar area and recurrence in the ipsilateral masticator space. The second patient had the
primary tumor in the floor of mouth with recurrence involving the base of tongue, while the third
patient had a primary tumor in the oral tongue with recurrence involving the floor of mouth.
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The single type D failure had the primary tumor in the left mandibular gingiva and
recurred along the left masticator space allowing the rGTV to partially grow outside the CTV2
boundaries, however the centroid was still located inside CTV2.
For patients with type E failure, one had the primary tumor in the right mandibular
gingiva and the recurrence in the contralateral mandibular gingiva approximately 2 years
following treatment. The second patient had the primary tumor in the left buccal mucosa; the
recurrence manifested as retrograde perineural spread that extended to the left pterygopalatine
fossa, foramen rotundum, foramen ovale, cavernous sinus, and through the superior orbital
fissure into the left orbit (Figure 7.4). The third patient had T1 primary tumor in the central floor
of mouth and the recurrence in the left alveolar mandibular ridge approximately 3 years
following treatment. Lastly, the fourth patient had the primary tumor in the left mandibular
gingiva and the recurrence in the ipsilateral masticator space at the first follow up following
treatment.
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Figure 7. 4: A Case illustration.
The top panel depicts two patients with type E recurrence in the ipsilateral parotid nodal area
following parotid sparing IMRT. Both patients were diagnosed with T2N2b right sided buccal
mucosa primaries and subsequently failed at the ipsilateral parotid area outside all target
volumes. The lower panel depicts another example of type E failure in a patient diagnosed with
T3N2b at the buccal mucosa with post-IMRT ipsilateral perineural spread along the maxillary
and mandibular nerves (bottom left, bottom right).
7.3.4 Regional Failure typology
Of the 19 patients with regional disease failure without synchronous local recurrence,
only 7 patients (37%) were type A central high dose failures. Twelve patients (63%) had nontype A local failure; 5 (26%) were type C (intermediate or low dose), five (26%) were
extraneous type E, and 2 (11%) were type G low neck failure. Two of patients with type A
failure had multifocal recurrence. One patient with a left oral tongue primary developed
synchronous ipsilateral type A recurrence at level III and contralateral type C (low dose)
recurrence at level IIa. The second patient had the primary disease in the right retromolar
trigone with multi-nodal recurrence at ipsilateral neck level IIb and an ipsilateral retropharyngeal
lymph node (type D).
For the five patients with type C failure, one patient had a right hard palate primary with
multifocal type C (low dose) failure with two foci of recurrence, both at contralateral level IIa.
The second patient had the primary tumor in the left maxillary ridge and recurred in the low
dose region at the ipsilateral level Ib. The third and fourth patients had primary tumors of the
oral tongue with recurrences in levels Ia (intermediate dose) and contralateral Ib (low dose),
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respectively. The fifth patient had a primary tumor in the right retromolar trigone and recurrence
in the ipsilateral level Ib (intermediate dose).
Four of the five patients with type E extraneous failure had their primary tumor in the
buccal mucosa. Two patients had ipsilateral parotid nodal recurrence in the area of spared
parotid gland (Figure 7. 4) while the other two patients had recurrences in the un-irradiated
contralateral side. The fifth patient had the primary tumor in the left maxillary alveolar ridge with
recurrence in the un-irradiated contralateral level II.
Regarding the two patients with type G low neck failure, one had the primary tumor in
the left mandibular with negative dissection of ipsilateral neck levels II, III, and IV, however, the
patient then recurred in the ipsilateral level VIb (i.e. pre-tracheal recurrence). This failure is
analogous to type D as fD95% for this patient was 10 Gy (i.e. fD95% had less than 95% of the
dose prescribed to left supraclavicular region which was 58 Gy). The second patient had the
primary tumor in the left oral tongue with positive neck dissection of ipsilateral levels I, II, and V
then recurred in the contralateral levels III and IV. This failure is analogous to type C as fD95%
for this patient was 48.75 Gy (i.e. fD95% had higher than 95% of the dose prescribed to
contralateral supraclavicular field that encompassed both contralateral levels III and IV with a
prescription dose of 50 Gy).
7.3.5 Locoregional Failure typology
Nine patients had synchronous local and regional failure. The predominant typology for
each patient was determined according to the local failure component. Seven (78%) had type A
failure and two (22%) had type C. For patients with type A failure, 3 had synchronous non-typeA failure at the neck (2 had synchronous type C and one had synchronous type G). Both
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patients with type C failure had their primary tumor in the oral tongue. The first had recurrence
in the contralateral side of the tongue and neck level II (both at low dose CTV) while the second
had recurrence in the floor of mouth (intermediate dose CTV) and contralateral neck level IIa
(low dose CTV).
7.4 Discussion
Our results demonstrate that nearly half of the patients with local and/or regional failure
included in the current study had non-central high dose recurrence. We applied our novel
patterns of failure analysis and classification methods to further analyze those recurrences of
non-central high dose nature. Recurrences in operated tissues are less prone to present
concentrically as do recurrences that occur following definitive radiation. The likelihood of a
recurrence manifesting in the epicenter of origin disease that is removed surgically is unlikely,
particularly when large volumes of tissue are removed and replaced by free flaps, creating
significant variations in the irradiated anatomy compared to the presurgical anatomy.
Furthermore, the new tissue planes can create differing paths for tumor to spread through.
Thus, in the postoperative setting we essentially create a crude probabilistic model of where
microscopic disease may be hiding.
While concentric central recurrences occurred less commonly than we noted in the
definitive setting, over 75% of recurrences did occur within targeted tissues, the majority of
which were in the high dose tumor bed target (Type A), while the remainder were in subclinical
(Type C and G) targets. No technical or operator-dependent processes could conceivably
prevent such failures. Whether dose intensification to Type A targets would minimize these
recurrences is unclear. To date, the benefits of treatment intensification seem small. There is a
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paucity of data demonstrating that increasing radiation dose is beneficial, and even concurrent
chemoradiation only seems to benefit those at highest risk(196, 209). Type C failures may be
prevented by prescribing higher doses (i.e. shifting to higher TV levels), but it is unclear if these
relatively small dose increments (as the differences between dose to each CTV was < 10%)
would be beneficial, and also increasing dose to larger volumes can potentially increase the
risk: benefit ratio. Non-IMRT failure in the matching low-neck supraclavicular field was very
uncommon and only seen in two patients. Also, no failures were noted at the IMRTsupraclavicular field match-line confirming the safety of this technique.
Types B (peripheral high dose), D (peripheral elective dose) and E (extraneous) failure
are potentially dependent on technical or radiotherapy processes. Type B and D recurrences
are analogous to what has been described as “marginal miss”. Peripheral misses (type B)
were seen only in 4 patients (of whom one didn’t complete the prescribed radiation dose).
Three of these were in primary tumor sites, and more likely reflect the tumors finding pathways
more amenable for spread and growing out of the dose region rather than originating at the
periphery. Similarly, the one peripheral nodal failure was in a retropharyngeal node that is
typically not targeted but fell into a D type failure rather than E due to the proximity to the
primary tumor bed. The paucity of these peripheral type recurrences reflects an adequate CTV
delineation strategy, appropriate PTV margins, and precise dose delivery.
Type E extraneous recurrences were seen in approximately 17% of failures. Type E
failures are analogous to traditionally defined “out of field” recurrences. This pattern of failure
was mainly in patients who had primary tumors of the buccal mucosa or gingiva. Four patients
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had primary type E recurrence, and 5 had nodal type E recurrences. Two patients with type E
failure at the primary site had recurrences in sites relatively separate from the primary disease,
and so these “recurrences” may represent second primary tumors.
Retrograde ipsilateral perineural spread was the cause of Type E recurrence in two
patients (Figure 7.4) and was also observed in two other patients (1 Type C and 1 Type D) as
seen in Table 7.2. Daly et al. had reported on a patient who had developed failure at the
ipsilateral masseter due to presence of perineural invasion and retrograde tracking along the
mandibular nerve(202). Yao et al. had previously reported on two patients with extensive
perineural invasion and retrograde tracking who had developed failure within the infratemporal
fossa(199). We would also recommend that “nerves at risk in the tumor bed should undergo
biopsy and be covered in a retrograde fashion within the RT field”(202).
Three patients had recurrence in the contralateral undissected/unirradiated upper neck.
Prior studies have reported that positive ipsilateral lymph nodes are a predictive factor for
contralateral recurrence; conversely, contralateral lymph node metastases never occurred in
patients without ipsilateral lymph node involvement(210, 211). While these studies
demonstrated the association of ipsilateral lymph node involvement with contralateral
recurrence, the majority of patients in these studies were predominantly patients with oral
tongue cancer, and few patients had buccal cancer. We continue to favor comprehensive
bilateral radiation for patients with tumors in central oral cavity sites, such as the oral tongue
and floor of mouth. Yao et al. recommended that patients with ipsilateral lymph node
involvement in OCC should receive bilateral neck irradiation(199). Moreover, Chan et al.
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suggested that bilateral neck irradiation should be administered to patients with N2b
disease(204). However, again these studies were heavily weighted with patients with oral
tongue, and not buccal cancers. Thus, our approach to buccal and retromolar trigone tumors is
individualized. Those patients with low nodal burden are still treated to the ipsilateral neck, but
those with bulky nodes, multiple levels of nodes, or who have an epicentered lateral primary
site, but the primary disease extends centrally are treated to both sides of the neck.
Two patients had almost identical pattern of recurrence in the ipsilateral parotid nodes
as shown in Figure 7.4. Strict dose constraints to the parotid have been recommended to avoid
long-term risks of xerostomia(201). In our cohort, two patients with T2N2b buccal mucosa
primaries had recurrences in the ipsilateral parotid gland which was spared during PO-IMRT.
This phenomena has been also reported in previous studies(204). The proximity of buccal and
retromolar trigone tumors to the parotid bed makes ipsilateral parotid avoidance challenging.
We therefore recommend limiting the extent of radiation-induced xerostomia by focusing on
sparing the contralateral glands.
To date, a limited number of studies have exclusively investigated failure following POIMRT in OCC patients. Tables 7.3 and 7.4 tabulate our study’s patient/treatment and failure
characteristics compared to extant literature. Loco-regional control of our study are consistent
with that of previous studies(199-204, 212). Although Sher et al. reported low loco-regional
failure rates (7%), they acknowledged that it may have reflected the greater proportion of early
T and N staging in their cohort(203). Other disease characteristics are noted but are not directly
comparable as the subset of reported patients varied from study to study.
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Table 7. 3: Published Reports Describing Patterns of Failure Following Post-Operative
IMRT for Oral Cavity Cancer, Patient Characteristics.
Author

Time period

Patients with LRC (%,at Patients with LRF
PO-IMRT for x years)
following PO-IMRT
OCC (n)
for OCC (n,%)

Median RFS in T3-T4 pN+ Positive ECE PNI LVI CRT
months (range) (%) (%) margin (%) (%) (%) (%)
(%)

Yao et al. (9)

2001-2005

49

82 (2y)

8 (16%)

4.1 (3.0-12.1)

56a

69a

NR

NR

NR

NR

4b

Studer et al. (10)

2002-2007

28

92 (2y)

NR

NR

32b

75b

NR

NR

NR

NR

85b

b

b

b

b

b

b

Gomez et al. (11)

2000-2006

35

84 (2y)

6 (17%)

6.1 (4.1-26.0)

40

63

17

36

54

26

29b

Daly et al. (12)

2002-2009

30

53 (3y)

11 (37%)

8.1 (2.4-31.9)

45c

60c

10c

35c

50c

NR

60c

Sher et al. (13)

2004-2009

30

91 (2y)

2 (7%)

NR

26c

54c

0c

20c

43c

17c

77c

b

b

b

b

b

180

78 (2y)

8 (2-39)

40

68

17

34

61

5

26b

Metcalfe et al. (20) 2007-2012

45

89/94d (2y) 2 (4%)

6 (2-34)

43e

73e

24e

38e

45e

38e

28e

Current report

289

79 (2y)

4 (0-71)

44c

65c

7c

31c

41c

26c

41c

Chan et al. (17)

2005-2010
2001-2012

38 (21%)
63 (22%)

b

Abbreviations: PO-IMRT - post-operative intensity-modulated radiotherapy; OCC - oral cavity cancer; LRC - locoregional control; LRF - locoregional failure; RFS - recurrence
free survival; ECE - extracapsular extension; PNI - perineural invasion; LVI - lymphovascular invasion; CRT - chemoradiation; NR - not reported
a - % of all patients in the study (n = 55, 49 with PO-IMRT to OCC)
b - % of all patients who had received PO-IMRT
c - % of only patients who had failed following PO-IMRT
d - local control was 89% and regional control 94% at 2 years
e - % of all patients in the study (n = 106, 45 with PO-IMRT to OCC)

Table 7. 4: Published Reports Describing Patterns of Failure Following Post-Operative
IMRT for Oral Cavity Cancer, Failure Characteristics.
Author

LRF following initiation
of PO-IMRT (n)

Spatial Classification Method

In Field
Marginal
Out Field
Recurrences Recurrences Recurrences
(n)
(n)
(n)

Yao et al. (9)

11

Binary volume overlap with CTV

10

0

1

Studer et al. (10)

NR

NR

NR

NR

NR

Gomez et al. (11) 6

Binary volume overlap with target volume

4a

0

0

Daly et al. (12)

11

Percentage volume overlap with 100% isodose CTVb

7

2

2

Sher et al. (13)

2

Percentage volume overlap with 95% isodose CTVc

2

0

0

Chan et al. (14)

38

Percentage volume overlap with 95% isodose CTVd

26

7

5

Metcalfe et al. (20) 2

Percentage volume overlap with 95% isodose CTVd

0

2

Current report

Spatial/dosimetric classification

0
30->A,10>C,2->G

2->B,1->D

9->E

54

Abbreviations: CTV – clinical tumor volume; NR – not reported
a - Study reported 4 local failures (all within treatment volume) and 2 regional failures (spatial classification not specified)
b - Per Chao et al. (20), >95% of recurrent tumor falling within CTV is infield, 20-95% is marginal, and <20% is outfield
c - Per Popovtzer et al. (21), >50% of recurrent disease present within 95% isodose line is infield and <50% is marginal
d - Per Dawson et al. (22) ≥95% of recurrence volume within 95% isodose of intended treatment dose is infield, 20 to <95% is marginal, and <20% is outfield

To classify failures using a spatial component, several prior studies (199, 200, 202-204)
used varying volume overlap approaches (213-215). Here we highlight two limitations in these
prior studies: 1) volume overlap methods for spatial characterization and 2) the lack of a
dosimetric component in failure analysis. Given enough time, recurrence volumes can outgrow
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TV margins. Thus, the spatial characterization of “infield” vs. “outfield” is volume dependent and
biased by elapsed time. As the spatial component of our failure classification, we apply a
centroid-based approach. This approach has demonstrated to be more superior and accurate
than volumetric overlap approaches, as the latter tends to assign failures more
peripherally(216, 217). Moreover, the spatial component alone is insufficient for accurate and
specific reporting of failures. Without a dosimetric component, failures that are “infield” but in
fact did not receive the prescribed dose (i.e. Types B and D in our classification) could be
erroneously assumed to be biological failures. Subsequently, such “infield” failures are not
investigated further despite a potentially rectifiable technical or radiotherapy process.
As a retrospective series, the standard caveats apply. However, although patients were
not selected nor treated prospectively, all patients were reviewed by a multidisciplinary team.
This data was collated as a secondary analysis of part of a larger programmatic evaluation of
PO-IMRT outcomes for OCC; the reader is encouraged to peruse the clinical/oncologic report
previously published(208). Likewise, as a single institute series from a high-volume tertiary
center, the generalizability/scalability of our findings to facilities which do not utilize our
systematic quality assurance methods (e.g. multi-physician direct physical examination and
consensus review of target delineation) would be suspect(95, 218).
Nevertheless, despite these limitations, our study is the largest, to our knowledge,
systematic assessment of patterns of failure to OCC following PO-IMRT using a qualitycontrolled image-registration pipeline for methodologically rigorous pattern of failure
investigation.(207) Similarly, our study is the first to incorporate a dosimetric component in
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failure classification for OCC following PO-IMRT, in addition to utilizing a centroid-based spatial
component and a validated DIR method which is critical for accurate failure analysis(205-207).
We hope that by utilizing a standardized typology for reporting patterns of failure in OCC
following PO-IMRT, which can be adopted by multiple institutions, we can encourage other
comparable reporting practices for PO-IMRT, in a manner that allows improved detection of
possible modes of preventable error. This could allow for pooling of data to infer differences in
treatment approaches and subsequent outcomes amongst different institutions.
7.5 Conclusions
Prior studies have assessed loco-regional control following PO-IMRT to OCC in manner
which elides the reality of dosimetric gradients inherent in IMRT and precludes identification of
systematic sources of modifiable error which might impact these recurrences. A standardized
typology with both spatial and dosimetric components allows for more accurate and specific
reporting of the patterns of failure over traditional “infield” vs. “marginal” vs. “outfield” failure
classification schemes. Our study incorporates a dosimetric component in addition to utilizing a
centroid-based spatial component and a quantitatively validated DIR method. Approximately
half of the patients with local and/or regional failure included in the current study had noncentral high dose recurrence. Thus, contrary to non-OCC sites, a substantial proportion of
failures in our series, despite rigorous multiphysician quality assurance, are not definitive
biological failures and, as potentially modifiable risk-events, necessitate further investigation
and potential practice modification. Other groups are encouraged to undertake similar efforts as
single-site or pooled analyses for OCC following PO-IMRT.
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Chapter 8: Patterns-of-failure guided biological target volume definition: FDG-PET and
dosimetric analysis of dose escalation candidate subregions
This chapter is based upon:
Mohamed ASR, Cardenas CE, Garden AS, Awan MJ, Rock CD, Westergaard SA, Brandon
Gunn G, Belal AM, El-Gowily AG, Lai SY, Rosenthal DI, Fuller CD, Aristophanous M. Patternsof-failure guided biological target volume definition for head and neck cancer patients: FDGPET and dosimetric analysis of dose escalation candidate subregions. Radiother Oncol. 2017
Aug;124(2):248-255. doi: 10.1016/j.radonc.2017.07.017. Epub 2017 Jul 31. PMID: 28774596;
PMCID: PMC5600500.
This article is under a Creative Commons license (http://creativecommons.org/licenses/by/4.0/)
which permits reproduction in any format.
8.1 Introduction
Despite recent advances in radiation therapy (RT), such as intensity modulated
radiotherapy (IMRT) and image guided radiotherapy (IGRT), local and/or regional tumor
recurrence is still the major mode of therapy failure for head and neck squamous cell cancer
(HNSCC) patients.(25, 27, 32, 219) Identifying areas at higher risk of recurrence within gross
target volume (GTV) with subsequent dose escalation represents a promising strategy towards
reducing the rate of locoregional disease failure.(220-227)
Dose escalation in HNSCC is, nonetheless, limited by the proximity of multiple critical
normal tissues. A strategy to target smaller radio-resistant subvolumes of the gross disease
with higher radiation dose would be safer and more successful if the precise identification of
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these subvolumes is feasible. Biological imaging modalities are promising for the creation of
more spatially accurate maps of radio-resistant sub-regions of the disease compared with
standard anatomical modalities. 18F-fluorodeoxyglucose positron emission tomography (FDGPET) is the most widely utilized biological imaging modality in the clinical setting. Dose
escalation strategies based on FDG-PET imaging are emerging in multiple cancer
subsites.(228)
However, only a few HNSCC dose escalation clinical trials have been undertaken. In
those early phase trials, the definition of FDG-PET guided dose escalation sub-volumes had
been variable. The authors of the ARTFORCE phase II study designed their dose escalation
sub-volumes based on 50% of the maximum uptake in the primary tumor plus a 3 mm margin
to create a final PTV-FDG-PET.(229) Investigators from Ghent University Hospital
implemented different strategies in two phase I dose escalation studies, using focal dose
painting by contours based on the source-to-background ratio in one study (226) and dose
painting by number in the second study.(222)
The rationale of defining distinct FDG-PET standard uptake value (SUV) levels as a
threshold to dose escalate GTV subvolumes in HNSCC trials has not been validated in large
scale datasets and mainly has been extrapolated from non-head and neck subsites (e.g. a nonsmall cell lung cancer study showed that the 50% SUV high FDG uptake area of the preradiotherapy scan overlapped significantly with the residual metabolically active areas posttreatment). (230) The identification of “evidence-based” pretreatment FDG-PET sub-volumes to
guide future dose escalation studies is still an unmet need in HNSCC.
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To this end, we aim to map the spatial location of the origin of posttreatment tumor
recurrence to the pretreatment FDG-PET/CT in a large scale post-IMRT HNSCC failure dataset
using a quality assured deformable image registration methodology. We sought the following
specific aims:
1)

Identify the geometric origin of local and/or nodal recurrence relative to the pretreatment

FDG-PET scan and relative to the original treatment target volumes.
2)

Identify FDG-PET SUV thresholds that overlap with the majority of tumor recurrences’

origin.
3)

Determine the most feasible FDG-PET boost volume with the most overlap with

recurrences’ origin and with the smallest size relative to high dose clinical target volumes
(CTVs).
4)

Generate hypotheses for future FDG-PET based dose escalation clinical trials in

HNSCC.
8.2 Materials and Methods
8.2.1 Patient population
Patients with local and/or regional recurrence after curative-intent IMRT for HNSCC
between January 2006 and August 2010 were identified under an institutional review board
(IRB) approved protocol. Conditions for patient eligibility included:
1)Pathologically (histologically/cytologically) proven diagnosis of HNSCC.
2)Pathologic and/or radiologic evidence of local and/or regional recurrence after treatment.
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3)Available pre-IMRT FDG PET/CT scan and retrievable IMRT plans.
4)Available CT scan of failure site prior to any salvage therapy.
5)Patients with previous radiation to the head and neck area or synchronous cancer were
excluded.
8.2.3 IMRT Treatment Planning and Delivery
All patients had been positioned supine in an individualized thermoplastic head and
shoulder mask for CT simulation and treatment and a custom dental stent used as an intraoral
immobilization and displacement device. A treatment planning CT (pCT) scan was used for
defining target volumes (TVs). TV definition was done in the Pinnacle treatment planning
system (Pinnacle, Phillips Medical Systems, Andover, MA), with rigorous multi-physician quality
assurance.(231)
Treatment was uniformly delivered by linear accelerators using 6-MV photons. Three
clinical target volumes (CTV) had been defined: CTV1, which included gross tumor volume
(GTV) plus margin, where GTV included all known gross disease (primary tumor plus grossly
enlarged lymph nodes); CTV2, which included the mucosal, bony, and nodal volumes at
intermediate risk of harboring microscopic disease; CTV3, which included the mucosal, bony,
and nodal volumes at low risk of harboring microscopic disease. IMRT was delivered in 33-35
fractions. The dose prescribed to CTV1 was 66-70Gy, the dose prescribed to CTV2 ranged
from 60-63 Gy and the dose prescribed to CTV3 ranged from 56-57 Gy. The prescribed dose to
the uninvolved low- neck field was 50 Gy in 25 fractions. Each Planning Target Volume (PTV)
was defined as the CTV plus 3-4 mm margin, with daily IGRT.(232) Patients were treated using
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a monoisocentric technique with an antero-posterior low-neck supraclavicular field matched to
the IMRT fields or using whole neck IMRT for cases where gross nodes were located at the
match line.
8.2.4 Loco-regional Recurrence
Cases where local and/or regional recurrent disease were recorded had their postfailure/pre- salvage diagnostic images exported as DICOM files from the clinical PACS system
to Pinnacle, where radiological evident recurrent gross disease (rGTV) was manually
delineated by a radiation oncologist (ASRM) and reviewed by a head and neck service-specific
attending radiation oncologist (CDF). The date of failure was defined as the date of first followup study indicating recurrent disease.
8.2.5 Image registration
Planning CT (pCT), target volumes, and dose maps were restored for this analysis. The
metabolic tumor volume was identified on the pre-radiotherapy FDG-PET scan using an inhouse auto-segmentation algorithm (PET-GTVAS) (233), which has been optimized and
validated for HNSCC.(234) For each patient, both pretreatment FDG-PET/CT and recurrence
depicting CT (recCT) were co-registered with pCT scan using a prior validated atlas-based
deformable image registration commercial software, ADMIRE version 1.13.5 (ELEKTA,
Stockholm, Sweden 2016).(235, 236)
Subsequently, planning CTs; dose grids; original plan target volumes; recurrence CTs;
rGTVs; PET-CTs; PET-GTVAS; and deformation vector fields were all imported in a custom
written Matlab routine (MATLAB R2014b, The MathWorks Inc., Natick, MA, 2014). The
deformation vector fields were then applied to PET-GTVAS segmented on PET/CT and rGTV
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segmented on the recurrence CT to convert them into a deformed PET-GTVAS and a
deformed rGTV on the planning CT, respectively. Figure 8.1 depicts the workflow methodology
described above.

Figure 8. 1: Workflow methodology of the study.
8.2.6 Recurrence Origin Mapping
The center of mass of the registered rGTV was identified as the origin from where
failure expanded (i.e. nidus of the recurrence) and a nidus volume (NV) was created by adding
a 4 mm radius to account for uncertainties in registration and delineation. A margin of 4 mm
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was decided using error propagation (Eq. 1) (237) of the known uncertainties (2 mm for
registration and 3 mm for delineation) providing an overall uncertainty of 3.6 mm that was
rounded to 4 mm. Additional nidus volumes were generated by increasing the radius from 0 to
10 mm, in 2 mm increments, for a comprehensive evaluation of the uncertainty of the nidus
(origin of the recurrence). The location of deformed NVs was then compared relative to the
deformed PET- GTVAS contours location as well as the original plan target volumes and dose.
Eq. 1
𝛿𝐸 = √(𝛿𝑟)2 + (𝛿𝑑)2
Where δr is the uncertainty in registration and δd is the uncertainty in delineation.
8.2.7 Patterns of loco/regional recurrence
Failures were classified according to both geometric and dosimetric criteria as
previously described by our group.(235) In brief, the geometric mapping of recurrence origin
was done by correlating the NV of each rGTV to the corresponding TV in the planning CT.
Subsequently, the dosimetric characteristics were assessed by calculating the dose to 95% of
the failure volume (fD95%) then comparing it relative to the dose prescribed to the
corresponding TV of origin as determined by the geometric mapping. Finally, failures were
classified into five major types: Type A (central high dose where fD95% is ≥95% dose
prescribed to corresponding high dose TV of origin), Type B (peripheral high dose where
fD95% is <95 % dose prescribed to corresponding high dose TV of origin), Type C (central
elective dose where fD95% is ≥95% dose prescribed to corresponding lower dose TV of origin),
Type D (peripheral elective dose where fD95% is <95% dose prescribed to corresponding
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lower dose TV of origin), and Type E (extraneous dose where rGTV centroid originates outside
all TVs). Type F describes junctional failures at the IMRT/supraclavicular match line, and Type
G describes low neck failures at the low-neck supraclavicular field. The overall pattern of failure
for patients with type A recurrence and concurrent non-type A recurrence was defined as type
A. While patients who had more than one non-type A at the same time, pattern of failure of
each patient was classified according to the most predominant type based on rGTV volume.
5.2.8 PET boost volumes
For this analysis the 30%, 40%, 50%, 60% and 70% of the maximum SUV volumes
were identified on the pre-radiotherapy FDG-PET images and an isotropic margin of 0-20mm
(in an iterative increments of 2mm) was added around each iso-intensity volume to create
boost tumor volumes (BTV30+0, BTV30+2, …., BTV70+20). For each deformed BTV, the
overlap with the 4 mm NV of all recurrence lesions of type A nature was recorded. The BTV
was considered adequate to capture the nidus of recurrence if the overlap was greater than
95% provided that BTV volume is less than CTV1 volume. All BTVs with volume ≥ CTV1
volumes were excluded. For primary site recurrences, additional analysis was done to identify
the best possible BTV candidate by calculating the percent volume of the selected BTV relative
to the high dose CTV (thus minimizing the necessary boost volume). Because the generated
margins around BTVs were isotropic in nature, we also calculated the percent of voxels of each
boost volume that were outside the high dose CTV (0% is the best and 100% is worst). Lastly,
differences in the percent of lesions covered between the 0 and 10 mm margin nidus volumes
were used to assess each BTV’s robustness to uncertainty in the identification of the nidus. To
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identify the best possible boost tumor volume, an arbitrary score function (Eq. 2) was
determined and scores were calculated for each volume.
Eq. 2
𝑆𝑐𝑜𝑟𝑒 = [% 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑐𝑜𝑣𝑒𝑟𝑒𝑑 + (𝑅𝑜𝑏𝑢𝑠𝑡𝑛𝑒𝑠𝑠) + (100 − % 𝑜𝑓 𝐵𝑜𝑜𝑠𝑡 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑢𝑡𝑠𝑖𝑑𝑒 𝐶𝑇𝑉1)
+ (100 − % 𝑜𝑓 𝐶𝑇𝑉1 𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑏𝑦 𝑏𝑜𝑜𝑠𝑡 𝑣𝑜𝑙𝑢𝑚𝑒)]/4

Where Robustness = 100 − (% of 10 mm NVs covered − % of 0 mm NVs covered)
8.2.9 Statistical analysis
Statistical assessment and data tabulation were performed using JMP v 11Pro (SAS
institute, Cary, NC).
8.3 Results
8.3.1 Patients and tumor characteristics
A total of 47 patients were eligible for this analysis. Median age was 59 years (range
33-93). Median time from end of radiation treatment to recurrence was 8 months (range 1-58).
The PET-GTVAS had a median volume of 24 cm3 (range: 3-197) and SUVmax for these
volumes were found to have a median value of 16 (range 6 – 41). Patient, disease, and
treatment characteristics are summarized in table 8.1.
Table 8. 1: Patient, disease, and treatment characteristics.
Variables

No. of patients
(%)

Gender
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Male

42 (89%)

Female

5 (11%)

Smoking Status
Smoker

32 (68%)

Non-smoker

15 (32%)

Primary Site
Oropharynx

30 (64%)

Hypopharynx

7 (15%)

Oral cavity

1 (2%)

Nasopharynx

3 (6%)

Sinonasal

2 (4%)

Larynx

4 (9%)

T stage
T1

7 (15%)

T2

18 (38%)

T3

9 (19%)

T4

13 (28%)

N stage
N0

2 (4%)

N1

6 (13%)

N2a

4 (8%)

N2b

17 (36%)

N2c

13 (28%)

N3

5 (11%)

HPV status
Positive

17 (36%)

Negative

4 (9%)

Unknown

26 (55%)
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IMRT dose &
fractionation
Mean Dose (SD),

69.5 (1.5)

in Gy
Mean n. of

33 (1.6)

Fractions (SD)
Chemotherapy
Induction

5 (11)

Concurrent

17 (36)

Induction and

20 (42)

concurrent
No chemotherapy

5 (11)

8.3.2 Patterns of failure
Patients included in this analysis had failure at the primary site in 19 patients (40.4%),
at the nodal site in 18 patients (38.3%), and in both the primary and nodal sites in 10 patients
(21.3%). Forty-two patients (89.4%) were classified as type A failure. Five patients (10.6%)
were of non- type A failure; two were type C, one type D, and one type E.
A total of 66 rGTVs were identified. Median rGTV volume was 3.7 cm3 (IQR 2-9). Of
these, 54 (82%) were of type A, 5 (7.5%) were type C (i.e. central low dose), 1 (1.5%) was type
D (i.e. peripheral low dose), 5 (7.5%) were type E (i.e. out of field), and 1 (1.5%) was type G
(i.e. in the low neck supraclavicular field). For type A’s rGTVs, 26 (48%) were at the primary
site and 28 (52%) were at the nodal site. The mean (SD) of mean doses of all rGTVs’
originating in high dose regions was 71 Gy (2) and the mean of dose to 95% rGTVs’ volume
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was 69 Gy (3). Figure 8.2 depicts the patterns of failure classification per patient and per
individual recurrence lesion.

Figure 8. 2: Pie charts of the patterns of failure classification.
8.3.3 PET boost volumes
The range of BTVs that encompasses the recurrence origin (i.e. nidus volume) of all
type A rGTVs is listed in Figure 8.3. PET-GTVAS overlapped with 38% of NVs of the primary
sites and 32% of NVs of the nodal sites. With no added margins, the examined SUV thresholds
did not overlap with most of NVs. For example, when no margin expansion is included, BTV50
(i.e. BTV50+0) covered less than 20% of type A primary site’s nidus volumes, while lowering
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the threshold BTV30 only resulted in 50% coverage of primary site recurrence origin. However,
with additional margin expansion, more than one BTV alternative resulted in the coverage of
≥90% of the primary site nidus volumes as well as the coverage of ≥75% of all type A nidus
volumes as shown in Figure 8.3.

Figure 8. 3: Percent of NVs covered by BTVs for type A recurrences.
This figure shows the percent of type A recurrences’ origin covered by Boost Volume
when considering the nidus volume created by adding a 4 mm radius. Boost volumes with an
average volume greater than 100% of CTV1 are not shown as per our criteria, BTV volume
must be less than CTV1 volume. Recurrent lesions were classified per their anatomical
location, and coverage per class (n. of primary rGTVs=26, n. of nodal rGTVs=28, total type A’s
rGTVs=54) are shown in this figure.
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Nevertheless, as shown in Figure 8.4, the candidate BTVs with ≥90% of the primary site
nidus volumes coverage did not achieve equivalent performance when using the other metrics
of best BTV selection (i.e. the percent of BTV volume inside CTV1 relative to the entire CTV1
volume and the percent of voxels outside CTV1). BTV50+10mm had the best collective
performance with high NV coverage (92.3%), low average relative volume to CTV1 (41%), least
average percent voxels outside CTV1 (19%), and high average robustness metric (i.e.
increasing the margin expansion around the rGTV centroid from 0 to 10 mm led to a minor drop
in the percent of overlap [27%]). Appendix B figure B1 shows the overall performance score for
all BTVs whose volume did not exceed the size of CTV1. As depicted in figure B1,
BTV50+10mm outperformed all other volumes based on this criterion. Appendix figures B2, B3,
and B4 show percent of NVs covered per BTV as a function of NV margins. Figure 8.5a clearly
demonstrates that BTV50+10mm encompasses the vast majority of primary tumor recurrence’s
origin. While Figure 8.5b-d depicts a case demonstration of the candidate boost volume relative
to recurrence and planning target volumes.
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Figure 8. 4: PET boost volume characteristics.
This figure shows the PET boost volume metrics used for determining the “best” boost volume.
The blue bars show % of primary site nidus volumes covered per boost volume (100% is best,
0% is the worst). The red bars show the % of CTV1 that are being covered by BTV (less is
better, we don’t want the whole CTV1 to be boosted). The green bars show the % of voxels of
each boost volume that are outside the CTV1 (the idea is that we want the boost volume to be
mostly inside the CTV1, so 0% is best and 100% is worst). Lastly, the purple bars represent
each boost volume’s robustness. Robustness is calculated per volume by looking at the
difference in coverage for different nidus radius. The higher the number the more robust the
volume is. Boost volumes that are greater than CTV1 have been excluded. Volumes are
ordered by increasing % of patients covered. BTV50+10mm had the best collective
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performance with highest possible NV coverage (92.3%), least relative volume to CTV1 (41%),
least percent voxels outside CTV1 (19%), and reasonable robustness score (73%).
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Figure 8. 5: Heat map of recurrences and case illustration.
Panel A shows a heat map of percent of lesions covered (4mm nidus) for volumes segmented
using a 50% of SUVmax threshold value. The dots on Panel A represent patients with primary
recurrences, whereas the different rings represent the different margins increasing from the
center to the outer most ring by a 2 mm interval. Panels B-D show an example of a T2N2b left
tonsillar patient with local recurrence at the primary site. The 4mm nidus volume (magenta),
primary recurrence (black), BTV50 (green), BTV50+10mm (yellow), CTV1 (red), and CTV2
(blue) are highlighted.
8.4 Discussion
The strategy of increasing radiation dose to be delivered to subvolumes of gross tumor
with supposed higher radio-resistance while keeping surrounding normal structures at similar or
lower dose levels, appears promising as a step towards improving locoregional control and
consequently survival in multiple cancer sites. (220, 228, 230) The deployment of such strategy
requires optimal integration of spatially accurate biological imaging in radiation treatment
paradigms. FDG-PET/CT is a very attractive solution in this context because it is a widely used
tracer and a standard of care imaging modality that provides both anatomical as well as
biological aspects of tumors (e.g. tumor metabolism).(238-240) FDG-PET/CT has been
successfully used for HNSCC radiation treatment planning purposes,(241) however, its
effective use for dose escalation requires a validation of the geometric correlation between the
origin of posttreatment disease failure, pretreatment FDG-PET uptake, planning target
volumes, and radiation dose, which is the main aim of the current study. The uncertainties and
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limitations of PET are well known.(242) However, they were carefully considered and taken into
account in this analysis.
A few prior studies have attempted to address the correlation of patterns of failure to
pretreatment FDG-PET for head and neck squamous carcinomas.(124, 243) These studies,
however, lacked the validation of the exact spatial correlation between the recurrence’s origin
and the pretreatment FDG uptake. Such knowledge is required to be able to define the
appropriate subvolumes to target in FDG-PET-guided dose escalation clinical trials. In addition,
the number of failures examined in these studies were few. A large scale failure dataset is
required to ensure a realistic representation of different patterns of failure encountered
clinically. A single previous study by Due et al. (244) was the first to attempt to spatially
correlate the patterns of failure relative to pretreatment FDG-PET on a cohort of 39 HNSCC
recurrences after IMRT. Their results showed that 54% of recurrences were originated inside
the FDG-positive volume delineated by the nuclear medicine physician.
In the current study, we used a previously validated deformable image registration
software for CT-CT registration in HNSCC (235, 236) to map the segmented recurrence
volume in post-failure diagnostic CT back to the simulation CT scan, planning target volumes,
and dose grid. Simultaneously, the CT of the pretreatment FDG-PET-CT was also registered to
the simulation CT. We used the failure’s centroid mapping method proven by prior work from
our group and by others (36, 37) as a more discriminative and accurate manner to localize the
origins of loco- regional recurrences than volume overlap methods, which may potentially and
incorrectly assign recurrences to more peripheral target volumes regions. We added a 4 mm
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margin expansion of the centroid of the mapped failure volume to create the nidus volume, as
the closest approximation of the 3D volume of the recurrence origin and to account for
registration and delineation uncertainties.
Our results showed that the majority of patients (89%) failed at the central high dose
regions. Surprisingly, as shown in figures 8.3, 8.4, and 8.5a the majority of type A recurrence
origin’s did not necessarily fall in voxels with the highest uptake of FDG and an additional 10
mm isotropic margin expansion around the 50% of the maximum SUV was required to create a
BTV that cover 92% of type A’s recurrences at the primary site. Other BTV volumes, though,
overlapped with the majority of recurrences. However, those volumes were considered
inappropriate for having either larger relative volume compared to CTV1 or higher percent of
voxels outside CTV1. BTV50+10mm, on the other hand, had the best collective performance
with the highest overlap with a recurrence’s origin, the smallest relative volume compared to
CTV1 (i.e. realistic boost subvolume), and the least percent of voxels outside CTV1.
These findings show a boost subvolume of 50% of the maximum FDG uptake would
cover less than 20% of primary site recurrence’s origin. Also, the voxels of highest FDG uptake
are not ineluctably the voxels of highest radio-resistance. Thereby, strategies of selective
targeting of the voxels of highest uptake by higher dose (e.g. dose painting by number) seem to
underestimate the recurrence risk in nearby voxels within the BTV50+10mm which have
relatively lower uptake. Consequently, subvolume definition strategies for FDG-PET-guided
dose escalation studies should be revised in the context of these findings.
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Critically, if we plan to identify regional sub-volume dependent dose modification (e.g.
PET- tracer-, MR parameter- or CT-texture-identified “boost” volumes) as a potential modifier of
local/regional tumor response, it is imperative that the underlying nomenclature and
methodology for defining said events be fully detailed and reproducible. Our attempt, within this
dataset, is to not only generate a definitive recommendation for “boostable” subvolume
identification, but a methodologic benchmark and process overview for additional
functional/biological/radiomic applications. Conceivably, PET SUV in this manuscript could be
replaced in an equivalent analytic framework with multiparametric MRI or radiomic texture
profiles. The imperative first step in any of these efforts would be a representational framework,
as detailed herein, which adequately describes with known spatial precision quantifiable event
probabilities.
Our study, however, does not go without caveats. Being retrospective in nature, the
typical limitations of any retrospective study apply. Also, we have assumed that isovolumetric
expansion of the recurrence from the center of mass of the recurrence volume would localize
the origin of recurrence, which may not be true in all head and neck cancer cases. However,
this is the best possible estimation based on empirical findings. We also did a robustness
analysis to address the effect of nidus volume on our findings as shown Appendix B figure B1B4. Because of the uncertainties related to non-rigid registration as well as inter-observer
contouring variability, we expanded the centroid of recurrence by 4 mm radius as detailed
above. This analysis provided additional depth in determining the best available BTVs since it
took into consideration the inherent uncertainties presented by arbitrarily choosing a NV with a
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4 mm radius. There are many uncertainties associated with the use of FDG-PET.(242) Some of
the ones that can influence the identification of the BTV the most are the voxel size
(5.5x5.5x3.7mm3), the uncertainties related to the reproducibility of SUVmax (i.e. 1-6%) (245),
as well as blurring due to potential patient motion inherent from the length of the scan. In this
work we decided to account for those uncertainties with the combination of different thresholds
as a percent of SUVmax with different isotropic margins, guided of course as was described in
detail by the patterns of failure analysis, combined with an additional robustness analysis of the
recurrence centroid. This robustness analysis showed that even with a 10 mm margin
expansion around the centroid, BTV50+10mm still covers the majority of primary site
recurrences (i.e. >73%).
Nevertheless, this is, to our knowledge, the largest series of HNSCC failure following
curative- intent IMRT to robustly and simultaneously characterize the spatial, biological, and
dosimetric foci of recurrence in an integrated spatial frame, using a validated pattern of failure
methodology. Our data serve to define a candidate BTV volume that appropriately covers the
subvolumes of highest radio-resistance based on objective patterns of failure mapping using
rigorous image-processing to afford increased spatial certainty as a prior for further
investigation and extra-institutional validation.
8.5 Conclusions
To conclude, we present 47 HNSCC patients with recurrence following curative intent
IMRT. Our results showed that the majority of recurrences occurred in the central high dose
regions. When correlated with pretreatment FDG-PET, the majority of these type A recurrences
originated in an area that would be covered by a 10 mm margin on the volume of 50% of the
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maximum FDG uptake. A validation of these findings is needed in multi-institutional and
prospective HNSCC treatment failure databases.
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9.1 Introduction
Head and neck squamous cell carcinomas (HNSCCs) prevail as the sixth most common
cancer worldwide with over 500,000 expected newly diagnosed cases reported annually(246). In
the United States, 40,000 new HNSCC cases are reported with approximately 7,890 deaths per
year(247). HNSCCs encompass a diverse array of cancers that can originate from subsites within
the oral cavity (44%), larynx (31%) or pharynx (25%)(248). Viral infections, specifically human
papilloma virus (HPV) primarily type 16 and Epstein-Barr virus, are associated with higher risk of
oropharynx and nasopharynx cancers respectively(249, 250). Protracted tobacco and alcohol
use as well as UV light exposure are among the traditional risk factors for development of
HNSCC(251). There has been a dramatic change in the affected patient cohort as risk factors
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has changed, represented by a decrease in tobacco use and concomitant increase in HPVassociated disease. This was reflected as a substantial rise in the incidence of HPV-associated
oropharynx cancers as compared to a decline in cancers of the larynx and hypopharynx(252).
Given the high morbidity and mortality associated with HNSCC, this type of cancer represents a
major health burden.
The refinement in head and neck irradiation techniques, specifically introduction of
intensity-modulated radiotherapy about 15 years ago, was a paradigm shift HNSCC
management that resulted in improvement of treatment outcomes(253). Continued efforts have
been made to investigate potential prognostic and predictive biomarkers to establish the
conceptual framework for precision medicine in management of HNSCC(254). One example is
the exploration of the correlation between disruptive alteration of the gene encoding the tumorsuppressor protein p53 (TP53) and treatment failure with subsequent decreased survival in
HNSCC patients(255).
Radiographic images, such as Computed Tomography (CT), have been routinely used
for diagnosis and treatment of HNSCC. However, the relationship between tumor imaging
phenotypes and underlying tumor genomic mechanisms remains underexplored. Precise and
effective treatment of cancer requires the integration of disease information from multiple
sources. Imaging-genomics research combines radiographic image analysis with genomic
research to improve disease diagnosis and prognosis, discover novel biomarkers, and identify
genomic mechanisms associated with phenotype formation(59-63). Such imaging-genomics
studies have been performed for multiple cancer types, including breast invasive carcinoma(5963), lung cancer(64, 65), glioblastoma multiforme(256), and clear cell renal cell carcinoma(257).
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To our knowledge, there are very few existing imaging-genomics studies for HNSCC.
One of the earliest studies from 2003 by Yang et al. investigated the correlation between temporal
changes in T1- and T2-weighted contrast-enhanced magnetic resonance imaging and genomic
analysis using oligonucleotide microarrays in murine squamous cell carcinoma tumor
models(258). Aerts et al. developed a multi-feature radiomic signature capturing intratumoural
heterogeneity that was linked to gene-expression patterns, validated in three independent data
sets of lung and head-and-neck cancer patients(259). Recently, Pickering et al. correlated
radiologist-selected CT imaging features of 27 oral cavity squamous cell carcinomas with the
expression of cyclin D1, angiogenesis-related genes, and epidermal growth factor
receptors(260).
In the current study, we innovatively investigated the comprehensive relationship
between the multi-layer tumor genomic system and the multiple aspects of tumor imaging
phenotype for HNSCC. We integrated multi-omics, whole-genome measurements from The
Cancer Genome Atlas (TCGA)(261) with radiomic data derived based on CT images from The
Cancer Imaging Archive (TCIA)(262) for matched patients, and identified statistically significant
associations between them. We also explored the potential of using CT imaging as a noninvasive marker predicting the tumor molecular status for HNSCC.
9.2 Materials and Methods
Clinical, radiological, and genomic data (Appendix Information Sections C1-C2) for 126
HNSCC patients from TCGA and TCIA were integrated and analyzed. CT images of the
patients were downloaded from TCIA and processed using Imaging Biomarker Explorer
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(IBEX)(263), an automatic medical image analysis software pipeline that generates tumor
radiomic features. The radiomic features were grouped into five categories: (1) gray level cooccurrence matrix, (2) gray level run length matrix, (3) neighbor intensity difference, (4)
intensity direct, and (5) size/shape(259). Appendix Information Section C. 1 introduces how the
radiomic features were generated. Multi-omics genomic data and patient clinical information
were acquired from TCGA using the open-source R software tool TCGA-Assembler(264).
Appendix Information Section C. 2 introduces the collection and processing of genomic data.
Genomic data, clinical data, and radiomic data were integrated to form the imaging-genomics
data (Table 9.1) for subsequent analysis. A total of 126 patient samples were used for analysis,
representing all matched cases in TCGA and TCIA HNSCC database(s).
Table 9. 1: Summary of the integrative imaging-genomics data used in the analysis.

Number of features and tumors in different data platforms
Data platform
Number of features
Radiomics
187 radiomic features
miRNA expressions
1046 miRNAs
Mutated genes
16573 genes
Gene expressions
20531 genes (179 pathways)
Copy number variations
19921 genes (179 pathways)
Promoter region DNA
19325 genes (179 pathways)
methylation

Number of Tumors
126
125
122
125
126
126

Numbers of tumors/patients in different categories
AJCC tumor stage
Stage I (n = 4), stage II (n = 14), stage III (n = 22), stage IV (n = 86)
Tumor site
Oral cavity (n = 69), larynx (n = 36), oropharynx (n = 21)
Current smoker (n = 52), former smoker (n = 45), never smoker (n =
Smoking behavior
29)
Sex
Male (n = 97), female (n = 29)
HPV status
HPV+ (n = 29), HPV ̶ (n = 96), not measured (n = 1)
Disruptive TP53
With disruptive TP53 mutation (n = 33), without disruptive TP53
mutation
mutation (n = 89), not measured (n = 4)
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CT parameters
CT scanner manufacturer
Slice thickness: median
(IQR)
Contrast
Tube voltage (kVp)
Tube current (mA): range
Data collection diameter
(mm): median (IQR)
Reconstruction diameter
(mm): median (IQR)
Others
Age (years)

GE (n = 61), Siemens (n = 33), Philips (n = 26), Toshiba (n = 5),
Picker (n = 1)
2.5 (1.25-3)
All are contrast-enhanced
120 (n = 98), 130 (n = 7), 135 (n = 1), 140 (n = 20)
59-600
500 (320-500)
250 (242-268)

Mean = 59.81, std = 11.28

The number of tumors for radiomics (i.e. 126) is the number of tumor cases with radiomic features. For genomic data
platforms, the number of tumors is the number of tumor cases with both radiomic features and genomic data of the
specific platform, which were used in our study.

A multi-step informatic and statistical pipeline was built to perform integrative data
processing and analysis (Figure 9.1). First, linear regression was used to identify statistically
significant associations between radiomic features and gene-level genomic features including
expressions of miRNAs and somatic mutations summarized at the gene level, adjusting for
patient age, tumor grade, tumor subsite, and patient smoking status (Appendeix Information
Sections C. 7 and C. 8). Second, for the whole-genome measurements, including gene
expressions, copy number variations (CNVs), and promoter region DNA methylation, we
investigated their associations with tumor radiomic features at the pathway level using a
modified Gene Set Enrichment Analysis (GSEA)(265) scheme that was also adjusted for the
confounding factors mentioned above (Appendix Information Sections C. 4-6). The genetic
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pathways in consideration are from the Kyoto Encyclopedia of Genes and Genomes
(KEGG)(266) database charactrerizing various aspects of the biomolecular system. Third,
based on radiomic features, random forest classifers(267) were used to predict patient HPV
status and TP53 mutation status in HNSCC (Appendix Information Section C. 9).

Figure 9. 1: Flowchart of processing the data.

9.3 Results

A total of 5,347 statistically significant associations (adjusted p-value ≤ 0.05) were
identified between various radiomic and genomic features. Appendix figure C.1 is a graphical
presentation of the identified associations. Table 9. 2 shows the numbers of identified
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associations between different categories of genomic features and radiomic features, based on
which Fisher’s exact test (268, 269) indicates that the frequency of statistically significant
associations depended on the feature category (p-value < 0.0001), meaning some feature
categories have more associations than others. The identified associations are statistically
significantly enriched among pathway transcriptional activities and all five categories of
radiomic features with adjusted p-values < 0.0001 (Appendix table C3). This implies that
transcriptional activities of genetic pathways modulate various aspects of tumor imaging
phenotype.
Table 9. 2: Numbers of statistically significant associations between genomic features of
different platforms and radiomic features of different categories.
Feature Category
Transcriptional
activity of pathway
Copy number
variation of pathway
Promoter region
DNA methylation
change of pathway
miRNA expressions
Mutated genes

Gray Level Cooccurrence Matrix

Gray Level Run
Length Matrix

Neighbor Intensity
Difference

Intensity
Direct

Size /
Shape

1709

304

131

1413

884

196

37

28

161

62

156

30

15

119

29

6
16

0
5

0
0

10
36

0
0

9.3.1 Associations between Radiomic Features and Genetic Pathways

Appendix C include all identified associations involving transcriptional activities, gene
CNVs, and promoter region DNA methylation changes of all KEGG pathways. Figure 9.2
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specifically presents that radiomic features are associated with cancer-related KEGG
pathways(266) that cover multiple aspects of the cancer molecular system, such as signal
transduction, cell growth and death, immune system, and cellular interactions and community.
Figure 9.2a, 2b, and 2c show the associations of transcriptional activities, gene CNVs, and
promoter region DNA methylation changes of cancer-related KEGG pathways, respectively.
There are many interesting findings in Figure 9.2a indicating pathway transcriptional activities
are correlated with and modulate multiple aspects of tumor imaging phenotype, and we
elaborate on them below.
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Figure 9. 2: Heatmap of associations between genomic and radiomic features.
This figure depicts statistically significant associations between radiomic features and (a)
transcriptional activities of cancer-related genetic pathways, (b) gene CNVs of cancer-related
genetic pathways, (c) gene promoter region DNA methylation changes of cancer-related
genetic pathways. In each heatmap, only genetic pathways and radiomic features with
statistically significant associations were shown. Each of the gray level co-occurrence matrix
features can be calculated using different offset parameter values, i.e. 1, 2, 3, 4, and 5, which
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results in 5 different instances of a feature. Because the 5 instances of a feature were usually
correlated, the directions (i.e. positive or negative) of the associations between a cancerrelated pathway and the different instances of a radiomic feature were always the same. Thus,
in the heatmaps, associations between different instances of a radiomic feature and a pathway
could be collapsed into one association. If a pathway had an association with at least one
instance of a radiomic feature, the association between the pathway and the radiomic feature
was included in the heatmap. Percentile and quantile radiomic features from the intensity direct
category were not included in the heatmaps for simplicity, because they have many instances
with different percentile or quantile values.
9.3.2 Cell Growth and Death
Multiple associations related to cell growth and death are identified in our analysis.
Transcriptional activities of ribosome genes are correlated with multiple aspects of tumor
imaging phenotype, including (1) tumor texture heterogeneity characterized by positive
association with entropy and negative associations with energy 1, homogeneity, and
homogeneity 2, (2) tumor size features, including convex hull volume, convex hull volume 3D,
mass, maximum 3D diameter, mean breadth, number of voxel, and surface area, and (3) tumor
shape irregularity, characterized by negative associations with roundness, sphericity, and
convex, and positive association with spherical disproportion. Ribosome genes support protein
synthesis and are important for various cellular processes, such as cell proliferation and
growth. Our result shows that they are more transcriptionally active in larger, more irregular and
heterogeneous tumors. The apoptosis pathway takes a tumor suppressive role by eliminating
damaged or redundant cells through activating caspases. Disruption or evasion of apoptosis
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can lead to tumor initiation, progression or metastasis(270). Consistently, we find that the
transcriptional activity of apoptosis pathway is negatively associated with tumor size
(characterized by convex hull volume, convex hull volume 3D, maximum 3D diameter, mean
breadth, and surface area) and tumor shape irregularity (characterized by its positive
associations with convex and sphericity, and negative association with spherical disproportion).
9.3.3 Immune System
Pathways related to immune regulation, including pathways of natural killer cell
mediated cytotoxicity, T cell receptor signaling, B cell receptor signaling, antigen processing
and presentation, and chemokine signaling, are all negatively associated with tumor size
features. One possible explanation is that patients with larger tumors have a less active
immune system and therefore are unable to effectively destroy tumor cells and curb tumor
growth. Similarly, we find a correlation between immune system activity and tumor shape
regularity, as the pathway activities are positively associated with sphericity and convex, and
negatively associated with spherical disproportion.
9.3.4 Cellular Interactions and Community
Pathways related to cell adhesion molecules, cytokine-cytokine receptor interaction,
ECM-receptor interaction, adherens junction, gap junction, and focal adhesion regulate cell-cell
interaction and signaling acting as intercellular regulators and mobilizers of cells, and maintain
cell and tissue architecture that limits cell movement and proliferation, which are two important
factors in cancer progression. Aberrant activities of these pathways can lead to the
development and metastasis of many types of cancer, including HNSCC(271). We find that
their activities are negatively associated with multiple tumor size features, indicating smaller
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tumors tend to have stronger activities of these pathways than large tumors. Activities of all
these pathways, except gap junction, are also correlated with tumor shape regularity
characterized by their positive associations with sphericity and negative associations with
spherical disproportion.
9.3.5 Signal Transduction
The transcriptional activities of several molecular signaling pathways, including MAPK
signaling pathway, TGF-beta signaling pathway, JAK-STAT signaling pathway, VEGF signaling
pathway, WNT signaling pathway, and ERBB signaling pathway, are negatively associated with
tumor size features, indicating that they are more active in small tumors than large tumors.
Previous report (272) has suggested TGF-beta signaling as a potent tumor suppressor in
HNSCC, which is supported by its negative association with tumor size identified in the current
study. The activities of MAPK, TGF-beta, JAK-STAT, and VEGF signaling pathways are
positively associated with tumor shape regularity.
Compared to pathway transcriptional activities, CNVs of cancer-related pathways have
much fewer statistically significant associations with radiomic features (Figure 9.2b). CNVs of
JAK-STAT signaling pathway, cytokine-cytokine receptor interaction, natural killer cell mediated
cytotoxicity, and antigen processing and presentation genes are correlated with tumor shape
regularity characterized by their positive associations with convex and sphericity, and negative
associations with spherical disproportion. CNVs of apoptosis genes are positively associated
with tumor texture homogeneity characterized by homogeneity and homogeneity 2, indicating
tumors with heterogeneous texture may have fewer copies of apoptosis genes than tumors with
homogeneous texture.
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Figure 9.2c shows the statistically significant associations between radiomic features and
promoter region DNA methylation changes of cancer-related pathways. DNA methylation
changes of ribosome genes have the largest number of associations with radiomic features (first
row in Figure 9.2c), including negative associations with two tumor size features maximum 3D
diameter and surface area, and positive associations with tumor shape regularity (characterized
by positive association with sphericity and negative association with spherical disproportion). The
directions of these associations are opposite of those for the transcriptional activities of ribosome
genes, which is expected, since methylation at promoter region usually negatively affects gene
expression. In addition, we find that DNA methylation changes of three immune related
pathways, i.e. natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, and
chemokine signaling pathway, are negatively associated with tumor shape regularity (Figure
9.2c). These are new results that may shed lights on the connection between immune pathways
with radiomic phenotypes. We report the analysis scheme and more findings in Appendix
Information Sections C4-6.
9.3.6 Associations between Radiomic Features and miRNA Expressions and Mutated Genes
9.3.6.1 MiRNA
Table S7 presents statistically significant associations between miRNA expressions and
radiomic features. MiR-320a has been reported as a negative regulator of tumor invasion and
metastasis(273). Its expression correlates with tumor texture homogeneity characterized by
positive associations with homogeneity and homogeneity 2 and negative associations with
entropy and global entropy. The radiomic feature global uniformity measures the overall
homogeneity of tumor pixel intensity(259) and is positively associated with the expressions of 8
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miRNAs including both antitumorigenic/antimetastatic and oncogenic miRNAs. The
antitumorigenic/antimetastatic miRNAs include miR-101(274), miR-15b(275), and miR-320a;
the oncogenic miRNAs include miR-106b and miR-25(276), miR-155(277), and miR-378(278);
the last miRNA miR-7 is involved in multiple cancer-related signaling pathways and has been
reported with both oncogenic and antitumorigenic roles(276).
9.3.6.2 Somatic Mutation
Table S8 shows statistically significant associations between radiomic features and genes with
somatic mutations in at least 10 patients. EP300 encodes the E1A binding protein p300, a
histone acetyltransferase regulating the transcription of genes involved in cell proliferation and
differentiation. Mutations in EP300 have been reported for HNSCC and may contribute to the
disease initiation and progression(279). Our analysis shows somatic mutations in EP300 are
negatively associated with inverse variance and positively associated with median absolute
deviation. COL11A1 encodes one of the two alpha chains of type XI collagen that is an
essential component of the interstitial extracellular matrix. COL11A1 may contribute to HNSCC
tumorigenesis and be a potential therapeutic target(280). We find mutations in COL11A1 are
negatively associated with inverse variance.
We report the analysis schemes and more details about the identified associations
involving miRNAs and somatic mutations in Appendix Information Sections 7 and 8.
9.3.7 Predictions of Patient HPV Status and Disruptive TP53 Mutation Using Radiomic
Features
We applied the random forest classifier(267) to predict the patient HPV status based on
tumor radiomic features. A two-tier five-fold cross-validation was used to tune the classifier
parameters and evaluate the generalization prediction performance. Predictive radiomic
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features were selected through a recursive feature elimination scheme. Table 9. 3 shows the
mean and standard deviation of the Area Under the receiver operating characteristic Curve
(AUC) across 30 cross-validation trials, which measures the prediction accuracy. There is no
significant difference between the average AUCs obtained using different numbers of features
for prediction. The highest average AUC achieved is 0.71, while the average AUC using only
five features in each cross-validation trial still reaches 0.706. Using the same classification and
feature selection scheme, we predicted whether a tumor possessed any disruptive TP53
mutation, a biomarker in HNSCC development and treatment(255). Loss-of-function alterations
are dominant among the TP53 mutations in the cancer cases. All disruptive TP53 mutations
are loss-of-function alterations and only one of the non-disruptive TP53 mutations is a gain-offunction alteration. Table 9. 3 shows the mean and standard deviation of obtained AUCs. The
highest average AUC is 0.641 with five features selected for prediction in each cross-validation
trial. See the Appendix Information Section C. 10 for details of the prediction and feature
selection scheme, and additional details of results, such as the most frequently selected
features for prediction and their frequencies.
Table 9. 3: Model performance.
Mean (standard deviation) of AUCs obtained through a two-tier five-fold cross-validation scheme that
includes 30 cross-validation trials when different numbers of radiomic features were selected for prediction
in each cross-validation trial.

Predictio
n target
HPV
status
Disruptiv
e TP53
mutation

All
features

100
features

50 features

20 features

0.701(0.13)

0.71(0.127)

0.697(0.13
3)

0.7(0.137)

0.587(0.07
1)

0.594(0.09
5)

0.624(0.08
7)

0.627(0.11
1)

10
features
0.71(0.13
3)
0.62(0.10
2)

5 features
0.706(0.14
6)
0.641(0.11
2)
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9.4 Discussion

Using TCGA and TCIA data, we conducted an exploratory yet comprehensive imaginggenomics study. To our knowledge, this is the first study that integrates radiomic features of CT
images with whole-genome measurements depicting multiple layers of tumor molecular system
for HNSCC. We report statistically significant associations between radiomic features
characterizing multiple aspects of the tumor imaging phenotype and various genomic features
(including transcriptional activity, CNV, DNA methylation, miRNA expression, and somatic
mutation). The identified associations support existing knowledge related to HNSCC
pathogenetic mechanisms and provide evidence for novel hypotheses on the relationship
between tumor genomic mechanisms and subsequent tumor phenotypes that can be validated
in future studies. Also, we attempted to use radiomic features to predict important molecular
biomarkers in HNSCC, such as HPV status and disruptive TP53 mutation, with decent AUC
values. These results provide basis for future investigations to establish the potential of using
non-invasive imaging approach to probe the genomic and molecular status of HNSCC.
Compared to pathway transcriptional activities, much fewer statistically significant
associations have been identified for pathway CNVs and DNA methylation changes (Table 9. 2
and Figure 9.2). There could be two reasons for this. First, transcriptional activity is closer to
phenotype formation than CNV and DNA methylation in the process of molecular system
regulating the development of phenotype. Basically, transcriptional activities can more directly
influence the generation of various phenotypes, while CNVs and DNA methylation changes may
have to function through transcription. Secondly, DNA mutation events, such as CNVs and
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somatic mutations, are rarely shared across many patients, resulting in a small number of
samples with the same mutation event that limits the statistical power for identifying potential
associations.
Our study is based on CT images of 126 HNSCCs and their multi-layer whole-genome
genomic data, which form a unique imaging-genomics dataset that was not available before
TCGA/TCIA era. This unique dataset enables our novel investigation of associations between
tumor phenotypes and multiple molecular layers for HNSCC. To our best knowledge, there is no
other dataset including matched imaging data, multi-omics genomic data, and clinical data for
HNSCC as our dataset does, on which we can repeat our analysis for validation. Our findings
have been uploaded to http://www.compgenome.org/Radiogenomics/ as a public resource to
facilitate future research on HNSCC imaging-genomics. Future studies can either use our results
as evidences to support their hypotheses or validate our findings through new analyses and
experiments. Although unique and novel, our imaging-genomics dataset is not large. Its sample
size might limit the statistical power for identifying imaging-genomics associations and the
accuracy of predicting tumor molecular status based on radiomic features. Nonetheless, we
believe our study will pave ways for future HNSCC imaging-genomics investigation using more
samples and advanced imaging technologies.
Bogowicz et al. also used radiomic features to predict HPV status for HNSCC and
achieved an AUC of 0.78(281), which is in a similar range but higher than our HPV prediction
accuracy (average AUC = 0.71). Multiple factors, such as different patient cohorts, can contribute
to the difference of prediction performance in the two studies. Considering the cohorts used in
both studies are not large (sample size < 150), the obtained prediction performances indicate the
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potential of using imaging to probe tumor molecular status in the future, with the accumulation of
imaging-genomics data and the development of imaging techniques.
More imaging-genomics analyses have been planned for HNSCC. One particularly
interesting approach is to integrate genomics, epigenomics, and proteomics data simultaneously
with imaging data to provide a more comprehensive depiction of how the multi-layer molecular
system regulates and produces various tumor imaging phenotypes. Graphical models can be
powerful tools for studying such complex relationship, due to their ability to model conditional
dependence and competing regulatory factors(282).
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Chapter 10: A high-throughput approach to identify effective systemic agents for the treatment
of anaplastic thyroid cancer
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10.1 Introduction

Thyroid cancer is the most common endocrine malignancy and its incidence continues
to rise in both men and women (142). Estimated new thyroid cancer cases in women is 32,130
in 2021 compared to 9,100 in 1992 and 12,150 compared to 3400 in men, respectively (283,
284). The age adjusted incidence of thyroid cancer increased more than 3.8-fold to near 14 per
100,000 between 1973 and 2015 (285). Papillary (PTC) and follicular thyroid carcinomas are
well-differentiated tumors and represent the most common thyroid cancer subtypes with good
overall prognosis and response to treatment (286). However, a subset of these well178

differentiated tumors progress to more aggressive poorly differentiated (PDTC) and anaplastic
thyroid cancer (ATC). PDTC and ATC represent a major clinical challenge due to the poor
therapeutic outcomes with a median survival of less than 12 months in the majority of patients,
despite the use of aggressive multimodality treatment (i.e. surgery, radiation, chemotherapy,
and/or targeted therapy) (287, 288).
The identification and development of novel systemic agents is rarely driven by focusing
on ATC alone; rather ATC is routinely incorporated into basket trials based on genomic and
epigenetic events (289). This is precisely how the BRAF-MEK combination gained clinical
traction in the context of ATC (67). However, despite substantial initial anti-tumor activity, most
patients develop resistance to treatment over time, consistent with findings in other solid
tumors such as melanoma (66). This presents a significant problem because translational
efforts in basket trials cannot proceed with sufficient focus to identify novel and effective ATC
targets.
Multiple studies published over the last decade have now provided a comprehensive
picture of the genomic, epigenetic and transcriptional program which accompanies ATC
development (290, 291). Unfortunately to date, ATC tumors have not demonstrated targetable
mutations sufficiently distinct from other tumors (292, 293). Thus, we must re-assess and reorient translational efforts for ATC. One approach is to evaluate the broad array of currently
available agents with anti-solid tumor activity, which may demonstrate substantial efficacy in
PDTC and ATC with already established safety profiles (i.e., drug repurposing).
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Most previous drug identification and preclinical testing efforts in the context of ATC
have been restricted by several deficiencies including: 1) limited availability of validated human
cell lines with a known genomic and epigenetic background, 2) limited utilization of orthotopic
models, and 3) limited availability of relevant patient derived xenograft (PDX) models (68). All
three of these factors can severely impact the ability to identify promising systemic agents, both
due to false positive and false negative results. For example, when targeted therapies such as
inhibitors of BRAF, EGFR, or ALK are tested in cancer cells lacking BRAF, EGFR, or ALK
alterations respectively, they are ineffective. However, these inhibitors are markedly effective
in cancer cell lines, animal models, and human patient tumors bearing the corresponding
genomic alteration. This is demonstrated by the distinct efficacy of BRAF inhibitors in tumors
that harbor BRAF mutations. Evaluating such inhibitors in a limited panel of wild-type BRAF
expressing cell lines would have easily generated a false negative result.
The increasing availability of both well-characterized PDTC and ATC human cell lines
as well as increasing stocks of PDX models, allows us to effectively identify drugs for the
deadly diseases. In this study, we utilized high-throughput drug screening (HTS) as an initial
filter for subsequent preclinical testing and drug validation in PTC, PDTC, and ATC.(69). Our
group has generated and authenticated a large panel of PTC, PDTC, and ATC cell lines along
with two ATC PDX models (70-72). They were used to perform a hierarchical preclinical drug
screen and validation, leveraging the complexity built into these preclinical models.
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10.2 Materials and Methods
10.2.1 Cell lines
Twelve human thyroid cancer cell lines were included in this study (ATC n=7, PDTC
n=1, PTC n=4). MDA-T85 (ATCC Cat# CRL-3354, RRID:CVCL_QW84) (70), MDA-T178,
MDA-T187 (RRID:CVCL_A1CS), MDA-T192 were generated from tumors obtained from
patients who underwent surgical treatment at The University of Texas MD Anderson Cancer
Center (MDACC). MDA-T178 and MDA-T187 were derived from 78- and 74-year-old women,
respectively, with a histopathologic diagnosis of ATC. MDA-T192 was derived from a
metastatic paratracheal lymph node in a 65-year-old woman with PDTC. The surgical
specimens were tested histopathologically to confirm the diagnosis, and single-cell suspension
was generated as previously described (70). Genomic DNA was extracted from frozen tissue
and cell lines using the Gentra Puregene kit (Qiagen # 158667). STR analysis for each cell line
and its matching tissue was performed at the Characterized Cell Line Core Facility at MDACC.
These STR profiles were then compared with those in the ATCC, the DSMZ, the JCRB, the
RIKEN (RRID:SCR_001065), and the MDA databases for possible matches. The TPC-1 cell
line (RRID:CVCL_6298) was kindly provided by Dr. Jerome Hershman (VA Greater Los
Angeles Healthcare System, Los Angeles, CA). The K2 cell line was provided by Dr. D.
Wynford-Thomas (Cardiff University, Cardiff, United Kingdom). Hth7 (RRID:CVCL_6289),
Hth104 (RRID:CVCL_A427), SW1736 (CLS Cat# 300453/p463_SW-1736, RRID:CVCL_3883),
and U-Hth83 (RRID:CVCL_0046) were kindly provided by Dr. Jeffrey Myers (MDACC). The
BCPAP cell line (DSMZ Cat# ACC-273, RRID:CVCL_0153) was purchased from DSMZ
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(Braunschweig, Germany). The 8505C cell line (TKG Cat# TKG 0439, RRID:CVCL_1054) was
purchased from ECACC. Cells from TPC-1, MDA-T85, MDA-T178, MDA-T187, MDA-T192, UHth83, and Hth104 were maintained in RPMI1640 medium (Sigma-Aldrich R8758) containing
10% fetal bovine serum (Sigma-Aldrich F0926), nonessential amino acid mixture (Cambrex
BioScience MT25025CI), 1 mM sodium pyruvate (Fisher Scientific MT25000CI), and 2 mM Lglutamine in a 37C incubator supplied with 95% air and 5% CO2. K2 cells were maintained in
DMEM/F12 medium (Sigma-Aldrich D8062) containing 10% fetal bovine serum and 2 mM Lglutamine. BCPAP cells were maintained in RPMI1640 medium containing 10% fetal bovine
serum and 2 mM L-glutamine. Hth7 and SW1736 cells were maintained in MEM medium
(Cambrex BioScience MT10010CV) containing 10% fetal bovine serum, nonessential amino
acid mixture, 1 mM sodium pyruvate, and 2 mM L-glutamine. 8505C cells were maintained in
MEM medium containing 10% fetal bovine serum, nonessential amino acid mixture, and 2 mM
L-glutamine.
10.2.2 Screening Library
HTS of 257 agents was performed at the Gulf Coast Consortium’s Combinatorial Drug
Discovery Program at the Institute of Biosciences and Technology (IBT), Texas A&M University
Health Science Center. The library includes 112 agents from the National Cancer Institute
Approved Oncology Set V (NCI_AOD5) collection; the remaining 145 agents were acquired
from commercial suppliers and assembled by IBT scientists to cover a wide range of potential
targets. These agents were predominantly FDA-approved agents and investigational
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compounds. All agents were prepared in 100% DMSO (Sigma–Aldrich D2650) at a stock
concentration of 10 mM.
10.2.3 High-throughput screening assay
As performed previously (294), a total of 500-1000 cells of each cell line were
suspended in 50 µl of medium per well and seeded into Greiner Black 384-well µClear plates
using a Multidrop Combi liquid dispenser (ThermoFisher Scientific). The plates were kept at
room temperature after seeding for 40-60 minutes prior to placing them into a cell culture
incubator to form a monolayer overnight at 37ᴼC in a humidified chamber with 95% air and 5%
CO2. After recovery, 50 nl of the agent was transferred into the wells using an Echo 550
acoustic dispensing platform (Labcyte). Cells from an untreated plate were fixed with 0.4%
paraformaldehyde (Fisher Scientific #31901) and cell nuclei were stained with 4′,6-diamidino-2phenylindole (DAPI, Sigma-Aldrich MBD0015) at the time of agent addition (Day 0) to provide
the number of cells present per well at the time of treatment. In the primary screen, three
concentrations were tested (0.01, 0.1, and 1 µM) with a fixed volume of DMSO (0.1% v/v) in
replicates. Each assay plate contained a fixed concentration of the agents in addition to a
negative control (0.1% DMSO), two positive controls (10 µM of cisplatin, Pharmachemie B.V
#2962769 and carboplatin, Selleckchem S1215), and an 8-point dose response curve of the
positive controls. After a 72-hour incubation with the agents, cells were fixed and nuclei were
stained with DAPI using an integrated Hydrospeed plate washer (Tecan Life Sciences) and
Multidrop Combi dispenser. Plates were imaged on an IN Cell Analyzer 6000 laser-based
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confocal imaging platform (General Electric Healthcare Bio-Sciences) and nuclei counted using
the algorithms developed using the IN Cell Developer Toolbox software (ver. 1.6).
10.2.4 Statistical analyses
Statistical analysis of assay performance was performed in accordance with the
National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (295).
Briefly, a running statistical evaluation was performed on each plate throughout the course of
the screening campaign to evaluate the consistency of results. Metrics evaluated included the
rate of growth of the negative controls, the coefficient of variance of the positive and negative
controls, and assay robustness determined from the Z’ statistic. Assay reproducibility and
experimental drift were determined using the minimum significance ratio calculated from the
standard deviation of IC50 values of the on-plate positive control dose response curves.
Pharmacologic data was normalized using the growth adjustment formula proposed by the
Hafner et al. (296)
log2 (𝑥(𝑐)⁄𝑥0 )

𝐺𝑅(𝑐) = 2log2(𝑥𝑛𝑒𝑔 ⁄𝑥0 ) − 1
where x(c) was defined as the observed cell count at the end of the assay, x0 was the median
cell count at the time of treatment (Day 0), and xneg the median cell count of the negative
control at the end of the assay. This method of normalization effectively removed alterations in
the rate of growth, allowing for more effective comparisons between cell lines, and
differentiated cytotoxic from cytostatic effects.
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To identify the most effective agents in each individual cell line, we selected those
agents with maximal growth inhibition at each dose level (top 25th percentile) and subsequently
used the non-parametric Mann–Whitney U test to compare the normalized index with other
agents and controls. P values less than 0.05 were considered statistically significant.
Furthermore, pharmacologic dose response data was summarized as an area under the curve
(AUC) value calculated by numerically integrating growth-adjusted values described in the
concentration-response curves. The data were fitted against a cascade of nonlinear regression
models, each with different initialization criteria, to identify the best fit using a combination of R
(Pipeline Pilot, RRID:SCR_014917, Dassault Systemes/Biovia, Vélizy-Villacoublay, France)
software platforms. Mechanistic clustering was performed by merging pharmacologic data with
an in-house database of mechanistic annotations. The core maintains a MySQL database of all
compounds used. All our collections are from commercial sources. When a collection is
purchased, the vendor supplies a file that contains the identification and location of every
compound purchased; that is how we know which compounds match to which result, making it
a 1:1 relationship. Most commercial vendors supply additional information such as known
targets for each of the compounds when known. When this information is available, we include
it within our internal database. We have, for certain projects, manually curated the metadata
for the compounds screened through a literature review using PubMed and other on-line data
sources such as the PubChem, PubChem Identifier Exchange Service, Drug Bank, ChEMBL,
ChemSpider, FDA, and DTP. All of this information can be found in the ‘mechanistic
annotations’ referred to in this work. We have attempted to record literature or vendor
supported Target Class, Target(s), Process, and Pathway information to help us cluster
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compounds into particular drug classes or signaling pathways. These data were then used to
generate a factorized adjacency matrix that was subsequently rendered as a minimum
spanning tree using the cluster, visNetwork, and Intergraph packages in R package
implementing methods. Subsequent to the identification of agents with maximal growth
inhibition in each cell line, we performed a confirmatory test for these agents using eight-point
dose-response curves.
10.2.5 IC50 and Colony formation analysis
To determine the IC50 of each agent, cells (0.3-1 × 104) were plated in 48-well plates
(Fisher Scientific #12-565-322) with 1 mL of medium in a 37C incubator supplied with 95% air
and 5% CO2. Docetaxel (Accord Healthcare #00955-1020-01), LBH-589 (Selleckchem S1030),
and pralatrexate (Selleckchem S1497) were added to cells 24 hours later and incubated for 72
hours at varying concentrations (6 replicates). We selected these three drugs because of
successful growth inhibition in the tested cell lines used in the initial high throughput screening
assay as well as the potential for future clinical implementation. MTT (Thiazoyl Blue
Tetrazolium Bromide, VWR # 97062-380) dissolved in 0.8% NaCl solution (Sigma–Aldrich
D8537) at 2 mg/mL was added to each well (0.1 mL) and incubated at 37C for 4 hours. The
liquid was then aspirated from the wells and discarded. Stained cells were dissolved in 0.5 mL
of DMSO and their absorption at 570 nm was measured using a SPECTROstar or CLARIOstar
plate reader. IC50 was determined using Prism 8.0 software.
For colony formation analysis, 100 or 200 cells were plated in 6-well plates (Fisher
Scientific #087721B) in triplicate. The test agents were added to wells after 24 hours and was
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then further incubated for 72 hours. Fresh media were then added to cells and incubated for an
additional 5-7 days in an incubator supplied with 95% air and 5% CO2 at 37C. Colonies were
stained with 0.05% crystal violet (Sigma-Aldrich C6158) in 10% buffered formalin (Fisher
Scientific SF1004) and counted. Figures were generated using Prism 8.0 software.
10.2.6 In vivo testing of selected agents
All animal experiments were performed in accordance with protocols approved by the
IRB and the Institutional Animal Care and Use Committee. Immunodeficient athymic nu/nu
mice (Envigo #069) were used for the orthotopic (297) and PDX models. PDX models were
generated from patients’ surgical specimens implanted directly in the flank of the mice (G0).
Once the tumor reached 1000 mm3, it was subsequently expanded to additional mice for a total
of three times (G1 to G3) to be deemed successfully established. MDA-ATC1 (298) was
developed from the same ATC patient specimen used to generate the MDA-T187 cell line.
MDA-ATC5 was developed from a 59-year-old man with ATC. Tumors were STR analyzed to
confirm match to DNA from patient’s tissues. Once tumors were established, mice were
randomized into groups. Five treatments with 5 mg/kg docetaxel diluted in 0.8% NaCl and 20
mg/kg pralatrexate dissolved in 2% DMSO and 48% polyethylene glycol (PEG) 300 (SigmaAldrich #202371) were given once every three days by intraperitoneal injection. LBH-589
(dissolved in 2% DMSO + 48% PEG 300) was given daily for 5 days at 20 mg/kg (first cycle),
followed by a rest period of 2 days, and then daily for 5 days at 10 mg/kg (second cycle), by
intraperitoneal injection (299). Control mice for docetaxel were treated with 0.8% NaCl, while
the LBH-589 and pralatrexate control mice were treated with 2% DMSO + 48% PEG 300.
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Tumor growth was monitored by Xenogen (IVIS 200 imaging system, Caliper Life Sciences,
Hopkinton, Massachusetts) in the presence of D-luciferin (Fisher Scientific L2912) using Living
Image 3.0 software for orthotopic models. Tumor volume was measured by caliper for PDX
models and calculated using the formula (V = length × width × depth).
10.2.7 Mitotic count and immunohistochemistry
The tumor specimens from orthotopic and PDX models were collected and fixed in 10%
neutral buffered formalin. Fixed tissues were processed into 5 μm thick sections, stained with
hematoxylin and eosin (H&E), and examined microscopically by a head and neck pathologist
using a BX41 Olympus microscope (Olympus, Tokyo, Japan) and an Aperio (Leica Biosystems,
Wetzlar, Germany) digital image scanner. Mitotic count was determined as described
previously (300). Briefly, 10 high-power fields were examined under microscope from H&E
stained slides and mitotic cells were counted. Immunohistochemistry (IHC) analyses were
performed against human-specific Ki-67 (DAKO #M7240 or Cell Signaling Technology #9027)
and cleaved caspase 3 (Cell Signaling Technology #9579). Diaminobenzidine was used as a
chromogen for antigen localization. Ki-67 and cleaved caspase 3 positive cells were counted
manually from 6 and 4 high-power fields, respectively. The percentage of positive cells was
calculated using the following formula: Total number of positive cells/(Total number of positive
cells + Total number of negative cells) * 100. Graphs were generated using Prism 8.0.
10.3 Results
10.3.1 Relative drug effectiveness as a function of dose and tumor mutational status
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Twelve human thyroid cancer cell lines were used in this study including seven ATC,
one PDTC, and four PTC lines (BRAFV600E and TP53 mutational status summarized in Table
10.1). After HTS of 257 agents, we were able to identify the most effective compounds (based
on their inhibition categories) for each cell line by a tree-structure analysis (Figure 10.1A).
Using this analysis, we identified relationships between thyroid cancer type, individual agent
dose, and BRAFV600E and TP53 mutational status. For example, at 0.1 μM, the most effective
classes of agents against ATC cell lines were anti-metabolites, inducers of reactive of oxygen
species (ROS), proteasome inhibitors, microtubule inhibitors, heat shock protein (HSP90)
inhibitors, and Polo-like kinase 1 (Plk1) inhibitors (Figure 10.1B). At the lower, 0.01 μM dose,
only anti-metabolites, proteasome inhibitors, and microtubule inhibitors remained effective.
Similar to ATC, all tested PTC cell lines demonstrated sensitivity to proteasome inhibitors,
microtubule inhibitors, ROS inducers, HSP90 inhibitors, targeted kinase inhibitors, and histone
deacetylase (HDAC) inhibitors at 0.1 μM. However, only proteasome inhibitors and microtubule
inhibitors remained effective at 0.01 μM. Several classes of agents including targeted kinase
inhibitors, proteasome inhibitors, and microtubule inhibitors demonstrated activity regardless of
BRAFV600E and TP53 mutational status. In addition, several classes including antimetabolites,
HSP90 inhibitors, and ROS inducers exhibited activity regardless of the BRAF mutational
status, while anthracenediones and HDAC inhibitors had preferential activity in wild-type (nonmutated) BRAF (Figure 10.1C). HDAC inhibitors were effective in cell lines that exhibited wildtype TP53 status while anti-metabolites and vinca alkaloids were most effective in the context
of TP53 mutations.
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Table 10. 1: Summary of cell lines and PDX models with their BRAF and TP53 mutational
status.
Cancer type

Cell line/PDX

Name

BRAF

TP53

PTC

Cell line

TPC-1

WT

WT

Cell line

K2

V600E

WT

Cell line

BCPAP

V600E

D259Y

Cell line

MDA-T85

V600E

WT

PDTC

Cell line

MDA-T192

WT

WT

ATC

Cell line

MDA-T178

WT

WT

Cell line

U-Hth83

WT

Y236C & P153fs

Cell line

Hth7

WT

G245S

Cell line

MDA-T187

V600E

K132N

Cell line

SW1736

V600E

No expression,
Q192*
Cell line

Hth104

V600E

No expression

Cell line

8505C

V600E

R248G

PDX

MDA-ATC1

V600E

K132N

PDX

MDA-ATC5

WT

WT

The mutation status of BRAF and TP53 was determined by whole exome sequencing,
Sequenom, or Sanger sequencing. The expression of TP53 in Hth104 cells was determined by
Western blot analysis after failed Sanger sequencing. MDA-ATC1 was generated from the
same patient who gave rise to MDA-T187 cell line and carrying the same BRAF and TP53
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mutations as determined by whole exome sequencing. Abbreviations: WT: wild-type; PTC:
papillary thyroid carcinoma; PDTC: poorly differentiated thyroid carcinoma, ATC: anaplastic
thyroid carcinoma; fs: frame shift; *: nonsense mutation.
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Figure 10. 1: HTS analysis.
Analysis of HTS. A, Tree analysis for U-Hth83 (left) and K2 (right) cells after HTS where the
size of the colored data point dots represents relative effectiveness of each individual agent. A
larger the dot indicates an increased effect. Each class with major effects were color coded for
easier identification. B, Boxplots of effective drugs in the initial screen at 0.1 μM concentration
compared with DMSO (Control), other ineffective drugs, and the effective drugs. * indicates
statistical significance P<0.0001 for both. C, A comparison of the activities of different classes
of agents using tree analysis in a BRAFWT (MDA-T192) versus BRAFV600E mutated BRAF cell
line (BCPAP).
We selected seventeen agents (Table 10.2) for further efficacy testing in all twelve cell
lines (sample outputs for U-Hth83 and K2 cell lines can be found in Figures 10.2A and 10.2B,
respectively). The selection criteria included the level of agent activity in the tested cell lines as
well as persistent activity at lower concentrations. Most of the seventeen agents selectively
inhibited cell growth in a dose-dependent manner, except for cabazitaxel which did not show
any change in the rate of cell growth in both the U-Hth83 and K2 cell lines. Vinblastine sulfate
did not change the growth rate of U-Hth83 cells under any of the tested doses, while
pralatrexate did not change the growth rate of K2 cells. All were consistent with the results from
the initial screening.
Table 10. 2: Agents selected for retesting.
Inhibition category

Agents

Antifolates

Pralatrexate
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HDAC Inhibitor

JNJ-26481585, LBH-589, NVP LAQ824

HSP90 Inhibitor

NVP AUY922

Microtubule inhibitor

Cabazitaxel, Docetaxel, Paclitaxel, Vinblastine sulfate, Vincristine
sulfate

PLK1 inhibitor

BI 2536

Proteasome inhibitor

BORTEZOMIB, Carfilzomib

Protein kinases

STAUROSPORINE

inhibitor
Pyrimidine analog

Gemcitabine hydrochloride

ROS inducer

ELESCLOMOL

Topoisomerase

Mitoxantrone

inhibitor
Agents were selected after stringent statistical analysis from 257 potential candidates. They
were listed by their inhibitory mechanisms.
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Figure 10. 2: Dose-response curves.
Confirmatory eight-point dose-response curves for selected agents against U-Hth83 (A) and K2
(B) cell lines. The green curves indicated the fraction of cells affected (FA) by the agents and
the orange curves indicated the cell growth index (GI).
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10.3.2 In vitro validation of selected compounds
Three agents, consisting of a microtubule inhibitor (docetaxel) (301), an antifolate
(pralatrexate) (302), and a HDAC inhibitor (LBH-589/panobinostat) (303), were chosen to be
further analyzed based on the screening data and their existing FDA approval for other nonthyroid cancers. Two thyroid cancer cell lines, U-Hth83 (ATC; BRAFWT, TP53P153fs) and K2
(PTC; BRAFV600E, TP53WT), were utilized for IC50 measurements which were used to
corroborate the HTS data (Table 10.3). To further validate the effects of the three agents in
terms of growth inhibition, a colony formation assay was used in the U-Hth83 (Figure 10.3A)
and K2 cell lines (Figure 10.3B). We found that all three agents were able to decrease the
number of colonies formed in both cell lines in a dose-dependent manner at nanomolar
concentrations, with the exception of pralatrexate in K2 cells.
Table 10. 3: IC50 of selected agents.
Cancer type

Cell line

Drug

Average IC50 (nM)

PTC

K2

Docetaxel

2.12+0.54

LBH-589

0.79+0.54

Pralatrexate

n/a

Docetaxel

1.02+0.26

LBH-589

0.06+0.01

Pralatrexate

1.35+0.11

ATC

U-Hth83

To determine the IC50 of each agent, docetaxel, LBH-589, or pralatrexate were added to cells for 72
hours at varying concentrations (6 replicates). Concentrations were selected based on the initial high
throughput screening assay. After drug treatment, MTT was added to stain cells followed by DMSO and

196

absorption at 570 nm was measured using a SPECTROstar or CLARIOstar plate reader. IC 50 was
determined using Prism 8.0 software. Average IC50 was determined from three independent assays. n/a:
the IC50 was beyond the range of the cell proliferation assays (10 M).
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Figure 10. 3: Colony formation assay.
Detecting cell growth by colony formation assay after docetaxel, LBH-589, and pralatrexate
treatments. U-Hth83 (A) and K2 (B) cells (100 cells/well) were plated in 6-well plates in
triplicates and only one well was shown here as an example. Docetaxel, LBH-589, and
pralatrexate at different concentrations were added to cells 24 hours later for 72 hours. After
72-hour treatment, agents were removed, and fresh media were added to cells. Cells were then
incubated for up to 7 days without disturbance to allow colonies to grow. To visualize colonies,
cells were stained with 0.05% crystal violet in 10% formalin. Controls were cells without agent
treatment. Colony numbers were converted to surviving fractions by Prism after transforming
colony numbers with log.
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10.3.3 In vivo validation of selected compounds
Docetaxel, pralatrexate, and LBH-589 anti-tumor activity was tested in orthotopic UHth83 or K2 tumors. LBH-589 significantly inhibited tumor growth in both U-Hth83 and K2
models (Figures 10.4 and 10.5A). Docetaxel inhibited U-Hth83 tumor growth (Figures 10.4 and
10.5B), while pralatrexate was able to inhibit K2 tumor growth (Figures 10.4 and 10.5C). No
significant changes in tumor volumes were detected in K2 mice treated with docetaxel and in
U-Hth83 mice treated with pralatrexate. To further reinforce our findings in the orthotopic
model, we tested the three agents in two ATC PDX models, MDA-ATC1 (BRAFV600E,
TP53K132N), and MDA-ATC5 (BRAFWT, TP53WT) (Table 10.1). Significant tumor growth inhibition
was detected in MDA-ATC1 and MDA-ATC5 following LBH-589 and pralatrexate treatments
(Figure 10.4), while docetaxel led to a significant tumor growth inhibition in MDA-ATC1.
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Figure 10. 4: Boxplots of the drug effect on orthotopic and PDX models.
Suppressing tumor growth by docetaxel, LBH-589, and pralatrexate in orthotopic (top) and PDX
(bottom) models. Top, U-Hth83 (left) and K2 (right) cells carrying luciferase (5x105) were
injected into nude mice thyroid orthotopically and tumor growth was monitored by Xenogen
twice a week. Treatment started on day 7 for vehicle control (12 mice for U-Hth83 and 10 mice
for K2), 5 mg/kg docetaxel (13 mice for U-Hth83 and 8 mice for K2), and 20 mg/kg pralatrexate
(13 mice for U-Hth83 and 10 mice for K2). Docetaxel and pralatrexate were given once every
three days by intraperitoneal injection for total of five treatments. LBH-589 was given once a
day for 5 days at 20 mg/kg (first cycle), rested for 2 days, and then once a day for 5 days at 10
mg/kg (second cycle) by intraperitoneal injection (12 mice for U-Hth83 and 10 mice for K2).
Tumor volume (ex vivo) was calculated after mice were euthanized by caliber and graph was
generated by Prism. P values were calculated by Student’s t-Test. Bottom, PDX models of
MDA-ATC1 (left) and MDA-ATC5 (right) were treated with docetaxel (10 mice for MDA-ATC1
and 9 mice for MDA-ATC5), LBH-589 (12 mice for MDA-ATC1 and 10 mice for MDA-ATC5), or
pralatrexate (9 mice for MDA-ATC1 and 8 mice for MDA-ATC5). Vehicle controls were 10 mice
for MDA-ATC1 and 16 mice for MDA-ATC5. The doses and treatment schedules for PDX
models were the same as described for the orthotopic models. SubQ tumor was measured by
caliber 2-3 times weekly. Percentage of tumor volume change was determined by correction
with the starting tumor volume.
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Figure 10. 5: Images of U-Hth83 and K2 orthotopic tumors by Xenogen and pictures of
ex vivo tumors.
Tumor cells (U-Hth83 or K2) were inoculated into mice thyroid orthotopically as described in
Materials and Methods. Images of Xenogen were shown before treatment and after first and
second cycles for LBH-589 or after 2-5 treatments for docetaxel and pralatrexate. Images of ex
vivo tumors were shown underneath. Two mice from each group were shown here as
examples. A, LBH-589 treatment in both U-Hth83 and K2. B, Docetaxel and pralatrexate
treatments in U-Hth83. C, Docetaxel and pralatrexate treatments in K2.
Agent toxicity evaluated as a function of changes in animal weight was moderate. LBH589 significantly reduced mouse weight in all four mouse models by up to 12% after the first
cycle of treatment at 20 mg/kg (Figure 10.6), while pralatrexate significantly decreased mouse
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weight in the MDA-ATC5 mice. To ensure mice survival and complete our treatment plan, LBH589 dosage was reduced to 10 mg/kg for the second cycle of treatment.

Figure 10. 6: Mice weights as a measurement of drug toxicity.
Mice weights from orthotopic (top) and PDX (bottom) as a measurement of agent toxicity. Top,
mice inoculated withU-Hth83 (left) and K2 (right) cells orthotopically were weighed before agent
treatments, 2-3 times weekly during treatment, and after all treatment. Percentage of average
mouse weight loss was corrected with the mouse weight before treatment. Bottom, mice
weights from PDX models MDA-ATC1 (left) and MDA-ATC5 (right) were shown after correction
from weight before treatment.
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Orthotopic and PDX models were further examined for apoptosis after drug treatment
through IHC of cleaved caspase 3 (Figure 10.7A). Using pralatrexate as an example, we
detected an increase in cleaved caspase 3 positive cells in both orthotopic (K2) and PDX
(MDA-ATC1) models after drug treatment compared to controls. For proliferation of orthotopic
and PDX models after drug treatment, IHC of Ki-67 (Figure 10.7B) and mitotic count (Figure
10.7C) were determined. IHC of Ki-67 demonstrated that the Ki-67 positive cells decreased in
both orthotopic (K2) and PDX (MDA-ATC1) models after pralatrexate treatment, compared to
controls (Figure 10.7B). Mitotic count identified the number of cells undergoing mitosis and was
used as a measurement of cell proliferation. We detected a dramatic decrease in mitotic count
in both models after pralatrexate treatment when compared to control tumors (Figure 10.7C).
All of these results confirmed that after pralatrexate treatment tumor cells have a decreased
proliferation and increased apoptosis in both orthotopic and PDX models and these results
supported our observation of a decrease in tumor volume.
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Figure 10. 7: IHC of cleaved caspase 3 and Ki-67.
IHC of cleaved caspase 3 (CC3) as an indicator of apoptosis and IHC of Ki-67 and mitotic
count as an indication of proliferation. Tumors from the orthotopic model K2 and the MDAATC1 PDX model (PDX#1) after treatment with pralatrexate are shown. All graphs were
generated using Prism. IHC staining with CC3 (A) or Ki-67 (B) in K2 and PDX#1. C, percentage
of CC3 positive cells (left) was counted from four high power fields and calculated using the
following formula: Total number of positive cells/(Total number of positive cells + Total number
of negative cells) * 100. Percentage of Ki-67 positive cells (middle) was counted from six high

205

power fields and calculated using the same formula as for CC3. Mitotic count (right) was
determined from ten high power fields.
10.4 Discussion

The potential of precision oncology is maximized in the context of “magic bullets”,
compounds targeted to a specific protein that ideally is mutated or fused in a manner distinct
from the normal variant. These compounds are subsequently matched to tumors demonstrating
the target event (i.e., mutation, fusion, amplification). BRAF inhibitors were first shown to have
profound anti-tumor activity in the context of melanoma more than a decade ago (304, 305). At
the time, the short term efficacy of BRAF inhibitors in the context of BRAF-mutant disease
provided tremendous advancement in the treatment of a disease without any meaningful
systemic option (304, 305). However, tumors developed resistance bypassing BRAF through
increased MEK activity (306). The combination of BRAF and MEK inhibitors of FDA approved
drugs for ATC (Vemurafenib, Dabrafenib, and Trametinib) attacked this resistance mechanism,
and the combinatorial approach has now become standard of care for patients with BRAFmutated advanced melanoma, with excellent, and fairly durable effects on progression free and
overall survival (307).
Variable therapeutic efficacy in a subset of tumors is largely a function of intrinsic tumor
biology (308), which provides the principal rationale for basket trials. Although this is primarily
applied to targeted agents such as BRAF inhibitors, intrinsic tumor biology can also drive
response to conventional cytotoxic agents (309). We sought to leverage a broad preclinical
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platform for PDTC and ATC to identify and evaluate potentially effective systemic agents. Our
findings demonstrate that HTS can effectively identify distinct classes of systemic agents that
have a variable effect against thyroid cancer cell lines with variable histopathologic and
mutational profiles. Although limited to 12 cell lines, this approach can be rapidly scaled to cell
line banks in excess of 40-50 cell lines, providing a robust interface between relative drug
effectiveness and molecular background as has been demonstrated by other groups (310).
However, this represents simply a first step in a preclinical testing process which must support
clinical trial development. In vitro screens fail to account for the significant modulatory effects of
the tumor microenvironment, potentially generating false positives, and more concerning, false
negative results, which could result in loss of potentially effective agent combinations (311319). Variability of each mouse’s individual response to the tested agents was expected (320).
In a recent study by Ghosh et al., following HTS, the effect of a BRAF inhibitor with a
multitargeting TK inhibitor was analyzed and demonstrated their synergistic effect on 4 cell
lines using both in vitro and in vivo (orthotopic) models. That study was limited to targeting
BRAF-mutated disease, which only represents approximately 35% of the ATC population (321),
and the HTS was composed of a select 32 drugs. In our study, the goal was to identify novel
classes of drugs that would be useful against both BRAFV600E-mutated and wild-type ATC. HTS
was augmented by in vitro validation, but most importantly, validation under in vivo conditions
using the gold standard preclinical approach which combines both orthotopic models with PDX
models. Furthermore, 257 agents were used in the initial HTS and we were able to identify the
agents that showed potent activity against most cell lines. We validated the activity of a
selected set of seventeen agents after stringent statistical analyses that showed the strongest
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efficacy using a confirmatory eight-point dose-response curve. Three of the seventeen agents
were chosen for a more detailed analysis as they were already FDA-approved to treat nonthyroid cancers.
LBH-589 (HDAC inhibitor), approved for the treatment of multiple myeloma (303), was
the most effective agent in terms of cell growth inhibition in vitro in both tested cell lines, as well
as in terms of tumor growth inhibition in vivo in all four mouse models (two orthotopic and two
PDX models). Combining our current findings with those of Catalano et al. we report significant
anti-tumor LBH-589 effects in total of 5 distinct ATC cell lines in vitro, 3 xenograft models (1
flank and 2 orthotopic), and 2 PDX models, clearly making this agent a strong candidate for
clinical trial consideration (322). LBH-589’s described effects on cell cycle arrest make it an
excellent candidate for combinatorial strategies with radiation, currently a mainstay of ATC
multi-modality treatment (323, 324).
Pralatrexate (antifolate/antimetabolite), approved for peripheral T-cell lymphoma (302),
significantly inhibited tumor growth in both PDX models (MDA-ATC1 and MDA-ATC5), but did
not consistently inhibit in vitro and in vivo growth in the human cell line models making it
potentially less attractive as a clinical agent. Although pralatrexate showed significant cell
growth inhibition in U-Hth83 cells in vitro, U-Hth83 orthotopic tumor growth was not inhibited in
vivo. Interestingly, the opposite was seen with the K2 cells where cell growth in vitro was not
inhibited significantly, while inhibition occurred in the orthotopic tumor model. The selective
inhibitory effect of pralatrexate in the K2 orthotopic tumors may be related to differences in the
tumor microenvironment. As such, we cannot conclude that the inhibitory effect of pralatrexate
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was tumor-type specific or BRAF/TP53-mutation specific. Our results of proliferation and
apoptosis after pralatrexate treatment confirmed that tumors have decreased proliferation and
increased apoptosis in both orthotopic and PDX models when compared to controls. Since the
mechanism of action for pralatrexate involves preferential accumulation in actively dividing cells
inhibiting the function of critical enzymes involved in DNA synthesis and inducing cell death
(302), these cellular functions are likely associated with other signaling transduction/metabolic
pathways and are not dependent on BRAF and TP53.
Docetaxel (microtubule inhibitor), approved for the treatment of multiple cancers
including breast cancer, non-small-cell lung cancer, and squamous cell carcinoma of the head
and neck (301), effectively inhibited colony formation in both U-Hth83 and K2 cell lines, but only
managed to inhibit growth in the U-Hth83 orthotopic and MDA-ATC1 PDX models.
Interestingly, both U-Hth83 and MDA-ATC1 have TP53 mutations, suggesting that docetaxel
may have a selective effect. Functional TP53 was found to induce apoptosis in docetaxeltreated prostate cancer cells (325). Together with our findings, docetaxel may be targeting p53
signaling transduction pathway and regulating cell survival.
Significant toxicity measured by weight loss was expected in mice treated with LBH589, as previously reported (303, 322). LBH-589 treatment for our in vivo models started at 20
mg/kg for the first five days (first cycle) following the manufacturer’s recommendation (299).
Significant weight loss was observed after the first cycle of treatment, which prompted us to
reduce the dose to 10 mg/kg during the second cycle to ensure study completion and mouse
survival. Similar weight loss with LBH-589 (8% at 20 mg/kg and 13% at 30 mg/kg) was also
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detected by Catalano et al. when they treated mice with CAL-62 cells (ATC) injected
subcutaneously (322), while increased mortality was observed at above 10 mg/kg in mice with
graft-versus-host disease (303). Dose adjustments were not required for pralatrexate and
docetaxel. In multiple myeloma patients treated with LBH-589, although weight loss per se was
not one of the major side effects, diarrhea was found in 68% of patients vs 42% on placebo and
vomiting in 26% of patients compared to 13% on placebo from the Phase III PANORAMA 1 trial
(326).
Although HTS was effective for identifying agents for additional comprehensive testing,
there are known limitations of in vitro HTS. Even when using robotic-based assays, there are
technical challenges to screening large libraries of compounds across multiple cell lines, which
is essential to account for genomic and epigenetic heterogeneity. However, these large-scale
screening efforts may identify false-positive candidates. We addressed this possibility by using
four distinct in vivo models (two orthotopic and two PDX models), while employing large
numbers of mice per test group (8-16 per group) to minimize potential experimental variations.
Given the breadth of our cell line and PDX model inventory, we could match genetic
backgrounds for the cell lines used in vitro and in vivo (orthotopic model) with the PDX models,
making our overall agent discovery approach as robust as possible.
In conclusion, we report a comprehensive approach to identifying novel treatments for
thyroid cancer, specifically ATC. Following HTS with 257 agents, we identified three candidate
agents and performed extensive in vitro and in vivo analyses, culminating with a large-scale
preclinical trial in four mouse models, two orthotopic and two PDX models. HDAC inhibitor,
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LBH-589, appeared to have the most effective tumor growth inhibition on thyroid cancer (both
ATC and PTC regardless of BRAF and TP53 mutations in all four in vivo models). The
inhibitory effect of docetaxel in vivo was specific for TP53-mutated tumors alone, while
pralatrexate was effective in both ATC and PTC regardless of BRAF and TP53 mutation status.
Our work demonstrates the feasibility of using this systematic approach for preclinical in vivo
drug testing and potential combination with FDA approved drugs in future. This platform
provides an avenue for the identification of novel agents, validation, and resistance evaluation.
Utilization of immunodeficient PDX models and immunocompetent murine models in the future
facilitates personalized therapeutics development as a strong justification for proceeding to
human clinical trials. Our study provides value to the field in two somewhat distinct yet
overlapping ways. First, it demonstrates that HTS can identify potentially effective compounds
against the PTC-ATC disease spectrum which have already been introduced into a clinical
setting for other malignancies. This is important, because it can prompt clinicians to revisit “old”
drugs using new combinatorial approaches, particularly by leveraging combinations of targeted
(BRAFi) and non-targeted agents (i.e. docetaxel) and through combinations with immune
checkpoint inhibitors (ICIs) which is in fact the current clinical strategy at our institution.
Second, it identifies existing compounds (i.e. HDAC inhibitors) which, although not currently
employed in clinical practice, may be a viable combinatorial strategy for early phase,
exploratory clinical trials with a reasonable toxicity profile. Following our methodology, others
can employ similar approaches to identify novel classes of systemic agents for the treatment of
ATC, as well as other malignancies.
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Chapter 11. Discussion
11. 1 General Summary
This work had a clinical and a translational component. In the clinical component, we
showed that the currently available clinical imaging modalities can be successfully used to
adapt RT dose during treatment according to the tumor response, predict oncologic disease
outcomes, characterize RT-induced toxicity, and identify the patterns of disease failure. We
used anatomical T2w MRI for the RT dose adaptation purpose. Our findings showed that after
proper standardization of the immobilization and image acquisition techniques we can achieve
high geometric fidelity of the images. These images can then be used to monitor the shrinkage
of the GTV during the RT course and optimize the clinical target volumes accordingly. Our
results showed that this MR-guided dose adaptation technique has a dosimetric advantage
over the standard of care and was associated with a reduction in normal tissue doses that
translated into a reduction of the odds of dysphagia ≥ grade 2 and feeding tube persistence at
6-months, and hypothyroidism at 1-year post-treatment.
In the second aim, we used quantitative MR imaging to interrogate its utility for
prediction of oncologic outcomes and characterization of RT-induced normal tissue toxicity. Our
findings showed that delta changes of ADC parameters derived from DWI images at mid-RT
can be used to predict local recurrence and recurrence free survival. We also showed that Ktrans
and Ve vascular parameters derived from DCE images can characterize the mandibular areas
of ORN (i.e. the most devastating normal tissue toxicity in the head and neck after RT) as
compared with healthy mandible.
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In the final clinical aim, we used CT images of recurrence and baseline CT planning
images to develop a methodology and workflow that involves the application of deformable
image registration software as a tool to standardize image co-registration in addition to granular
combined geometric- and dosimetric-based failure characterization to correctly attribute sites
and causes of loco-regional failure. We then successfully applied this methodology to identify
the patterns of failure following postoperative IMRT for oral cavity cancer patients and following
definitive IMRT in HNC patients of different disease subsite. Using this method, we showed that
the majority of recurrences occurred in the central high dose regions for patients treated with
definitive IMRT compared with mainly non-central high dose recurrences after postoperative
IMRT. We also correlated recurrences with pretreatment FDG-PET and identified that the
majority of the central high dose recurrences originated in an area that would be covered by a
10 mm margin on the volume of 50% of the maximum FDG uptake. This is a significant finding
since the main PET-guided dose escalation studies in the past only used the volume of 50% of
the maximum FDG uptake without additional margin which may be the main reason that
ultimately led to the failure of these studies.
In the translational component, we integrated radiomic imaging features derived from
pre-RT CT images with whole-genome measurements using TCGA and TCIA data. Our results
demonstrated a statistically significant associations between radiomic features characterizing
different tumor phenotypes and different genomic features such as transcriptional activity, DNA
methylation, miRNA expression, and somatic mutation. These findings represent a promising
potential towards non-invasively tract genomic changes in the tumor during treatment and use
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this information to adapt treatment accordingly. In the final project of this dissertation, we
developed a high-throughput approach to identify effective systemic agents against aggressive
head and neck tumors with poor prognosis like ATC. We successfully identified three candidate
drugs and performed extensive in vitro and in vivo validation using orthotopic and PDX models.
Among these drugs, HDAC inhibitor and LBH-589 showed the most effective tumor growth
inhibition that can be used in future clinical trials.
11. 2 Specific aim 1:
Determine the feasibility and dosimetric benefits of this MRI-based dose-adaption strategy for
HPV positive oropharyngeal cancer patients using serial in-treatment MRIs acquired in
radiation treatment positioning and immobilization setup.
We aimed in this part of the dissertation to integrate the anatomic MR images in RT
platforms to be able to adapt the RT dose according to treatment response in order to
accurately track high risk targets with serially reduced margins during therapy to limit normal
tissue dose and subsequent toxicity while maintaining uncompromised high dose to target
volumes, without the need of exogenous contrast. In project 1.1, we quantified the geometric
distortion in patient images by comparing their in-treatment position MRIs with the
corresponding planning CTs, using CT as the non-distorted gold standard. We used the T2w
MRs of 21 HNC patient acquired in the same immobilization position as in the RT planning
CTs. MRI to CT rigid registration was then done and geometric distortion comparison was
assessed by measuring 430 carefully selected anatomical landmarks on both images. The
median distortion for all landmarks in all scans was around 1 mm which is a clinically
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insignificant error compared to the gold standard CT. This ensured a good quality MR image to
proceed with the second half of Aim 1 which was to determine the feasibility and dosimetric
benefits of using MR-guided RT dose adaption strategy for HPV positive OPC. We designed an
in-silico study using the MR images acquired every two weeks during RT for patients with
locally advanced disease. For each patient a standard versus an adaptive IMRT plan was
created. For adaptive plans, we created an adaptive planning target volume based on
detectable tumor shrinkage on T2w images. We kept the standard 70 Gy dose prescription to
the adaptive volume to allow for maximum dose to any residual disease but in case of tumor
complete response only a floor dose of 50.16 Gy will be received. The average dose to 95% of
initial PTV volume was 70.7 Gy for standard plans versus 58.5 Gy for adaptive plans. The
results of this project showed that most OARs received lower doses using adaptive plans which
is translated to an average reduction in the probability of developing dysphagia ≥ grade2,
feeding tube persistence at 6-month post-treatment and hypothyroidism at 1-year posttreatment of 11%, 4%, and 5%, respectively. Since the original hypothesis of that aim was that
T2 weighted MRI can be used for MR-guided RT dose adaptation to achieve same tumor
control as standard therapy but with additional sparing of surrounding normal tissue, we
conclude that the hypothesis for this aim was successfully met.
11. 3 Specific aim 2:
Determine quantitative MRI parameters associated with tumor response, oncologic outcomes,
and normal tissue toxicity in head and neck cancer patients treated with definitive radiation
therapy.
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In Aim 2 of this work, we sought to determine the benefits of using quantitative MR
imaging parameters as a tool to predict RT outcomes and characterize RT-induced toxicity. In
the first project of this aim, we assessed DWI parameters associated with tumor response and
oncologic outcomes in HNC patients treated with RT. We enrolled 81 patients in an active
prospective imaging study at our institution. Patients had MRIs pre-, mid-, and post-RT
completion. Treatment response was assessed at mid-RT and at 8-12 weeks post-RT and
local, regional, and distant control as well as recurrence-free and overall survival at 2-year
post-RT. Our results showed that primary tumor delta ADCmean <7% at mid-RT is a significant
parameter associated with worse local control and recurrence-free survival. Uni- and multivariable analysis of prognostic outcomes showed that it was an independent predictive factor.
This shows that patients with no significant increase of primary tumor site ADC at mid-RT
relative to baseline values are at high risk of disease relapse. In the second project, we aimed
to characterize the quantitative DCE-MRI parameters associated with advanced mandibular
ORN compared to the contralateral normal mandible. We included patients with the diagnosis
of advanced ORN after curative-intent RT of HNC. Thirty patients were included with 38
months median time from RT completion to ORN development. The results of this study
showed a statistically significant higher Ktrans and Ve in ORN volumes-of-interest compared with
control volumes of the contralateral healthy mandible. Using combined Ktrans and Ve
parameters, 90% of patients included in the study had at least a two-fold increase of either of
the studied parameters in the ORN volumes-of-interest compared with control volumes. These
results confirm there is a quantitatively significant higher degree of leakiness in the mandibular
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vasculature as measured using DCE-MRI parameters of ORN areas compared with healthy
mandible. This also suggests that a two-fold increase in either Ktrans or Ve parameters is an
alarming sign of ORN development if detected in patients with otherwise clinically apparent
normal mandible after radiation treatment especially in areas exposed to higher doses of RT.
Therefore, our hypothesis that quantitative MRI parameters can be used for prediction of tumor
response, long-term oncologic outcomes, as well as the characterization of RT-induced normal
tissue toxicity was successfully supported by the projects’ results.
11. 4 Specific aim 3:
Develop and apply a methodology to standardize the analysis and reporting of the patterns of
failure after radiation for head and neck cancer patients.
This part of the dissertation aimed to develop and apply a novel methodology to
standardize the analysis and reporting of the patterns of loco-regional failure after IMRT/IMPT
of HNC. In project 3.1, we included 21 patients with evidence of local and/or regional failure
following IMRT for HNC and manually delineated recurrent gross disease on the diagnostic CT
documenting recurrence which was co-registered with the original planning CT using both
deformable and rigid image registration. Subsequently, recurrence volumes were mapped to
the planning CT for comparison relative to original planning target volumes and dose using a
centroid-based approaches. Failures were then classified into five distinct types based on
combined spatial and dosimetric criteria. The results of this work showed that rigid image
registration tends to assign failures more peripherally and that DIR-based methods accurately
mapped the vast majority of failures to the high dose volumes suggesting biological rather than
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technology-related causes of failure. We then applied this methodology to identify spatial and
dosimetric patterns of failure for oral cavity cancer patients receiving post-operative IMRT and
identify the radio-resistant subvolumes in pretreatment FDG-PET by mapping the spatial
location of the origin of tumor recurrence in projects 3.2 and 3.3 respectively. The results of
project 3.2 showed that 50% of OCC patients with local/regional failure had non-central high
dose recurrence and identified potential causes the increase the intermediate and extraneous
dose recurrences in these patients. While patients treated with definitive IMRT in project 3.3,
the majority of loco-regional recurrences originated in the regions of central-high-dose. When
correlated with pretreatment FDG-PET, these recurrences originated in an area that would be
covered by additional 10 mm margin on the volume of 50% of the maximum FDG uptake. Such
findings highlight the importance of proper definition of the subvolumes to target in FDG-PETguided dose escalation clinical trials. Based on these results, we deem the hypothesis of this
Specific Aim to be correct.
11. 5 Specific aim 4:
Determine the associations between imaging phenotypes and genomic mechanisms in head
and neck tumors and identify effective systemic agents against aggressive tumors with a
reasonable toxicity profile to allow for rapid translational development.
In project 4.1 of this translational research component of the dissertation, we aimed to
establish if imaging radiomics features of head and neck tumors could be indicative of
important genomic biomarkers. We integrated whole-genome multi-omics data from the TCGA
with matched CT images from TCIA for a set of 126 HNC patients to identify statistically
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significant associations between radiomic and genomic features. Our results showed a
widespread of statistically significant associations between genomic features (including miRNA
expressions, somatic mutations, and transcriptional activities, copy number variations, and
promoter region DNA methylation changes of pathways) and radiomic features characterizing
the size, shape, and texture of tumor. A model for prediction of HPV and TP53 mutation status
using radiomic features was also developed and achieved an AUC of 0.71 and 0.641,
respectively. These findings suggest that radiomic features are associated with genomic
characteristics at multiple molecular layers in HNC and provides justification for continued
development of radiomics as biomarkers for relevant genomic alterations that can be adopted
for prognostic and treatment adaptation purposes. For project 4.2, we aimed to identify
effective systemic agents against aggressive thyroid carcinoma variants. We used 12 human
thyroid cancer cell lines with comprehensive genomic characterization in a high-throughput
screening of 257 compounds to select agents with maximal growth inhibition. Cell proliferation,
colony formation, orthotopic thyroid models, and patient-derived xenograft models were used to
validate the selected agents. Our results identified a selected group of agents that were
effective in the initial screen. Subsequently, docetaxel, LBH-589, and pralatrexate were
selected for additional in vitro and in vivo analysis as they have been previously approved by
the FDA for other cancers. A significant tumor growth inhibition was demonstrated in all tested
models treated with LBH-589, while pralatrexate demonstrated significant tumor growth
inhibition in the orthotopic papillary thyroid carcinoma model and two PDX models, and
docetaxel demonstrated significant tumor growth inhibition only in the context of mutant TP53.
These results confirmed that a high-throughput screening can be used to identify classes of
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systemic agents which demonstrate preferential effectiveness against aggressive thyroid
cancers, particularly those with mutant TP53. Preclinical validation in both orthotopic and PDX
models, which are accurate in vivo models mimicking tumor microenvironment, may support
initiation of early phase clinical trials in non-BRAF mutated or refractory to BRAF/MEK inhibition
ATC. Therefore, we find the hypothesis of this aim to be also correct.
11.6 Future research and applications
The results of the projects included in this dissertation support the potential
development of many future research protocols and clinical trials. It is worth reporting that the
results of Aim 1 project, was the basis of the currently active clinical trial protocol
(NCT03224000).(327) In this protocol we use a 2-stage Bayesian phase II study to examine
weekly RT dose-adaptation based on MRI-guided tumor response as explained in project 1.2.
Individual patient’s plan is designed to optimize dose reduction to organs at risk and minimize
locoregional failure probability based on serial MRI during RT. The primary aim of the trial is to
assess the non-inferiority of MR-guided dose adaptation for patients with low risk HPVassociated OPC compared standard RT. The stage 1 of this study already enrolled 15 patients
and LRC at 6 months was found to be sufficiently safe as per the Bayesian model, so stage 2
of the protocol is now active for enrollment to an additional 60 patients, randomized to either
MR-guided RT or standard IMRT.
Regarding the future directions based on Aim 2, we are planning to validate the DWI
results using external data sets to establish if our delta ADC threshold at mid-RT can be used
as a biomarker of high-risk patients for future dose escalation RT clinical trial. In addition, we
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are planning to determine if DWI parameters can be also used to predict toxicity outcomes.
This will include salivary glands parameters and xerostomia, swallowing muscle parameters
and dysphagia, and taste bud bearing tongue mucosa parameters and dysgeusia. In a similar
vein, we will assess if the vascular changes in primary tumor volumes as measured by DCEMRI can be also predictive of oncologic outcomes. If successful, we will be able to build a
comprehensive model of multiparametric MR imaging biomarkers of tumor response and
disease outcomes that can be used to stratify patients in future HNC clinical trials. Moreover,
we plan to use the DCE-MRI vascular signature of ORN to develop a prophylactic clinical trial
of pentoxifylline and tocopherol treatment of high-risk patients after RT. The initial results from
this Aim will be also included as preliminary data for a programmatic P01 NIH submission
named “InHANCE: Imaging Innovation for Head And Neck Cancer Evaluation & Elimination of
Toxicity.” The central scientific theme of this P01 application will be to improve the therapeutic
ratio for HNC by reducing normal tissue injury and the incipient loss of quality of life from
locoregional therapies (i.e. surgery and radiotherapy). This will be performed by using patientspecific data acquired via advanced imaging methods with application of statistical learning
analytic approaches to effectively predict, detect, prevent and mitigate therapy-related normal
toxicity in HNC survivors.
The patterns of failure analysis methodology developed in Aim 3 has been already
implemented by different groups and in different cancer sites as the standard methodology for
RT patterns of failure analysis.(328-330) We are also in the midst of applying this methodology
for the secondary analysis of the patterns of failure in the Australian TROG 07.03 RadioHUM
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clinical trial. This will be also applied for the data from a consortium of five international
institution from US, Asia, and Middle East as part of the Sister Institution Network Fund (SINF).
We will also apply this methodology to identify the origin of tumor recurrence relative to
baseline functional MR parameters to allow for better characterization of radioresistant tumor
subvolumes.
For Aim 4, we plan to validate the identified radiogenomic associations using a larger
dataset of HNC patients. This carry a huge potential for dynamically detect the genomic profiles
of evolving tumors and/or recurrences without the need of frequent invasive biopsies.
Moreover, our results from the high-throughput approach to identify effective agents for the
treatment of aggressive thyroid tumors demonstrate the feasibility of using this approach for
preclinical in vivo drug testing and potential combination with FDA-approved drugs in future.
This platform also provides an avenue for the identification and validation of novel agents.
Utilization of immunodeficient PDX models and immunocompetent murine models in the future
will allow for the efficient development of personalized systemic treatment of different
aggressive tumor types and will constitute a strong justification for proceeding to clinical trials.
We also plan to include the effective agents identified in this aim in combination with RT and
use MR diffusion parameters as a tool for prediction of multimodality treatment response in
mouse models of aggressive head and neck tumors. In this study, we will correlate the imaging
findings with spatially co-registered histopathological data of cellular response to treatment at
spectrum of tumor models with variable radiation sensitivity. This would identify imaging
parameters associated with radioresistent subvolumes for further treatment intensification.
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11.7 Conclusions
In this work, we were able to integrate anatomic MR images in dose adaptation RT
strategies which led to reduction in normal tissue complication probability and subsequent
integration in currently active clinical trial. We also successfully demonstrated the utility of
quantitative MR parameters as a biomarker for tumor response, disease outcomes, and normal
tissue toxicity. In addition, we developed a novel methodology for analysis, reporting, and
interpretation of the patterns of disease failure after radiation therapy. Furthermore, we were
able to identify association between genomic features and imaging radiomic features
representing different head and neck tumor phenotypes. Finally, we identified and validated
classes of systemic agents with preferential effectiveness against aggressive thyroid tumors
particularly those with mutant TP53.
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Appendix A: Supplement to Chapter 5
Appendix A.1 DCE-MRI parameter histograms for all 30 patients included in the analysis.
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Appendix A.2 Correlation of radiation dose and DCE-MRI parameters.
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Appendix B: Supplement to Chapter 8

Figure B1. Performance score for each BTV used in this study. Volumes greater than CTV1
were excluded.
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Figure B2 This figure shows coverage data for all recurrent volumes per nidus radius size and
boost volume. Boost volumes are ordered per increasing coverage for 4mm nidus data.
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Figure B3 This figure shows coverage data for primary recurrent volumes per nidus radius
size and boost volume. Boost volumes are ordered per increasing coverage for 4mm nidus
data. In addition, Robustness is included to show the difference per volume between 0mm
and 10mm nidus coverage.

243

Figure B4 This figure shows coverage data for node recurrent volumes per nidus radius
size and boost volume. Boost volumes are ordered per increasing coverage for 4mm
nidus data.
Appendix C: Supplement to Chapter 9
Section C. 1 Preparation of Radiomic Data.

Imaging Characteristics

Contrast-enhanced Computed Tomography (CT) images were obtained from TCIA with a section
thickness ranging from 0.4mm to 5mm. Slice thickness was chiefly 1mm and 3mm in 33.6% and
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26.1% of the included scans, respectively. Axial images were acquired by using a matrix of
512×512 pixels and reconstructed with a voxel size of 0.05cm×0.05cm along the x- and y-axis in
85.8% of the scans. Hence, a trilinear interpolation voxel resampling filter was applied to these
scans using Imaging Biomarker Explorer (IBEX)(263) software to yield voxel sizes congruent
with the mode of the dataset. The contrast-enhanced images were generated after one hundred
twenty milliliters of contrast material was injected into patient body at a rate of 3mL/sec, which
was followed by scanning after a 90-second delay.

Manual Segmentation of Regions of Interest (ROI)

Gross tumor volumes (GTVs) for primary tumor (GTVp) constituted our regions of interest for this
project. GTVs were defined as per ICRU 62/83, specifically, “the gross demonstrable extent and
location of the tumor”(331). Tumor volumes were manually segmented on each individual
patient’s diagnostic contrast-enhanced CT axial images or simulation CT scans by trained
personnel independently. They were blinded to relevant clinical meta-data and their
segmentation was revised by an expert radiation oncologist, along the regulations we followed
for previous projects(332). The segmentation process was governed by the guidelines of the
International Commission on Radiation Units and Measurements (ICRU) report 83.
Segmentation primarily relied on the findings from physical examination, fiberoptic
nasopharyngolaryngoscopy and imaging studies. Manual segmentation was performed by using
commercial treatment planning software VelocityAI™ 3.0.1 software. Regions of interest were
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then exported in digital imaging and communications and medicine (DICOM) format to IBEX(263)
software for further extraction of quantitative imaging features.

Texture Analysis

Texture analysis was performed using IBEX(263), which utilizes the Matlab platform (Mathworks
Inc, Natick, VA). Primary tumor GTV contours in DICOM-RTSTRUCT format were imported into
IBEX. Features explored in this analysis comprise a group of agnostic imaging features that
encompass intensity, shape and texture. These features are typically classified as first, second
and higher order texture features(333). First-order features, based on intensity values and the
shape of the ROI, are those derived from histogram analysis prior to any mathematical
transformation and regardless of spatial configuration. Intensity-based features such as kurtosis
and skewness can provide information about the overall distribution of grey levels but due to their
nature, are unable to inform about the specific spatial distribution of gray levels within the tumor.
To quantify intratumoral heterogeneity incorporating spatial information, textural analysis was
employed which constitutes to the second-order statistical output. These include methods such
as gray level co-occurrence matrix, gray level run length matrix, and neighbor intensity difference.
In these methods, a mathematical transformation is applied to the CT image to create a so-called
parent matrix. From this parent matrix, a multitude of calculations for features such as energy,
entropy, dissimilarity, and correlation may be performed. Voxel size was resampled in the three
dimensions into constant values beforehand, via a trilinear interpolation preprocessing filter.
Accordingly, voxel size was set to 0.98 mm in the x-dimension, 0.98 mm in the y-dimension and
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2.5 mm in the z-dimension. Many of the aforementioned algorithms had various parameters that
can be modified to yield drastically different results. To that end, we explored many of these
features exhaustively using multiple iterations of filters with varying parameters. Examples of
parameters include neighborhood size (measured in voxels) or sigma, among others.

We used IBEX(263) to generate radiomic features of five categories, which are gray level
co-occurrence matrix, gray level run length matrix, neighbor intensity difference, intensity direct,
and size/shape. Table C1 gives a list of the radiomic features. The information was provided by
the developers of IBEX(263). More elaborate definitions of these statistical texture features along
with relevant equations were provided by previous literature(259, 334-340).

Table C1.

Radiomic features derived from CT images

Referen
Feature Category

Features

Definition
ces
The Correlation texture
measures the linear

Auto-Correlation

(335)

Gray Level Co-

dependency of grey levels on

occurrence Matrix

those of neighbouring pixels.
A measure of the skewness
Cluster Prominence

(335)
or asymmetry
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A measure of the skewness
Cluster Shade

(335)
or asymmetry
Assess if non-random
structure exists in the data by

Cluster Tendency

measuring the probability that

(335)

the data is generated by a
uniform data distribution
Returns a measure of the
intensity contrast between a

(336,

pixel and its neighbor over

337)

Contrast 1

the whole image.
Returns a measure of how
correlated a pixel is to its

(336,

neighbor over the whole

337)

Correlation

image.
The entropy for the diagonal

(259,

probabilities

336)

Difference Entropy

Dissimilarity is conceptually
similar to the Contrast feature
Dissimilarity

(335)
in terms of grey level
variations
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Describes the grey level

(336,

energy

337)

Energy 1

Entropy is a informationtheoretic concept that gives a
Entropy

(335)
metric for the information
contained within grey level
(259,

Homogeneity

336,
337)
(259,

Homogeneity 2

336,
337)
The first measure of

(259,

information theoretic

336,

correlation

337)

The second measure of

(259,

information theoretic

336,

correlation

337)

Information Measure
Correlation 1

Information Measure
Correlation 2

(259,
Inverse Difference Moment

Inverse difference moment
336,

Norm

after being normalized to
337)
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improve classification
performance of this feature
Inverse difference after being
(259,
normalized to improve
Inverse Difference Norm

336,
classification ability of this
337)
feature.

Inverse Variance

(259)

Maximum Probability

(335)
(259,
The average for the cross-

Sum Average

336,
diagonal probabilities
337)
(259,
The entropy for the cross-

Sum Entropy

336,
diagonal probabilities
337)
(259,
The variance for the cross-

Sum Variance

336,
diagonal probabilities
337)
This feature assesses the

Gray Level Run Length
Gray Level Non-uniformity

distribution of runs over the

(338)

Matrix
grey values
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High Gray Level Run

This is a feature that

Emphasis

emphasizes high grey levels,

(338)

This feature emphasizes long
Long Run Emphasis

(338)
run lengths
This feature emphasizes runs
in the lower right quadrant of

Long Run High Gray Level
the GLRLM, where long run

(338)

Emphasis
lengths and high grey levels
are located
This feature emphasizes runs
in the upper right quadrant of
Long Run Low Gray Level
the GLRLM, where long run

(338)

Emphasis
lengths and low grey levels
are located
Low Gray Level Run

This is a feature where low

Emphasis

grey levels are emphasized

(338)

This feature assesses the
Run Length Non-uniformity

distribution of runs over the

(338)

run lengths
This feature assesses the
Run Percentage

(338)
fraction of the number of

251

realized runs and the
maximum number of
potential runs
This feature emphasizes
Short Run Emphasis

(338)
short run lengths
This feature emphasizes runs
in the lower left quadrant of

Short Run High Gray Level
the GLRLM, where short run

(338)

Emphasis
lengths and high grey levels
are located
This feature emphasizes runs
in the upper left quadrant of
Short Run Low Gray Level
the GLRLM, where short run

(338)

Emphasis
lengths and low grey levels
are located
Textures with large changes
in grey levels between
Busyness

(339)

Neighbor Intensity

neighboring voxels are called

Difference

busy
Summing level differences
Coarseness

(339)
gives an indication of the
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level of the spatial rate of
change in intensity
Complex textures are nonComplexity

uniform and rapid changes in

(339)

grey levels are common
Contrast depends on the
dynamic range of the grey
Contrast 2

levels as well as the spatial

(339)

frequency of intensity
changes
Texture Strength

(339)

Energy 2

(259)
The intensity entropy among

Global Entropy

(259)
all the voxels
The intensity maximum

Global Maximum
Intensity Direct

(259)
among all the voxels.
The intensity mean among all

Global Mean

(259)
the voxels.
The intensity median among

Global Median

(259)
all the voxels.
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The intensity minimum
Global Minimum

(259)
among all the voxels.
The intensity standard

Global Std

deviation among all the

(259)

voxels.
The intensity uniformity
Global Uniformity

(259)
among all the voxels.
The interquartile range of the

Inter-Quartile Range

intensity values among all the

(259)

voxels.
Measure the peakedness of
Kurtosis

(259)
all the voxels' intensity.
First, at each voxel, compute
entropy in its neighborhood
region. Then, compute the

Local Entropy Maximum

(259)
maximum among all the
voxel's entropy calculated
from step 1.
First, at each voxel, compute

Local Entropy Mean

entropy in its neighborhood

(259)

region. Then, compute the
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mean among all the voxel's
entropy calculated from step
1.
First, at each voxel, compute
entropy in its neighborhood
region. Then, compute the
Local Entropy Median

(259)
median among all the voxel's
entropy calculated from step
1.
First, at each voxel, compute
entropy in its neighborhood
region. Then, compute the

Local Entropy Minimum

(259)
minimum among all the
voxel's entropy calculated
from step 1.
First, at each voxel, compute
entropy in its neighborhood
region. Then, compute the

Local Entropy Std

(259)
standard deviation among all
the voxel's entropy calculated
from step 1.
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First, at each voxel, compute
range value (maximum
value-minimum value) in its
Local Range Maximum

neighborhood region. Then,

(259)

compute the median among
all the voxel's range value
calculated from step 1.
First, at each voxel, compute
range value (maximum
value-minimum value) in its
Local Range Mean

neighborhood region. Then,

(259)

compute the mean among all
the voxel's range value
calculated from step 1.
First, at each voxel, compute
range value (maximum
value-minimum value) in its
Local Range Median

neighborhood region. Then,

(259)

compute the median among
all the voxel's range value
calculated from step 1.
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First, at each voxel, compute
range value (maximum
value-minimum value) in its
Local Range Minimum

neighborhood region. Then,

(259)

compute the minimum
among all the voxel's range
value calculated from step 1.
First, at each voxel, compute
range value (maximum
value-minimum value) in its
neighborhood region. Then,
Local Range Std

(259)
compute the standard
deviation among all the
voxel's range value
calculated from step 1.
First, at each voxel, compute
standard deviation in its

Local Std Maximum

neighborhood region. Then,

(259)

compute the maximum
among all the voxel's
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standard deviation value
calculated from step 1.
First, at each voxel, compute
standard deviation in its
neighborhood region. Then,
Local Std Mean

compute the mean among all

(259)

the voxel's standard
deviation value calculated
from step 1.
First, at each voxel, compute
standard deviation in its
neighborhood region. Then,
Local Std Median

compute the median among

(259)

all the voxel's standard
deviation value calculated
from step 1.
First, at each voxel, compute
standard deviation in its
Local Std Minimum

neighborhood region. Then,

(259)

compute the minimum
among all the voxel's
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standard deviation value
calculated from step 1.
First, at each voxel, compute
standard deviation in its
neighborhood region. Then,
Local Std Std

compute the standard

(259)

deviation all the voxel's
standard deviation value
calculated from step 1.
The mean absolute deviation
Mean Absolute Deviation

of the intensity values among

(259)

all the voxels.
The median absolute
Median Absolute Deviation

deviation of the intensity

(259)

values among all the voxels.
Percentiles of the intensity
Percentile

(259)
values among all the voxels.
Quantiles of the intensity

Quantile

(259)
values among all the voxels.
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The intensity range
Range

(maximum value - minimum

(259)

value) among all the voxels.
Root Mean Square

(259)
Measure the asymmetry of all

Skewness

(259)
the voxels' intensity.

Variance

(259)
Compactness1 =

Compactness 1

(Volume)/(sqrt(pi)*(SurfaceAr

(259)

ea)^(2/3))
Compactness2 =
Compactness 2

36*pi*(Volume^2)/((SurfaceA

(259)

rea)^3).
Size/Shape

Measure the proportion of the
Convex

pixels in the convex hull that

(259)

are also in the region.
The mean volume of the 2D
convex hulls that are the
Convex Hull Volume

(259)
convex envelopes of each
slice's binary mask.
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3D volume of the convex hull
3D Convex Hull Volume

that is the convex envelope

(259)

of binary mask.
Mass

(259)
Maximum 3D Diameter =
largest pairwise Euclidean

Maximum 3D Diameter

distance between voxels on

(259)

the surface of the tumor
volume.
Denotes integral of mean
Mean Breadth

(259)
curvature
The number of voxels

Number Of Voxels

treating the edge voxels

(259)

differently.
Measures the angle between
Orientation

the x-axis and the major axis

(259)

of the ellipse in 2D.
Measures how much the
Roundness

binary mask is close to circle

(259)

in 2D.
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Measures the deviation of a
tumor’s shape from a sphere
Spherical Disproportion

(259)
based on its effective
diameter
Measures how close a

Sphericity

(259)
tumor’s shape is to a sphere
The surface area of the

Surface Area

(340)
binary mask.
Surface Area Density =
(surface area of the binary

(259,

mask)/(volume of the binary

340)

Surface Area Density

mask).

For some features in the gray level co-occurrence matrix category and the intensity direct
category, multiple feature instances were calculated for a single feature using different parameter
settings. For example, for each feature in the gray level co-occurrence matrix category, five
feature instances were generated with the offset parameter being 1, 2, 3, 4, and 5, which
calculated the feature values over different distances, so the name of a feature from the gray
level co-occurrence matrix category usually includes the offset parameter value; for percentile
and quantile in the intensity direct category, feature instances with different percentile and
quantile values were calculated. We used IBEX(263) to generate 196 radiomic features based
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on the tumor CT images and then removed the features whose values were identical to others.
Additionally, two size/shape features, i.e. voxel size and number of objects, were excluded from
analysis, because they did not vary (much) over the tumor cases and thus were not useful for
analysis. All tumor cases had the same voxel size value equal to 0.002384174. The number of
objects for all tumor cases was 1, except four of them were 2 and one of them was 3. After
removal, 187 radiomic features were kept and used in the analysis. The number of features in
each category is shown in Table C2.

Table C. 2

Numbers of features from different radiomic feature categories

Gray level coFeature

Neighbor
Gray level run

occurrence
category

Intensit

Size/Sha

y direct

pe

51

15

intensity
length matrix

matrix

difference

Feature
105

11

5

number

Section C. 2 Preparation of Genomic Data.

The genomic data used in this analysis were generated by TCGA(261). All tumor biospecimens
were collected according to TCGA protocol. Each tumor biospecimen was extracted from the
tissue adjacent to the tissue block where a slide was obtained for disease diagnosis of the patient.
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Each tumor sample must pass a pathology review to be qualified for generating genomic data.
TCGA protocol required that a tumor sample must contain at least 60% tumor cell nuclei with
less than 20% necrosis to be included in the study. The American Joint Committee on Cancer
(AJCC) staging system was used to stage all the tumor cases.

All TCGA genomic data and clinical information were retrieved from TCGA data server
using TCGA-Assembler(264), an open-source R package that can automatically download,
assemble, and process public TCGA data. TCGA used the Illumina HiSeq 2000 sequencing
platform to generate RNA-seq data, which were then processed by the MapSplice genome
alignment algorithm(341) and the RSEM gene expression estimation algorithm(342). We used the
normalized read counts of RNA-seq data for analysis. MiRNA-seq data were generated using
the Illumina Genome Analyzer and HiSeq 2000 sequencing platforms and the RPM (Reads Per
Million miRNAs mapped) values were used for analysis. In TCGA, the Affymetrix® Genome-Wide
Human SNP Array 6.0 and the circular binary segmentation algorithm(343) were used to generate
copy number values of DNA fragments, based on which TCGA-Assembler was used to calculate
an average copy number for each gene in each sample. Somatic mutation data were generated
through exome sequencing using the Illumina Genome Analyzer sequencing platform. Three
mutation callers, including VarScan 2 (for SNVs/Indels)(344), SomaticSniper (for SNVs)(345), and
GATK IndelGenotyper v2.0 (for Indels)(346), were used to identify candidate mutations. TCGA
took the union of the mutations identified by these three callers and additional filtering and
processing were taken to ensure the quality of mutation calls(347). TCGA DNA methylation data
were generated using Infinium HumanMethylation450 BeadChip from Illumina, which measures
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the methylation level of about 485,000 CpG sites. We used TCGA-Assembler to calculate an
average methylation level of CpG sites in the promoter region of each gene, which includes 1500
base pairs upstream of the transcription start site.

Section C. 3 Overview of Identified Associations.

Through linear regression analysis and Gene Set Enrichment Analysis (GSEA)(265, 348), a total of
5350 statistically significant associations (adjusted p-value ≤ 0.05) were identified between
various radiomic features and genomic features. Genomic features include miRNA expressions,
somatic gene mutations, and transcriptional activities, gene CNVs, and promoter region DNA
methylation changes of genetic pathways documented in the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database(266). The radiomic features were grouped into five categories,
which are gray level co-occurrence matrix, gray level run length matrix, neighbor intensity
difference, intensity direct, and size/shape. For details of linear regression analysis and GSEA,
see Appendix Information Sections C4-9.

Fig. 2a in the main text is a graphical presentation of the identified associations. Fig. 2b
in the main text shows the numbers of identified associations between different categories of
genomic features and different categories of radiomic features, based on which Fisher’s exact
test(268, 269) indicated that the frequency of statistically significant associations depended on
the feature category (p-value ≤ 1.0×10−8), meaning some feature categories had more
associations than others.
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For each pair of genomic feature category and radiomic feature category, we used
Fisher’s exact test to evaluate the enrichment of associations between them with the resulted
adjusted p-value presented in Table C. 3. Take the associations between pathway transcriptional
activities and size/shape features as an example to explain how the enrichment significance is
evaluated. The total number of genomic features used in the association analysis is 179
(transcriptional activities of pathways) + 179 (copy number variations of pathways) + 179
(promoter region DNA methylation changes of pathways) + 292 (miRNA expressions) + 70
(mutated genes) + 173 (protein expressions) = 1072, so there are 1072×187 = 200464 potential
associations, among which 179×15 = 2685 potential associations are between pathway
transcriptional activities and size/shape radiomic features. From Figure 9. 2b in the main text,
5350 statistically significant associations have been identified, among which 884 associations
are between pathway transcriptional activities and size/shape features. Based on these numbers,
Fisher's exact test gives a p-value smaller than 1.0×10 30, after correction over all 30 tests
included in Table C. 3 using the Benjamini–Hochberg (BH) procedure.(349) We can see the
identified associations were statistically significantly enriched among pathway transcriptional
activities and all five categories of radiomic features (adjusted p-values < 1.0×10−30). This implies
that transcriptional activities of genetic pathways modulate various aspects of the tumor imaging
phenotype.

Table C. 3 Adjusted p-values evaluating the enrichments of statistically significant associations
between genomic features of different platforms and radiomic features of different categories
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Gray Level Co-

Gray Level

Neighbor

occurrence

Run Length

Intensity

Matrix

Matrix

Difference

Feature
Category

Intensit

Size/Sha

y Direct

pe

<1.0×10-

<1.0×10-

30

30

Transcriptional
activity of

-30

<1.0×10

-30

<1.0×10

-30

<1.0×10

pathway
Copy number
variation of

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

1

pathway
Promoter region
DNA methylation
change of
pathway
miRNA
expressions
Mutated genes

Section C. 4 Associations Between Radiomic Features and Pathway Transcriptional Activities.
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We investigated the associations between radiomic features and the transcriptional activities of
genetic pathways documented by the KEGG database(266). Genes with unreliable expressions
were removed to avoid significant noise in data or bias in analysis results. A gene was excluded
from the analysis, if its read count per million reads mapped was less than 1 in more than a half
of the samples. 13562 genes were kept after gene filtering. Their normalized read counts were
log2 transformed and used for analysis. The association analysis was performed through two
steps, i.e. linear regression analysis and GSEA(265). The linear regression analysis was
performed for each gene and each radiomic feature to examine whether the gene's expression
affected the radiomic feature, with adjustments of patient age, tumor stage, tumor subsite, and
patient smoke status, which was formulated as

xi = β0 + β1 mi + β2 ai + β3 g2,i + β4 g3,i + β5 g4,i + β6 s2,i + β7 s3,i + β8 o2,i + β9 o3,i + ε,

(1)

where xi was the value of the radiomic feature for patient i, mi was the expression level of the
gene in patient i, ai was the age of patient i, g2,i , g3,i , and g4,i were three 0/1 indicators coding the
patient tumor stage (stage I: g2,i = 0, g3,i = 0, g4,i = 0; stage II: g2,i = 1, g3,i = 0, g4,i = 0; stage
III: g2,i = 0, g3,i = 1, g4,i = 0; stage IV: g2,i = 0, g3,i = 0, g4,i = 1), s2,i and s3,i were two 0/1
indicators coding the tumor subsite (larynx: s2,i = 0 and s3,i = 0; oral cavity: s2,i = 1 and s3,i = 0;
oropharynx: s2,i = 0 and s3,i = 1), o2,i and o3,i were two 0/1 indicators coding the patient smoke
status (current smoker: o2,i = 0 and o3,i = 0; former smoker: o2,i = 1 and o3,i = 0; never smoker:
o2,i = 0 and o3,i = 1). A t-value that could be used for evaluating the statistical significance of β1
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was calculated. We then used the Bioconductor R package PIANO(348) to perform GSEA using
the t-values as the gene-level statistics. GSEA studies whether the behavior of a set of genes as
a whole group correlates with the change of a radiomic feature(265). It is based on known gene
sets that are genetic pathways or functional gene modules. In our analysis, we used the KEGG
pathways collected in the Molecular Signature Database(265) that includes 179 genetic pathways
covering various genetic and molecular functions. GSEA calculated the gene-set-level statistic
and the associated nominal p-value evaluating the statistical significance of the gene-set-level
statistic based on 10000 random gene sets. The BH procedure was used to control the False
Discovery Rate (FDR) of the identified associations for each radiomic feature among its
association tests with all KEGG pathways.(349) An association was statistically significant if the
adjusted p-value was no larger than 0.05. Positive association and negative association, i.e. the
two different association directions, were tested separately between a gene set and a radiomic
feature. Note that because the gene-level statistics (t-values) were obtained through linear
regression analysis with adjustments to patient age, tumor grade, tumor subsite, and patient
smoke status, our GSEA results were also adjusted to these confounding variables. To our
knowledge, this was the first time that GSEA was performed with adjustments to co-variables.

Figure 9.2a in the main text shows the statistically significant associations between
radiomic features and transcriptional activities of some cancer-related pathways. One of the
pathways was cell cycle and its transcriptional activity was positively associated with tumor
texture homogeneity characterized by its associations with energy 1, entropy, homogeneity, and
homogeneity 2.
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Section C. 5 Associations Between Radiomic Features and Gene Copy Number Variations of
Pathways.

We studied the associations between radiomic features and gene copy number variations
(CNVs) of pathways. The analysis procedure followed that of the pathway transcriptional activity
associations. First, the linear regression analysis with adjustments to patient age, tumor grade,
tumor subsite, and patient smoke status was performed for each pair of gene and radiomic
feature following Equation (1), where mi here was the copy number of the gene in patient i and
all other variables in the equation were kept unchanged. Then, GSEA was performed using the
t-value of coefficient β1 obtained in the linear regression analysis as the gene-level statistic.
Nominal p-values evaluating the statistical significance of gene-set-level statistics were
calculated based on 10000 random gene sets and the FDR was controlled using the BH
procedure for each radiomic feature among all its association tests with the 179 KEGG pathways.
Before the analysis, genes were ranked according to their standard deviations of copy numbers
over the samples from the largest to the smallest. The top 14000 genes were selected for the
analysis.

Section C. 6 Associations Between Radiomic Features and Pathway DNA Methylation
Changes.
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We studied the associations between radiomic features and promoter region DNA methylation
changes at the pathway level. The analysis procedure followed those of pathway transcriptional
activity and CNVs. The linear regression analysis still followed Equation (1), where mi here was
the DNA methylation value in the promoter region of the gene in patient i and all other variables
in the equation were kept unchanged. GSEA was performed using the t-value of coefficient β1
as the gene-level statistic. Nominal p-values evaluating the statistical significance of gene-setlevel statistics were calculated based on 10000 random gene sets and the FDR was controlled
using the BH procedure for each radiomic feature among all its association tests with the 179
KEGG pathways. Before the analysis, genes were ranked according to their standard deviations
of methylation levels over all patients from the largest to the smallest. The top 14000 genes were
selected for the analysis.

Figure 9. 2c in the main text shows the statistically significant associations between
radiomic features and promoter region DNA methylation changes of some cancer-related KEGG
pathways. Promoter region DNA methylation change of the adherens junction pathway was
correlated with tumor shape regularity characterized by its positive association with sphericity.

Section C. 7 Associations Between Radiomic Features and miRNA Expressions.

Before the analysis, to select only miRNAs with reliable expression levels for analysis, we
removed miRNAs whose RPM values are less than 2 in more than a half of the samples, which
resulted in 292 miRNAs for the analysis. Log2 transformation of the RPM data was then taken.
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We used the linear regression analysis to identify the associations between radiomic features
and miRNA expressions with adjustments to patient age, tumor grade, tumor subsite, and patient
smoke status. The linear regression analysis was performed for each pair of miRNA and radiomic
feature following Equation (1), where mi here was the expression level of the miRNA in patient i
and all other variables in the equation were kept unchanged. The p-value of coefficient β1 was
obtained in regression analysis and then adjusted using the BH procedure to
control the FDR over all association tests of each radiomic feature. Before the analysis, to select
only miRNAs with reliable expression levels for analysis, we removed miRNAs whose RPM
values are less than 2 in more than a half of the samples, which resulted in 292 miRNAs for the
analysis. Log2 transformation of the RPM data was then taken.

Table C. 4 summarizes all statistically significant associations between miRNA
expressions and radiomic features. MiR-320a has been reported as a negative regulator of tumor
invasion and metastasis(273). Its expression correlated with tumor texture homogeneity
characterized by positive associations with homogeneity and homogeneity 2 and negative
associations with entropy and global entropy. The radiomic feature global uniformity measures
the overall homogeneity of tumor pixel intensity(259) and was positively associated with the
expressions of 8 miRNAs including both antitumorigenic/antimetastatic and oncogenic miRNAs.
The antitumorigenic/antimetastatic miRNAs include miR-101 (targeting EZH2, a histone-lysine
N-methyltransferase enzyme epigenetically silencing tumor suppressor genes(274)), miR-15b
(targeting VEGF, an important factor in the neo-angiogenesis process that is crucial for cells to
reach and disseminate through the circulation system(275)), and miR-320a; the oncogenic
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miRNAs include miR-106b and miR-25 (both from miR-106b-25 cluster that is over-expressed
in HNSCC and promotes cell proliferation(276)), miR-155 (upregulated in HNSCC and targeting
tumor suppressors such as adenomatous polyposis coli(277)), and miR-378 (reported to repress
a potential tumor suppressor gene TOB2 in nasopharyngeal carcinoma(278)); the last miRNA
miR-7 is involved in multiple cancer-related signaling pathways and has been reported mainly as
a tumor suppressor, but with the opposite effect also documented(276).

Table C. 4 Statistically significant associations between radiomic features and miRNA
expressions

Gene

Adjusted PRadiomic Feature

Symbol

Coefficient
value

hsa-mirGlobal Uniformity

0.03203

0.017687

Global Uniformity

0.03203

0.01729

hsa-mir-155

Global Uniformity

0.03203

0.019309

hsa-mir-15b

Global Uniformity

0.049439

0.017349

hsa-mir-25

Global Uniformity

0.03203

0.01822

Entropy (offset = 4)

0.049795

-0.33106

101-2
hsa-mir106b

hsa-mir320a
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hsa-mirEntropy (offset = 5)

0.040612

-0.3402

0.045543

0.027079

0.038173

0.028195

0.040392

0.032628

0.03204

0.034094

Global Entropy

0.024199

-0.17216

Global Uniformity

0.013523

0.02116

hsa-mir-378

Global Uniformity

0.03203

0.018323

hsa-mir-582

Skewness

0.03015

-1.49173

hsa-mir-7-1

Global Uniformity

0.03203

0.017998

320a
hsa-mir-

Homogeneity (offset =

320a

4)

hsa-mir-

Homogeneity (offset =

320a

5)

hsa-mir-

Homogeneity 2 (offset

320a

= 4)

hsa-mir-

Homogeneity 2 (offset

320a

= 5)

hsa-mir320a
hsa-mir320a

For Coefficient column, positive value indicates positive association and negative value indicates
negative association. A radiomic feature from the gray level co-occurrence matrix category can
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be calculated using different offset parameter values, i.e. 1, 2, 3, 4, and 5, which forms five
different instances of a feature.

Section C. 8 Associations Between Radiomic Features and Somatically Mutated Genes.

We used the linear regression analysis to identify the associations between radiomic features
and somatically mutated genes with adjustments to patient age, tumor grade, tumor subsite, and
patient smoke status. To achieve reliable results, genes with somatic mutations in less than 10
patients were excluded, which resulted in 70 genes for the analysis. The linear regression
analysis was performed for each pair of somatically mutated gene and radiomic feature following
Equation (1), where mi here was a 0/1 indicator indicating whether patient i had any somatic
mutation in the gene and all other variables kept unchanged. The p-value of coefficient β1 was
obtained in the regression analysis and then adjusted using the BH procedure to control the FDR
over all association tests of each radiomic feature.

Table C. 5 summarizes all identified associations between radiomic features and
somatically mutated genes. PCDH15 is a member of the cadherin superfamily that encodes
integral membrane proteins regulating calcium-dependent cell-cell adhesion. Mutations in
PCDH15 correlated with the texture homogeneity of HNSCC characterized by energy 1. AHNAK2
has been reported to be over-expressed in pancreatic cancer.(350)
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Our analysis indicated that HER3 expression was positively associated with a tumor texture
feature named correlation, which measures the correlation between a pixel’s intensity and their
neighbors’ intensities across tumor.

Table C.5 Statistically significant associations between radiomic features and somatically
mutated genes

Gene

Adjusted

Coeffi

Number of Samples

Number of Samples

P-value

cient

With Mutations

Without Mutations

11

111

11

111

11

111

11

111

11

111

11

111

Radiomic Feature
Symbol
PCDH1

0.0601
Energy 1 (offset = 2)

0.049784

5

2

PCDH1

0.0593
Energy 1 (offset = 3)

0.042448

5

14

PCDH1

0.0593
Energy 1 (offset = 4)

0.03184

5

67

PCDH1

0.0590
Energy 1 (offset = 5)

0.026395

5
PCDH1

23
Maximum Probability

0.1083
0.046293

5

(offset = 1)

PCDH1

Maximum Probability

55
0.1061
0.044694

5

(offset = 2)

99
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PCDH1

Maximum Probability

0.1047
0.043507

5

(offset = 3)

PCDH1

Maximum Probability
(offset = 4)

PCDH1

Maximum Probability
(offset = 5)

LINC00

Long Run Low Gray

111

11

111

12

110

12

110

12

110

12

110

12

110

12

110

0.1073
1
0.8389
0.034502

969

11
42

0.016698
5

111

0.1060
0.027814

5

11
75

Level Emphasis

88
-

LINC00
Global Median

0.041526

47.747

969
8
LINC00

Median Absolute

41.601
0.045561

969

Deviation

47

LINC00

30 Percentile

0.033253

969

98.535
-

LINC00
35 Percentile

0.03213

98.343

969
2
LINC00
40 Percentile

0.031563

97.457

969
4
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LINC00
45 Percentile

0.032072

84.927

12

110

10

112

10

112

10

112

10

112

10

112

10

112

10

112

11

111

10

112

969
3
Long Run Low Gray
CUBN

0.8999
0.034502

Level Emphasis

71
-

CUBN

Global Median

0.037448
52.973

Median Absolute
CUBN

47.648
0.023872

Deviation

97
-

CUBN

30 Percentile

0.0248

109.32
5
-

CUBN

35 Percentile

0.024188

109.31
6
-

CUBN

40 Percentile

0.024937

107.84
9

CUBN

45 Percentile

0.028463

95 Percentile

0.039029

TUBB8

57.908

P7
AC0245

-93.82

78
Long Run Low Gray

0.9212
0.030238

60.3

Level Emphasis

28
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AC0245
Global Median

0.037448

55.816

10

112

10

112

10

112

10

112

10

112

10

112

10

112

10

112

60.3
3
AC0245

Median Absolute

49.368
0.021757

60.3

Deviation

81
-

AC0245
30 Percentile

0.0248

113.10

60.3
3
AC0245
35 Percentile

0.024188

113.18

60.3
1
AC0245
40 Percentile

0.02435

111.88

60.3
9
AC0245
45 Percentile

0.024681

97.568

60.3
3
Inverse Variance
EP300

0.007322

0.0529

(offset = 2)
1
Inverse Variance
EP300

0.002273

0.0592

(offset = 3)
7
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Inverse Variance
EP300

0.003468

0.0608

10

112

10

112

10

112

10

112

10

112

10

112

10

112

10

112

(offset = 4)
6
Inverse Variance
EP300

0.007857

0.0612

(offset = 5)
2
Long Run Low Gray
EP300

0.9296
0.030238

Level Emphasis

82
-

EP300

Global Median

0.041526

49.254
5

Median Absolute
EP300

48.699
0.021757

Deviation

17
-

EP300

30 Percentile

0.0248

107.69
1
-

EP300

35 Percentile

0.024188

107.36
3
-

EP300

40 Percentile

0.024937

105.93
9
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EP300

45 Percentile

0.028463

91.392

10

112

17

105

17

105

17

105

17

105

17

105

17

105

17

105

4
COL11

Inverse Variance

A1

(offset = 2)

0.007322

0.0420
3
-

COL11

Inverse Variance

A1

(offset = 3)

0.008623

0.0427
5
-

COL11

Inverse Variance

A1

(offset = 4)

0.048034

0.0394
5
-

COL11
Global Median

0.037448

41.974

A1
8
COL11
30 Percentile

0.046828

79.051

A1
1
COL11

35 Percentile

0.040247

A1

79.889
-

COL11
40 Percentile

0.040164

79.053

A1
5
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COL11
45 Percentile

0.037421

69.491

17

105

11

111

11

111

11

111

11

111

11

111

11

111

11

111

A1
3
AHNA

Long Run Low Gray

0.9201
0.030238

K2

Level Emphasis

64
-

AHNA
Global Median

0.037448

52.603

K2
6
AHNA

Median Absolute

47.204
0.021757

K2

Deviation

61
-

AHNA
30 Percentile

0.0248

108.04

K2
4
AHNA
35 Percentile

0.024188

109.80

K2
3
AHNA
40 Percentile

0.02435

109.17

K2
6
AHNA
45 Percentile

0.024681

95.183

K2
7
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For Coefficient column, positive value indicates positive association and negative value indicates negative
association. A radiomic feature from the gray level co-occurrence matrix category can be calculated using different
offset parameter values, i.e. 1, 2, 3, 4, and 5, which forms five different instances of a feature. Percentile and quantile
from the intensity direct category can also be calculated using different parameter values resulting in multiple feature
instances.

Section C. 9 Associations Between Radiomic Features and Protein Expressions

We used the linear regression analysis to identify the associations between radiomic
features and protein (or phospho-protein) expressions with adjustments to patient age, tumor
grade, tumor subsite, and patient smoke status. The linear regression analysis was performed
for each pair of protein and radiomic feature following Equation (1), where mi here was the
expression level of the protein in patient and all other variables in the equation were kept
unchanged. The p-value of coefficient β1 was obtained in the regression analysis and then
adjusted using the BH
procedure to control the FDR over all association tests of each radiomic feature.

Table C. 6 summarizes the identified associations between radiomic features and
protein expressions. HER3 (encoded by ERBB3) is a member of the epidermal growth factor
receptor (EGFR) family and can function as an oncoprotein. Our analysis indicated that HER3
expression was positively associated with a tumor texture feature named correlation, which
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measures the correlation between a pixel’s intensity and their neighbors’ intensities across
tumor.
Table C. 6 Statistically significant associations between radiomic features and protein
expressions.

Gene Symbol

Radiomic Feature

MAPK1|ERK2-

Maximum 3D

R-C

Diameter

ERBB3|HER3-

Correlation (offset =

R-V

5)

TSC2|Tuberin-

Maximum 3D

R-C

Diameter

Adjusted P-

Coefficie

value

nt

0.026239

0.86837

0.046202

0.045507

0.026239

0.957955

For Gene Symbol column, characters before "|" is the gene encoding the protein and characters
after "|" is the antibody used for measuring the protein expression. For Coefficient column,
positive value indicates positive association and negative value indicates negative association.
A radiomic feature from the gray level co-occurrence matrix category can be calculated using
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different offset parameter values, i.e. 1, 2, 3, 4, and 5, which forms five different instances of a
feature.
Section C. 10 Prediction of HNSCC HPV Status and Disruptive TP53 Mutation Using Radiomic
Features.
We used random forest classifiers(267, 351) to predict HPV status and disruptive TP53
mutation in tumor (i.e. to predict whether a tumor possesses any disruptive TP53 mutation),
based on radiomic features. We used CRAN R package "randomForest" (https://cran.rproject.org/web/packages/randomForest/index.html) to implement the classification pipeline. A
two-tier nested cross-validation scheme was used to evaluate the generalization prediction
performance (see Figure C. 1). The parameters of the random forest algorithm, including the
number of features used for decision at each node in a tree and the maximum size of a terminal
node (leaf) in a tree were tuned through the inner-tier cross-validation, in which the set of
parameters that generated the highest average prediction accuracy on the testing data in the
inner-tier cross-validation trials were used to train the classifier on the outer-tier training data and
the trained classifier was used to predict the labels of outer-tier testing data. The outer-tier crossvalidation evaluated the generalization prediction performance of the whole classification
scenario including the parameter tuning. For the maximum size of terminal node, the candidate
parameter values were 1 and 2. The candidate values for the number of features used for
decision at each node were generated based on the suggestion from the user manual of the
randomForest R package by calculating unique (floor(seq(fmin , fmax , 10))), where unique(⋅) was
the R function returning the unique elements of an input numeric vector, floor(⋅) was the R
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function returning a numeric vector containing the largest integers not greater than the
corresponding elements of the input vector, and seq(fmin , fmax , 10) was the R function returning
a sequence of eleven equally spanned numeric values starting at fmin and ending at fmax. fmin =
max (floor(√p⁄3), 1) and fmax = min (floor(√p× 3), p), where p was the number of features in the
data, max(⋅ , ⋅) returned the larger value of the two inputs, and min(⋅ , ⋅) returned the smaller
value of the two inputs. Basically, there were eleven candidate values for the number of features
used for decision at each node, which were evenly spanned from fmin to fmax. The number of
random trees in the random forest classifier was always set at 10000. Before analysis, all
radiomic features were standardized to have a 0 mean and a unit standard deviation.

An importance measure was used to evaluate the prediction power (i.e. importance) of
features. It was calculated based on permuting the out-of-bag (OOB) data. OOB data were
samples excluded from constructing a tree and used for testing the classification accuracy of the
constructed tree. For each tree, the classification accuracy of the OOB portion of the data was
recorded. Then the same was done after randomly permuting the values of a feature. The
difference between the two classification accuracies were then averaged over all trees, and
normalized (divided) by the standard deviation of the difference, which formed the importance
measure of feature. Features were ranked according to their importance measure for selecting
top predictive features. We applied a recursive feature elimination scheme as shown in Figure
C. 1 The prediction performance evaluation was first conducted using all features. Then, for each
pair of outer-tier training data and testing data, the features were ranked based on their
importance measures obtained on the training data and the top 100 features were selected. Both
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the training data and the testing data were modified to include only these 100 most important
features, while the other features were removed. Then the prediction performance was reevaluated based on the 100 features. This feature elimination process went on recursively to
select the best 50 features out of the 100 features, the best 20 features out of the 50 features,
the best 10 features out of the 20 features, and finally the best 5 features out of the 10 features.
As a result, the generalization prediction performance was evaluated for the cases of all features,
100 features, 50 features, 20 features, 10 features, and 5 features. The Area Under the Receiver
Operating Characteristic (ROC) Curve (AUC) was used as the performance metric for prediction
accuracy. Both the outer-tier and inner-tier cross-validation schemes were five-fold crossvalidations, with the classification performance summarized over 30 cross-validation trials.

We used the above feature selection and prediction scheme to predict patient HPV status
based on radiomic features. When five features were selected in each cross-validation trial for
prediction, the top five features most frequently selected for prediction were global maximum,
skewness, sum variance (offset = 5), sum variance (offset = 4), and local range std, which were
used in 24, 17, 14, 10, and 9 out of the 30 cross-validation trials, respectively. Offset was a
parameter used to calculate radiomic features in the gray level co-occurrence matrix category
and it took multiple values (i.e. 1, 2, 3, 4, 5), each of which resulted in a different instance of the
feature. The most frequently selected feature, i.e. global maximum, is the maximum intensity
value of all voxels in a tumor; skewness measures the asymmetry of the intensity distribution of
all voxels in a tumor; sum variance is related to the heterogeneity of tumor texture; local range
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std calculates the standard deviation of the intensity range of the neighborhoods for all tumor
voxels, forming a feature related to pixel intensity heterogeneity.

Using the same analysis scheme, we predicted disruptive TP53 mutations in tumors using
radiomic features and selected predictive ones from them. When five features were selected in
each cross-validation trial for prediction, the top five features most frequently selected for
prediction were mean absolute deviation, global maximum, sum entropy (offset = 5), texture
strength, and global entropy, which were selected in 20, 16, 14, 13, and 11 out of the 30 crossvalidation trials, respectively. Mean absolute deviation, sum entropy, and global entropy measure
the heterogeneity of tumor voxel intensity or texture. Texture strength evaluates the saliency of
tumor texture primitives. Global maximum, the most frequently selected feature for predicting
HPV status, is the second most frequently selected feature here for predicting disruptive TP53
mutation.

The frequencies of the most frequently selected features across cross-validation trials are
not very high in both prediction tasks. It may be caused by the relatively small sample sizes, i.e.
125 tumor samples for predicting patient HPV status and 122 tumor samples for predicting
disruptive TP53 mutations in tumors. Due to the small sample size, the data distribution in each
cross-validation trail may substantially vary, thus different features can be selected for prediction
across trials.
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Figure C. 1 A flowchart showing the two-tier nested cross-validation scheme for evaluating the
generalization prediction performance.
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